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4Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
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Background: Pulmonary embolism (PE) is a leading cause of death in pregnancy and post partum, but the
symptoms of PE are common in normal pregnancy. Simple diagnostic tests are needed to select women for
diagnostic imaging.
Objective: To estimate the accuracy, effectiveness and cost-effectiveness of clinical features, decision rules
and biomarkers for selecting pregnant or postpartum women with a suspected PE for imaging.
Design: An expert consensus study to develop new clinical decision rules, a case–control study of women
with a diagnosed PE or a suspected PE, a biomarker study of women with a suspected PE or diagnosed
deep-vein thrombosis (DVT) and decision-analysis modelling.
Setting: Emergency departments and consultant-led maternity units.
Participants: Pregnant/postpartum women with a diagnosed PE from any hospital reporting to the UK
Obstetric Surveillance System research platform and pregnant/postpartum women with a suspected PE or
diagnosed DVT at 11 prospectively recruiting sites.
Interventions: Clinical features, decision rules and biomarkers.
Main outcome measures: Sensitivity, specificity, area under receiver operating characteristic (AUROC)
curve, quality-adjusted life-years (QALYs) and health-care costs.
Results: The primary analysis involved 181 women with PE and 259 women without PE in the case–control
study and 18 women with DVT, 18 with PE and 247 women without either in the biomarker study. Most
clinical features showed no association with PE. The AUROC curves for the clinical decision rules were as
follows: primary consensus, 0.626; sensitive consensus, 0.620; specific consensus, 0.589; PE rule-out criteria,
0.621; simplified Geneva score, 0.579; Wells’s PE criteria (permissive), 0.577; and Wells’s PE criteria (strict),
0.732. The sensitivities and specificities of the D-dimer measurement were 88.4% and 8.8%, respectively,
using a standard threshold, and 69.8% and 32.8%, respectively, using a pregnancy-specific threshold.
Previous venous thromboembolism, long-haul travel, multiple pregnancy, oxygen saturation, recent surgery,
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temperature and PE-related chest radiograph abnormality were predictors of PE on multivariable analysis.
We were unable to derive a rule through multivariable analysis or recursive partitioning with adequate
accuracy. The AUROC curves for the biomarkers were as follows: activated partial thromboplastin time – 0.669,
B-type natriuretic peptide – 0.549, C-reactive protein – 0.542, Clauss fibrinogen – 0.589, enzyme-linked
immunosorbent assay D-dimer – 0.668, Innovance D-dimer (Siemens Healthcare Diagnostics Products GmbH,
distributed by Sysmex UK Ltd, Milton Keynes, UK) – 0.651, mid-regional pro-atrial natriuretic peptide
(MRproANP) – 0.524, prothrombin fragment 1 + 2 – 0.562, plasmin-antiplasmin – 0.639, Prothombin
time – 0.613, thrombin generation lag time – 0.702, thrombin generation endogenous potential – 0.559,
thrombin generation peak – 0.596, thrombin generation time to peak – 0.655, tissue factor – 0.531 and
troponin – 0.597. The repeat analysis excluding women who had received anticoagulation was limited by
the small number of women with PE (n = 4). The health economic analysis showed that a strategy of
scanning all women with a suspected PE accrued more QALYs and incurred fewer costs than any selective
strategy based on a clinical decision rule and was therefore the dominant strategy.
Limitations: The findings apply specifically to the diagnostic assessment of women with a suspected PE in
secondary care.
Conclusions: Clinical features, decision rules and biomarkers do not accurately, effectively or
cost-effectively select pregnant or postpartum women with a suspected PE for diagnostic imaging.
Future work: New diagnostic technologies need to be developed to detect PE in pregnancy.
Trial registration: Current Controlled Trials ISRCTN21245595.
Funding details: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 22, No. 47. See the NIHR Journals Library website for further project information.
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Plain English summary
A blood clot in the lung is a potentially fatal complication of pregnancy that can be difficult to diagnose.Symptoms that suggest a blood clot, such as chest pain or breathlessness, are common in pregnancy.
Diagnosis usually requires a scan that involves giving a small dose of radiation to the mother and possibly
to the baby.
A clinical decision rule uses information from the woman’s medical history and examination to estimate
the risk that she has a blood clot. Blood tests that are abnormal in people with blood clots can perform a
similar role. We wanted to find out whether or not clinical decision rules or blood tests could be used to
decide which women with a suspected blood clot should have a scan.
We collected information from 181 pregnant or recently pregnant women with blood clots in their lungs
and 259 women without blood clots who had been investigated in hospital for a suspected blood clot.
We also collected blood samples from 36 women with blood clots in their lungs or legs, and 247 with
no blood clot. We found that the blood clots were very difficult to diagnose without a scan. None of the
clinical decision rules or blood tests was able to reliably determine which women had a blood clot. The
economic analysis showed that scanning every woman with a suspected blood clot was a worthwhile use
of NHS resources. This is because the risks of scanning are very small, whereas the benefits of detecting
and treating blood clots are very large.
Clinical decision rules and blood tests should not be used to select which women with a suspected blood
clot in pregnancy have a scan. Future research needs to develop new ways of diagnosing blood clots
in pregnancy.
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Scientific summary
Background
Pulmonary embolism (PE) is a leading cause of death in pregnancy and post partum. Symptoms suggesting
PE are very common in pregnancy and post partum. As a consequence, many pregnant and postpartum
women undergo radiological investigation for a suspected PE with a low yield of positive diagnosis. Clinical
decision rules use features of the patient history and examination in a structured manner to estimate
the probability of disease. A number of biomarkers are known to be increased in the presence of PE.
Clinical decision rules or biomarkers could be used to select women with suspected PE for radiological
investigation or discharge without imaging.
Objectives
We aimed to estimate the diagnostic accuracy, effectiveness and cost-effectiveness of strategies (including
clinical decision rules) for selecting pregnant or postpartum women with a suspected PE for imaging,
and determine the feasibility and value of information of further prospective research.
Our specific objectives were to:
l use expert consensus to derive three new clinical decision rules (with different trade-offs between
sensitivity and specificity) for pregnant and postpartum women with a suspected PE
l estimate the diagnostic accuracy of clinical variables, our expert-derived clinical decision rules, existing
clinical decision rules [Wells’s PE criteria, Geneva score and a PE rule-out criteria (PERC)] and the D-dimer
measurement in pregnant and postpartum women with suspected PE
l use a statistical analysis of women with a diagnosed or suspected PE to derive a new clinical decision
rule for pregnant and postpartum women with suspected PE
l explore the potential diagnostic value of biomarkers for PE in pregnant and postpartum women
l determine the feasibility of using a prospective cohort design to validate a new clinical decision rule
or biomarker
l estimate the effectiveness of different strategies, in terms of adverse outcomes from venous
thromboembolism (VTE), bleeding and radiation exposure, and cost-effectiveness, measured as the
incremental cost per quality-adjusted life-year (QALY)
l estimate the value of information associated with further research.
Methods
The study involved (1) an expert consensus study to develop three new clinical decision rules; (2) a case–control
study of women with a diagnosed PE identified through the UK Obstetric Surveillance System (UKOSS)
research platform and women with a suspected PE recruited from emergency departments and maternity
units at 11 prospectively recruiting sites; (3) a biomarker study involving the prospectively recruited women
and additional women with diagnosed deep-vein thrombosis (DVT); and (4) decision-analysis modelling of
effectiveness, cost-effectiveness and value of information.
The study population included (1) any pregnant or postpartum women with a diagnosed PE who had
presented with suspected PE to a hospital reporting to the UKOSS research platform; (2) pregnant and
postpartum women presenting with suspected PE to 11 prospectively recruiting sites; and (3) women with
DVT diagnosed at the prospectively recruiting sites. We excluded women who required resuscitation at
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presentation from all groups and those who were unable to consent or who had an existing diagnosis of
PE from the prospectively recruited group.
The nominated clinician for UKOSS and the research nurse/midwife at prospectively recruiting sites
collected data detailing potential clinical predictors, blood tests results, diagnostic imaging, treatment and
adverse events. Research nurses/midwives also collected a blood sample from women with suspected PE or
diagnosed DVT at the prospectively recruiting sites, and reviewed hospital records at 30 days. Prospectively
recruited women were then sent a questionnaire to record adverse events, health-care use and health
utility. Two independent assessors, blind to clinical predictors and blood results, classified participants as
having PE using diagnostic imaging results and details of treatments and adverse events. The primary
analysis was limited to women with PE diagnosed by imaging or post-mortem examination, and women
with PE ruled out after imaging. Secondary analyses explored the impact of including women with clinically
diagnosed PE or PE ruled out without imaging, and the impact of excluding subsegmental PE.
Blood samples were centrifuged, stored and then transported to Guy’s and St Thomas’ NHS Foundation
Trust for analysis using the following assays: D-dimer [enzyme-linked immunosorbent assay (ELISA)],
D-dimer [Innovance (Siemens Healthcare Diagnostics Products GmbH, distributed by Sysmex UK Ltd,
Milton Keynes, UK)], plasmin–antiplasmin, prothrombin fragment 1 + 2 (PF 1 + 2), thrombin generation,
prothrombin time, activated partial thromboplastin time (APTT), Clauss fibrinogen, soluble tissue factor,
troponin I, B-type natriuretic peptide (BNP), C-reactive protein (CRP) and mid-regional pro-atrial natriuretic
peptide (MRproANP).
The sample size was ultimately determined by the incidence of a diagnosed and suspected PE, but we
estimated that over 18 months we would identify 150 women with a diagnosed PE and 250 women with
a suspected PE, resulting in around 155 patients and 245 controls. This would allow the estimation of
sensitivity or specificity of 90% with standard errors (SEs) of around 2.5% and 2.0%, respectively. We
increased the planned sample size after starting recruitment to ensure that adequate numbers would be
included in the primary analysis.
Logistic regression was used to identify associations between clinical predictors and a PE diagnosis. The
diagnostic performance of existing clinical decision rules (Wells’s PE criteria, simplified revised Geneva score
and PERC rule) and those developed by expert consensus was assessed by constructing receiver operating
characteristic (ROC) curves, calculating the area under the curve (AUC) and calculating the sensitivity and
specificity at key decision-making thresholds. The diagnostic performance of biomarkers was assessed by
comparing distributions in women with and without PE, constructing ROC curves, calculating the AUC and
calculating sensitivity and specificity at a predefined threshold based on the 99th percentile for a normal
population.
Decision-analysis modelling was used to estimate the costs incurred and the expected outcomes from
thromboembolism, bleeding and radiation exposure if a hypothetical cohort of pregnant or postpartum
women based on the study population was investigated for suspected PE using different strategies,
including no imaging, selective imaging and imaging for all. Outcomes were modelled to estimate the
QALYs accrued by each strategy and the incremental cost per QALY gained by each strategy compared
with the next most effective alternative.
Results
The expert consensus study derived three clinical decision rules for use in pregnant and postpartum
women with a suspected PE: a primary rule that provided an optimal balance of sensitivity and specificity,
a sensitive rule that maximised sensitivity at the expense of specificity and a specific rule that maximised
specificity at the expense of sensitivity.
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We identified 198 women with a diagnosed PE who met our inclusion criteria, of whom 163 had a PE
confirmed by imaging or post-mortem examination and were included in the primary analysis. We identified
324 women with suspected PE, of whom 18 had PE confirmed by imaging and 259 had PE ruled out after
imaging. The primary analysis therefore involved 181 women with PE and 259 women without PE.
Univariable logistic regression showed that the number of previous pregnancies beyond 24 weeks’ gestation
(p = 0.017), surgery (including caesarean section) in the previous 4 weeks (p = 0.001), no history of varicose
veins (p = 0.045), no long-haul travel during pregnancy (p = 0.006), receiving thromboprophylaxis (p < 0.001),
higher temperature (p = 0.003), lower oxygen saturation (p < 0.001), overall diagnostic impression, suggesting
PE using a strict interpretation (p < 0.001), PE-related chest radiograph abnormality (p = 0.01) and non-PE-
related chest radiograph abnormality (p = 0.001) were associated with PE. All other clinical features showed
no significant association with PE.
The AUC and sensitivity and specificity at the usual recommended threshold for the clinical decision rules
were 0.626, 60.9% and 58.5% for the primary consensus rule; 0.620, 95.9% and 3.5% for the sensitive
consensus rule; 0.589, 36.1% and 78.3% for the specific consensus rule; 0.621, 67.5% and 51.9% for
the PERC score; 0.579, 44.4% and 63.6% for the simplified Geneva score; 0.577, 49.0% and 61.7% for
Wells’s PE criteria using a permissive interpretation of diagnostic impression; and 0.732, 37.6% and 89.5%
for Wells’s PE criteria using a strict interpretation of diagnostic impression.
D-dimer measurements were recorded as part of routine care for 44 out of 198 (22%) women with
a diagnosed PE and 156 out of 324 (48%) women with a suspected PE. The primary analysis, using
results from 43 women with PE and 125 without PE, showed that sensitivity and specificity were 88.4%
[95% confidence interval (CI) 74.1% to 95.6%] and 8.8% (95% CI 4.7% to 15.6%) using the hospital
laboratory threshold, and 69.8% (95% CI 53.7% to 82.3%) and 32.8% (95% CI 24.8% to 41.9%) using
predefined gestation-specific thresholds.
Multivariable analysis showed that the most accurate model used previous VTE, long-haul travel during
pregnancy, multiple pregnancy, oxygen saturation (as a continuous variable), surgery in the previous
4 weeks, temperature (as a continuous variable) and PE-related chest radiograph abnormality to predict PE
with an AUC of 0.724 (95% CI 0.669 to 0.779). The ROC curve shows that specificity would have to be as
low as 20% to achieve a level of sensitivity (> 95%) that was acceptable to allow imaging to be avoided.
We therefore did not proceed to internal validation or attempt to make the model more clinically credible
or usable.
The optimal model developed by recursive partitioning used body mass index (BMI), trimester, oxygen
saturation and heart rate. The AUC was 0.657 (95% CI 0.611 to 0.703) and the threshold that provided a
level of sensitivity of > 95% had a corresponding specificity of 5%.
Usable blood samples were taken from 18 women with diagnosed DVT and 310 women with suspected
PE, of whom 18 had PE confirmed by imaging and 247 had PE ruled out after imaging and were included
in the primary analysis. Mean biomarker levels significantly differed between women with and without PE
only for Clauss fibrinogen (p = 0.007), ELISA D-dimer (p = 0.001), Innovance D-dimer (p = 0.004), thrombin
generation lag time (p < 0.001), thrombin generation time to peak (p = 0.001) and plasmin antiplasmin
(p = 0.004). The AUC for each biomarker was as follows: 0.669 (95% CI 0.570 to 0.768) for APTT, 0.549
(95% CI 0.453 to 0.645) for BNP, 0.542 (95% CI 0.445 to 0.639) for CRP, 0.589 (95% CI 0.476 to 0.701)
for Clauss fibrinogen, 0.668 (95% CI 0.561 to 0.776) for the ELISA D-dimer, 0.651 (95% CI 0.545 to 0.758) for
the Innovance D-dimer, 0.524 (95% CI 0.418 to 0.630) for MRproANP, 0.562 (95% CI 0.462 to 0.661) for PF
1+ 2, 0.639 (95% CI 0.536 to 0.742) for plasmin–antiplasmin, 0.613 (95% CI 0.508 to 0.718) for prothombin
time, 0.702 (95% CI 0.598 to 0.806) for thrombin generation lag time, 0.559 (95% CI 0.437 to 0.681) for
thrombin generation endogenous potential, 0.596 (95% CI 0.478 to 0.715) for thrombin generation peak,
0.655 (95% CI 0.541 to 0.769) for thrombin generation time to peak, 0.531 (95% CI 0.424 to 0.638)
for tissue factor and 0.597 (95% CI 0.499 to 0.695) for troponin. The ROC curve analysis showed that only
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thrombin generation lag time had any potential to rule out PE with sufficient sensitivity while achieving
meaningful specificity, with a sensitivity of 97% and a specificity of 25% at the threshold that optimised
sensitivity. The repeat analysis excluding women who had received anticoagulation was limited by the small
number of women who had PE (n = 4).
The study recruited women with suspected PE (prevalence of 7.1%) at a rate of 1.7 women per site
per month. This suggests that a prospective cohort study would require 50 sites to recruit for 2 years to
achieve a sample size of 2040, including 145 women with PE, which would be sufficient to estimate the
sensitivity with acceptable precision.
The health economic analysis showed that a strategy of scanning all women with suspected PE accrued
more QALYs and incurred fewer costs than any selective strategy based on a clinical decision rule, and
was therefore the dominant strategy. This finding was robust in the sensitivity analysis and the scenario
analysis exploring assumptions in the model. A threshold analysis showed that a clinical decision rule
to select women for imaging would need to have a sensitivity exceeding 97.5% to be cost-effective
compared with the non-selective use of scanning. The value-of-information analysis showed that the value
of conducting further research into parameters used in the economic model was likely to be below the
cost of conducting further research into any subset of feasible parameters.
Conclusions
We were unable to identify any clinical decision rule or biomarker that could be used to rule out PE in pregnant
and postpartum women with acceptable sensitivity while achieving worthwhile specificity. Decision-analysis
modelling showed that a strategy of non-selective scanning for all women dominated selective strategies based
on decision rules. We found that many clinical features thought to be diagnostically useful for PE showed either
no association or a counter-intuitive association with the absence of PE. This may be explained by the selection
of women for investigation in secondary care. Those with risk factors for PE or clinical features suggesting PE
may be more likely to be referred or to self-present for investigation. The prevalence of PE in those with
suspected PE (7.1% overall and 6.5% in the primary analysis population) was higher than suggested by previous
data, indicating that, potentially, the NHS is already selecting an appropriate population for hospital investigation.
The accuracy of the biomarkers is likely to have been undermined by the receipt of anticoagulation prior
to sampling, but the removal of samples from women who had received anticoagulation left too few
women with PE for a meaningful analysis. This highlights a significant practical problem in testing and
using biomarkers when guidelines recommend thromboprophylaxis for many women and early use of
anticoagulation if PE is suspected.
Our findings do not support the use of clinical decision rules and biomarkers (including D-dimer) in
selecting women with suspected PE for imaging. We cannot conclude that all women should receive
imaging, as a proportion of the study cohort with suspected PE did not receive imaging and we found no
evidence of missed PE. However, a low threshold for scanning is likely to be appropriate given the costs
and risks of misdiagnosis highlighted in the decision-analysis modelling.
We have shown that a prospective cohort study to derive or validate a clinical decision rule or biomarker
would be feasible, albeit would require a large number of sites (more than one-quarter of all maternity
units in the UK) and substantial resources. However, the accuracy of decision rules and biomarkers
reported in our study is insufficient to justify a large prospective cohort study to derive a new decision rule
or test existing decision rules or biomarkers. Future research efforts would be better directed at developing
new biomarkers or alternative diagnostic techniques.
The current Royal College of Obstetricians and Gynaecologists guidance suggests that women should be
given information about the risks and benefits of investigation and involved in decision-making. Our
SCIENTIFIC SUMMARY
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decision-analysis model has identified data sources and methods for weighing the relative risks and
benefits of imaging, but has also highlighted the complexity of decision-making. Future research could
be used to develop better ways of presenting information regarding the relative risks and benefits of
investigation for suspected PE in pregnancy and post partum.
Trial registration
This trial is registered as ISRCTN21245595.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background and rationale
Pregnant and postpartum women are at an increased risk of developing venous thromboembolism (VTE),
which may involve deep-vein thrombosis (DVT) (a blood clot in the veins of a limb, which may be clinically
silent or cause limb pain and/or swelling) or a pulmonary embolism (PE) (a blood clot in the artery of the
lungs, causing respiratory symptoms such as shortness of breath and chest pain).
Pulmonary embolism is a leading cause of death in pregnancy and post partum, affecting women who would
otherwise expect to have a long life expectancy in full health. The outcome for the fetus is dependent on the
outcome for the mother, so maternal mortality, which is currently estimated at 0.85 [95% confidence interval
(CI) 0.52 to 1.32] per 100,000 maternities,1 and morbidity associated with PE has inevitable consequences
for fetal mortality and morbidity. Women with an appropriately diagnosed and treated PE are at a low risk
of experiencing adverse outcomes, so accurate diagnosis can result in substantial benefits. However, the
investigations used to diagnose PE [diagnostic imaging with ventilation–perfusion (VQ) scanning or
computerised tomography (CT) pulmonary angiography (CTPA)] carry risks of radiation exposure, risk of
reaction to contrast media and false-positive diagnoses, are inconvenient for patients and incur costs for
health services. Clinicians investigating suspected PE in pregnant and postpartum women therefore need
to choose between risking the potentially catastrophic consequences of a missed diagnosis if imaging
is withheld and risking iatrogenic harm to women without PE if imaging is overused.
Pregnant and postpartum women with symptoms suggesting PE could be selected for diagnostic imaging
on the basis of clinical features or blood tests (biomarkers). A previous history or family history of VTE,
immobilisation, surgery and a number of medical and obstetric complications are known to be associated
with an increased risk of VTE.2 Abnormal observations, such as a rapid heart rate, rapid respiratory rate or
reduced peripheral oxygen saturation, may be caused by PE, although these may be caused by other
pathologies or a normal physiological response to pregnancy.
Individual clinical features are unlikely to have sufficient accuracy to select women for diagnostic imaging,
but could be combined to form a clinical decision rule (CDR). This uses a number of clinical features in a
structured manner to generate an estimate of the clinical risk of PE or a rule to determine whether or not
PE should be investigated. In the general (non-pregnant) population with suspected PE, Wells’s score3 and
revised Geneva score4 have been developed to estimate the risk of developing PE, whereas the PE rule-out
criteria (PERC) rule5 has been developed to select patients for investigation (details of the scores and the
rule are provided in Chapter 3). These scores and the rule have been extensively validated in the general
population with a suspected PE, but the differences between the pregnant and non-pregnant populations
mean that findings cannot be automatically extrapolated to the pregnant or postpartum population.
A number of biomarkers have been suggested for use in the PE diagnosis but, to date, only the D-dimer
measurement has been used in routine clinical practice. Plasma D-dimers are specific cross-linked fibrin
derivatives produced when fibrin is degraded by plasmin, with elevated levels indicating thrombolysis. They
are elevated in VTE but also in other conditions such as pregnancy, pre-eclampsia, infections, malignancy
and surgery. The D-dimer threshold for positivity is usually set to optimise sensitivity (> 95%) at the
expense of specificity. In the general population with a suspected PE, the D-dimer measurement has
been recommended alongside a clinical risk score (such as Wells’s score) as a way of ruling out PE in
low-risk patients without the need for diagnostic imaging. The lack of specificity in the pregnant and
postpartum population means that separate validation in this population is required, perhaps using a
pregnancy-specific threshold for positivity. There is some evidence that using a higher threshold for
positivity can improve the D-dimer specificity in pregnancy without compromising sensitivity.6
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In summary, although clinical features (structured as a CDR) and the D-dimer measurement are widely
used to select patients with a suspected PE for diagnostic imaging in the general population with a
suspected PE, evidence of their performance in the relevant population is required before they can be
advocated for use in pregnant or postpartum women with a suspected PE.
Literature review
Diagnostic studies of pregnant or postpartum women undergoing imaging for a suspected PE could
provide evidence to support the use of clinical features, decision rules or biomarkers to select women for
imaging if they compare these index tests to an imaging reference standard. They could also provide
estimates of the prevalence of PE in the investigated population to inform the design of future studies.
In January 2014, we systematically searched electronic databases for diagnostic studies of pregnant or
postpartum women undergoing imaging for a suspected PE7 and identified 11 relevant articles, along with
a conference abstract and a paper in press. We have since updated the literature searches and have
identified an additional four papers, along with the published version of the paper in press.8 These are
outlined in Table 1.
In addition to these studies of pregnant and postpartum women with a suspected PE, Kline et al.25
undertook a systematic review of studies of people with suspected PE, which included pregnant and
postpartum women. The authors identified 17 studies including 25,399 patients, of whom 506 (2%) were
pregnant, with a 4.1% (95% CI 2.6% to 6.0%) prevalence of PE.
The analysis reported by Kline et al.25 and 10 of the studies identified by our review reported the overall
prevalence of PE, which was generally found to be low when compared with the non-pregnant population,
but did not examine the diagnostic accuracy of clinical features, CDRs or the D-dimer measurement. The
remaining seven studies were mostly small and had a low prevalence of PE, and thus had limited power
to estimate diagnostic accuracy (especially sensitivity) or detect an association with a reference standard
diagnosis of PE.
Cahill et al.12 found that chest pain and low oxygen saturation were associated with a diagnosis of PE, but
other features [dyspnoea, tachycardia, Alveolar–arterial (A–a) gradient] showed no evidence of association.
Deutsch et al.15 also found that chest pain showed some association with a diagnosis of PE, while other
features (dyspnoea, heart rate, respiratory rate, blood pressure, oxygen saturation, A–a gradient) did not.
Bourjeily et al.18 found no association between dyspnoea, chest pain, pleuritic chest pain, haemoptysis, cough,
DVT signs, wheeze, pleural rub, heart rate, respiratory rate or systolic blood pressure and a diagnosis of PE.
Two studies have suggested that the modified Wells’s score may be useful in pregnant or postpartum
women. O’Connor et al.17 reported that a modified Wells’s score of ≥ 6 units (meaning that PE is likely)
has a sensitivity of 100% and a specificity of 90% for PE, whereas Cutts et al.8 reported a sensitivity of
100% (95% CI 40% to 100%) and a specificity of 60% (52% to 67%). The wide CIs for sensitivity mean
that further research is required. Other CDRs, such as the Geneva score and the PERC rule, have not yet
been tested in pregnant or postpartum women with a suspected PE.
Studies of the D-dimer measurement in pregnant and postpartum women8,13,16,17 suggest that high levels
of positivity at conventional thresholds limit the diagnostic value of this test. However, indirect evidence
from studies of the D-dimer measurement for suspected DVT in pregnancy suggests potential diagnostic
value. Chan et al.26 reported 100% sensitivity (95% CI 77% to 100%) and 60% specificity (95% CI 52%
to 68%) for the qualitative SimpliRED (Agen Biomedical, Brisbane, QLD, Australia) D-dimer in suspected
DVT and, although another study of five commercially available assays6 reported specificities ranging from
6% to 23%, further analysis suggested that using a higher threshold for positivity could improve sensitivity
without compromising specificity.
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
TABLE 1 Diagnostic studies of pregnant or postpartum women with a suspected PE
Study (year of
publication) Country Population Index tests Reference standard Main findings
Balan et al. (1997)9 UK 82 pregnant women, one
hospital, 5 years
None VQ scan VQ scan: 31 (38%) normal, 19 (23%) low probability,
14 (17%) intermediate, 18 (22%) high probability
Chan et al. (2002)10 Canada 113 pregnant women, two
hospitals, 4 and 10 years
None VQ scan VQ scan: 83 (73.5%) normal, 28 (24.8%)
non-diagnostic, two (1.8%) high probability
Scarsbrook et al.
(2007)11
UK 94 pregnant women, one
hospital, 5 years
None VQ scan VQ scan: 89 (92%) normal, seven (7%)
non-diagnostic, one (1%) high probability
Cahill et al. (2009)12 USA 304 pregnant or postpartum
women, one hospital, 5 years
Clinical featuresa 108 CTPA and 196 VQ
scan
CTPA: 18 (5.9%) diagnosed PE
Clinical features: low oxygen saturation and chest pain
predicted PE, other features did not
Damodaram et al.
(2009)13
UK 37 pregnant women, one
hospital, 4 years
D-dimer VQ scan VQ scan: 13 (35%) low probability, 24 (65%)
intermediate or high probability
D-dimer: 73% sensitivity, 15% specificity
Shahir et al. (2010)14 USA 199 pregnant women, one
hospital, 8 years
None 106 CTPA and 99 VQ
scan
CTPA: 4/106 (3.7%) PE
VQ scans: zero high probability, two (2%) intermediate
probability, 19 (19%) low probability, 14 (14%) very
low probability, 63 (64%) normal, one (1%) inconclusive
Deutsch et al. (2010)15 USA 102 pregnant or postpartum
women, one hospital, 7 years
Clinical featuresb CTPA CTPA: 13/102 (13%) PE
Clinical features: only chest pain predicted PE
Hassanin et al. (2011)16 Egypt 60 postpartum women, one
hospital, years not reported
D-dimer CTPA CTPA: four (6.6%) PE
D-dimer: positive in all patients
O’Connor et al. (2011)17 Ireland 125 pregnant or postpartum
women, one hospital, 5 years
Modified Wells’s score
D-dimer
Arterial blood gas
measurement with PE
ECG
CTPA CTPA: 5/103 (5%) PE
Modified Wells’s score: 100% sensitivity, 90%
specificity
D-dimer: 0% sensitivity, 74% specificity
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TABLE 1 Diagnostic studies of pregnant or postpartum women with a suspected PE (continued )
Study (year of
publication) Country Population Index tests Reference standard Main findings
Bourjeily et al. (2012)18 USA 343 pregnant women, one
hospital, 5 years
Clinical featuresc CTPA CTPA: eight (2.3%) PE
Clinical features: no association found between clinical
features and PE
Abele and Sunner
(2013)19
Canada 74 pregnant women, three
hospitals, 1.5 years
None Perfusion scan and CTPA
if abnormal
Perfusion scan: 61 (82.4%) normal perfusion,
13 (17.6%) abnormal – one (1.4%) PE on CTPA
Nijkeuter [(2013)
abstract]20
The
Netherlands
149 pregnant women, three
hospitals, 9 years
None CTPA CTPA: six (4.2%) PE, eight (5.6%) inconclusive,
129 (90.2%) normal
Cutts et al. (2014)8 UK and
Australia
183 pregnant women, two
hospitals, 4 years
Modified Wells’s score
D-dimer
VQ scan VQ scan: four (2%) high probability, six (3%)
non-diagnostic, 173 (95%) normal
D-dimer: 48/51 positive
Modified Wells’s score predicted PE
Browne et al. (2014)21 Ireland 124 pregnant and postpartum
women, one hospital, 3 years
None CTPA CTPA: 1/70 (1.4%) PE in pregnant women,
5/54 (9.3%) PE in postpartum women
Bajc et al. (2015)22 Sweden 127 pregnant women, one
hospital, 5 years
None VQ SPECT VQ SPECT: 11/127 (9%) PE
Jordan et al. (2015)23 USA 50 pregnant or postpartum
women, one hospital, 4 years
None CTPA CTPA: 1/50 (2%) PE
Ramsay et al. (2015)24 UK 127 pregnant women, one
hospital, 3 years
None VQ scan VQ scan: 2/127 (1.6%) PE
ECG, electrocardiogram; VQ SPECT, ventilation–perfusion single photon emission computed tomography.
a Chest pain, dyspnoea, heart rate, oxygen saturation and Alveolar–arterial gradient.
b Chest pain, dyspnoea, heart rate, respiratory rate, blood pressure, oxygen saturation and Alveolar–arterial gradient.
c Chest pain, dyspnoea, pleuritic chest pain, haemoptysis, cough, DVT signs, wheeze, pleural rub, heart rate and respiratory rate, systolic blood pressure.
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4
In summary, diagnostic studies of pregnant and postpartum women with a suspected PE currently provide
insufficient evidence to support their use as a way of selecting women for diagnostic imaging.
Risk factors for pulmonary embolism in pregnancy and post partum
Stronger evidence exists relating to predicting the risk of a pregnant or postpartum woman developing PE
(as opposed to diagnosing PE in a pregnant or postpartum woman with suspected PE). Epidemiological
studies have compared women who developed PE in pregnancy or post partum with a control group
without PE to identify the risk factors for developing PE in pregnancy. Knight et al.27 compared women
with antenatal PE identified through the UK Obstetric Surveillance System (UKOSS) research platform
with pregnant control group participants and showed that multiparity and body mass index (BMI) were
independent predictors of developing PE. Kane et al.28 used patients identified by the Scottish Morbidity
Record 2 to show that women aged > 35 years, with previous VTE, pre-eclampsia, antenatal haemorrhage
or postnatal haemorrhage were more likely to develop PE than those without these characteristics.
Henriksson et al.29 showed that VTE is associated with pregnancy following in vitro fertilisation. Sultan
et al.30 linked primary (Clinical Practice Research Datalink) and secondary (Hospital Episode Statistics)
care records to show that BMI, complications of pregnancy (pre-eclampsia, antenatal or postnatal
haemorrhage, diabetes mellitus, hyperemesis), comorbidities (varicose veins, cardiac disease, hypertension)
and recent hospital admission were associated with an increased risk of developing PE. A similar analysis
in postpartum women30 showed that smoking, varicose veins, comorbidities, pre-eclampsia/eclampsia,
diabetes mellitus, parity, postpartum haemorrhage, caesarean section, stillbirth, postpartum infection,
maternal age, BMI and infant birthweight were predictors of VTE included in a clinical prediction model.
These risk factors for developing PE in pregnancy and post partum could be used to select women with
suspected PE for imaging. However, there are two reasons why risk factors may not be diagnostically useful.
First, guidelines2 recommend using thromboprophylaxis in pregnancy and post partum to attenuate the
thromboembolic risk associated with recognised risk factors. Second, public and professional awareness of
risk factors may prompt a lower threshold for presentation and referral to diagnostic services when risk
factors are present. The use of risk factors to select women for imaging therefore needs evaluation in a
population with suspected PE.
Current practice
Guidelines from the Royal College of Obstetricians and Gynaecologists (RCOG)2 recommend that pregnant
or postpartum women with a suspected PE should receive diagnostic imaging with VQ scan or CTPA. The
guidelines recommend against the use of D-dimer testing and highlight the lack of evidence to support the
use of clinical probability assessment in pregnancy. Guidelines from the American Thoracic Society31 also
recommend the non-selective use of diagnostic imaging, whereas guidelines from the European Society of
Cardiology32 suggest a possible role for D-dimer in selecting patients.
These recommendations for pregnant and postpartum women contrast with guidelines from the National
Institute for Health and Care Excellence (NICE)33 and the American College of Chest Physicians34 for the
general (non-pregnant) population with a suspected PE, for whom diagnostic imaging is selectively used
based upon structured clinical assessment and D-dimer measurement.
The differences in thresholds for investigation are reflected in the differences in the prevalence of PE in the
investigated populations. In a review of studies of patients investigated for a suspected PE, Kline et al.25
reported a prevalence of 4.1% for pregnant patients compared with 12.4% for non-pregnant patients.
Most of the studies in our review reported a prevalence of PE below 10%.
DOI: 10.3310/hta22470 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 47
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
Need for further research
Existing research suggests that clinical assessment, CDRs and/or D-dimer measurement could be used to
select women for imaging, but more precise estimates of diagnostic value are needed before a selective
strategy can be recommended. Furthermore, the appropriate use of clinical assessment or biomarkers to
select women for imaging can be determined only by explicitly weighing the risks, costs and benefits of
different strategies.
Research is required to improve our estimates of the diagnostic accuracy of clinical assessment and biomarkers.
A prospective cohort study is in theory the best method for measuring accuracy and developing and validating
a CDR, but it would be severely limited by the low incidence of PE in pregnancy and the low prevalence of PE
in women presenting with a suspected PE. The incidence of VTE (DVT and PE combined) is cited to be 1 in
1000 pregnancies.2 A recent meta-analysis35 supports this estimate and reports a pooled incidence of PE of
0.4 per 1000 pregnancies, with individual study estimates35 ranging from 0.1 to 0.67 per 1000 pregnancies.
Estimates from UK studies are at the lower end of this range, with data from UKOSS27 suggesting an incidence
of 0.13 antenatal PE per 1000 pregnancies and data from the Scottish Morbidity Record 228 suggesting 0.2
antenatal and postnatal PE per 1000 pregnancies. Meanwhile, most of the studies in our literature review
reported a rate of one or two patients with PE per hospital per year.
Diagnostic sensitivity is the key determinant of the acceptability of any strategy to select women for
diagnostic imaging. Patients and clinicians need to know that sensitivity has been estimated with sufficient
precision to ensure that women with a negative diagnostic assessment have a low risk of developing PE.
The precision of estimates of sensitivity depends on the number of patients recruited with PE. Using a
cohort design to accrue sufficient numbers of participants with PE to estimate sensitivity with sufficient
precision would be prohibitively expensive and difficult to deliver.
A case–control design offers an alternative when the low prevalence of disease makes a cohort design
unfeasible or unacceptably inefficient. The identification of women with the diagnosis of interest (PE in
pregnancy or post partum) allows us to recruit sufficient numbers with PE to make reasonably precise
estimates of sensitivity. The case–control design carries an increased risk of bias compared with that of the
cohort design,36 but this can be reduced by ensuring that the control group is a representative sample of
women with suspected PE who have negative imaging and that the patients are a representative sample of
women presenting with a suspected PE who are diagnosed and treated for PE.
Existing decision rules may not be appropriate to the pregnant and postpartum population, but can be
tested in a case–control or cohort study. A decision rule for the pregnant and postpartum population
could be derived from a case–control or cohort study, but would need validation in a new study. Expert
consensus provides a relatively quick and cheap method for deriving a CDR that could then be validated in
a case–control or cohort study.
Secondary research in the form of decision-analysis modelling is required to explicitly weigh the costs, risks and
benefits of different strategies for selecting women for diagnostic imaging. This allows us to estimate how
diagnostic tests lead to differences in clinically meaningful outcomes. Decision-analysis modelling is particularly
important in this situation, when the best method of estimating diagnostic parameters (a cohort study) may
not be feasible. Decision-analysis modelling allows us to explore the potential impact of uncertainty on our
findings. A value-of-information analysis can then be undertaken to determine whether or not further research
would be worthwhile to obtain more accurate or precise estimates of diagnostic accuracy.
INTRODUCTION
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Aims and objectives
We aimed to estimate the diagnostic accuracy, effectiveness and cost-effectiveness of strategies (including
CDRs) for selecting pregnant or postpartum women with a suspected PE for imaging, and to determine
the feasibility and value of information of further prospective research.
Our specific objectives were to:
1. use expert consensus to derive three new CDRs (with different trade-offs between sensitivity and
specificity) for pregnant and postpartum women with a suspected PE
2. estimate the diagnostic accuracy of clinical variables, our expert-derived CDRs, existing CDRs (Wells’s score,
Geneva score and PERC score) and D-dimer in pregnant and postpartum women with a suspected PE
3. use a statistical analysis of women with a diagnosed or suspected PE to derive a new CDR for pregnant
and postpartum women with a suspected PE
4. explore the potential diagnostic value of biomarkers for PE in pregnant and postpartum women
5. determine the feasibility of using a prospective cohort design to validate a new CDR or biomarker
6. estimate the effectiveness, in terms of adverse outcomes from VTE, bleeding and radiation exposure,
and the cost-effectiveness, measured as the incremental cost per quality-adjusted life-year (QALY),
of different strategies
7. estimate the value of information associated with further research.
Overview of the study design
We undertook an expert consensus study to address objective 1. A Delphi study was used to identify and
select potential clinical predictors and a consensus group was used to create the CDRs.
We undertook a case–control study to address objectives 2 and 3. The design should strictly be described
as a prospective cohort study of pregnant or postpartum women with a suspected PE augmented with a
retrospective cohort of pregnant or postpartum women with a diagnosed PE. However, for the purposes
of brevity and to avoid concerns that using the term ‘cohort study’ may under-represent the risk of bias
associated with the design, we will use the term ‘case–control study’ throughout this report.
Women with a suspected PE were identified through a prospective study of pregnant or postpartum women
presenting to hospital with a suspected PE. Women with a diagnosed PE were retrospectively identified
through UKOSS, a UK-wide obstetric surveillance system that has been set up to conduct research on
uncommon disorders of pregnancy. Details of the UKOSS methods are available at www.npeu.ox.ac.uk/
ukoss/methodology. The cases involved women with a diagnosed PE and a small number of women with a
suspected PE who ultimately had a diagnosed PE, whereas the control participants were women with a
suspected PE who had PE ruled out.
We undertook a biomarker study to address objective 4. The women with a suspected PE from the
case–control study and any pregnant or postpartum woman diagnosed with DVT at the participating
hospitals were asked to provide blood samples for analysis. The inclusion of women with diagnosed
DVT was planned as an efficient way of increasing the number in the cohort with VTE. There are good
pathophysiological reasons for expecting candidate biomarkers to have similar sensitivity for DVT and PE,
and studies of D-dimer measurement in the non-pregnant population have shown similar sensitivity and
specificity for DVT and PE.37
We addressed objective 5 by determining recruitment rates in the prospective study of women with a
suspected PE and determining the prevalence of PE in this population. This would allow us to estimate the
potential size and duration of a cohort study powered to estimate the sensitivity of a CDR or biomarker
with adequate precision.
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We developed a decision-analysis model to address objectives 6 and 7. It was designed to estimate the
costs incurred and the expected outcomes from thromboembolism, bleeding and radiation exposure
if a hypothetical cohort of pregnant or postpartum women were investigated for a suspected PE using
different strategies with a range of sensitivities and specificities, varying from no testing/treatment to
imaging for all. The diagnostic accuracy of the strategies was estimated from the case–control study and
other parameters were estimated from the systematic literature reviews. Clinical outcomes were modelled
to estimate the costs and QALYs accrued by each strategy. We then estimated the value of information
associated with further prospective research.
Health technologies being assessed
The focus of our evaluation was any health technology that can be used to select pregnant or post partum
women with a suspected PE for diagnostic imaging, including clinical features, risk factors and biomarkers,
either alone or combined to form a CDR. An initial literature review undertaken during proposal development
identified a number of potential clinical features, risk factors, biomarkers and CDRs that could be used to
select women for diagnostic imaging. These formed the basis for data collection and analysis. We specifically
ensured that we included the constituent elements of CDRs validated for use in the non-pregnant population
with a suspected PE (Wells’s score, Geneva score, PERC score and D-dimer).
We also used expert opinion in the project team to identify potential clinical predictors that were not
identified by our literature review, including other symptoms (chest pain, dyspnoea, syncope, palpitations),
other risk factors (gestational age, smoking status, family history, thrombophilia, varicose veins, intravenous
recreational drug use), examination findings (respiratory rate, blood pressure, temperature) and routine
investigations [electrocardiogram (ECG), chest radiograph].
We used the following methods to structure clinical variables into a CDR:
l existing CDRs (PERC rule, Wells’s score, Geneva score) modified to be appropriate to the pregnant and
postpartum population
l expert opinion to create up to three CDRs with varying trade-off between sensitivity and specificity that
could be tested in the case–control study population
l statistical derivation of a CDR using the case–control study population.
In terms of biomarkers, D-dimer is the only biomarker currently used in routine practice to select patients
for VTE imaging, but it is unlikely to have adequate specificity in pregnancy at conventional thresholds for
positivity. We therefore planned to examine the accuracy of D-dimer [enzyme-linked immunosorbent assay
(ELISA) and Innovance (Siemens Healthcare Diagnostics Products GmbH, distributed by Sysmex UK Ltd,
Milton Keynes, UK)] with a higher (pregnancy-specific) threshold for positivity. We also planned to evaluate
the following biomarkers: cardiac troponin I, B-type natriuretic peptide (BNP), prothrombin fragment 1 + 2
(PF 1 + 2), plasmin–antiplasmin complexes, prothrombin time (PT), activated partial thromboplastin time
(APTT), Clauss fibrinogen levels, thrombin generation, soluble tissue factor, C-reactive protein (CRP),
and mid-regional pro-atrial natriuretic peptide (MRProANP).
INTRODUCTION
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Chapter 2 Expert consensus clinical decision
rule study
Introduction
Clinical decision rules combine a number of symptoms, signs and simple investigation findings into
assessment tools to guide therapeutic or diagnostic decisions at a patient’s bedside. Effective CDRs have
the potential to standardise care, improve outcomes and increase efficiency. Consensus methodological
guidelines38 recommend that the variables in CDRs are initially determined statistically using data from a
representative sample of relevant patients. Identified variables, which appear to provide satisfactory
diagnostic accuracy for the target condition, are then tested in external samples during validation studies
to confirm their performance. Finally, the impact of CDRs on patient outcomes is evaluated in impact
studies.39 Although many statistically derived CDRs have shown excellent results, there are examples
of when clinician gestalt or CDRs based on expert clinical opinion have demonstrated equivalent or
superior accuracy.
Aims and objectives
We undertook an expert consensus study to derive three CDRs to select pregnant or postpartum women
with suspected PE to receive diagnostic imaging. We intended that one rule would be developed with
what we anticipated would be an optimal balance of sensitivity and specificity (the primary rule), another
would optimise sensitivity at the expense of specificity (the sensitive rule) and another would optimise
specificity at the expense of sensitivity (the specific rule). The consequences of the rule being false negative
(failure to diagnose PE) are clearly more serious than the consequences of the rule being false positive
(unnecessary imaging), so we anticipated that the optimal balance of sensitivity and specificity in the
primary rule would be high sensitivity with modest specificity. The sensitive rule would therefore aim to
further reduce the risk of false-negative assessments, whereas the specific rule would be specific only
relative to the primary rule.
Methods
A two-stage consensus process, guided by best-practice guidelines, was conducted to reduce biases arising
from the subjectivity of expert views, and to maximise content and face validity.40–42
In the first stage, a modified Delphi survey was conducted to identify candidate predictors of PE. Purposive
sampling was used to recruit a heterogeneous group of subjects encompassing the full spectrum of
expertise relevant to UK PE management in pregnancy. A sample size of 20 panel members was chosen in
accordance with guidelines from the Research And Development (RAND) Corporation.43 Self-completed
questionnaires were subsequently administered using a pre-piloted web-hosted questionnaire. The survey
was conducted between January and October 2016.
The classical Delphi approach was modified slightly with the replacement of an open first round with a
systematic literature review to identify possible PE predictors.7 Participants were asked to rate the predictive
value of each variable on a 1 (not predictive) to 5 (very strongly predictive) Likert scale and to justify their
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opinion in free text. A mixed-methods approach was taken to summarise each round’s findings. In
subsequent Delphi iterations, participants were provided with quantitative (percentage results and
frequency histograms) and qualitative (free-text answers grouped by theme) results of the previous
round and a summary of their previous opinions.
Up to four Delphi rounds were planned, dependent on when group agreement or stability of opinion was
achieved on at least 80% of variables. Judgements on the consensus and stability of opinion on each
variable were guided by quantitative measures of agreement (> 70% agreement for weak/strong prediction)
and changes in responses between rounds. Patient and public representatives commented on the patient
acceptability of each predictor variable generated through Delphi consultation.
Similarly, a series of four face-to-face consensus meetings of clinical Diagnosis of Pulmonary Embolism in
Pregnancy (DiPEP) co-investigators were planned. In the initial meeting, the nominal group technique
(NGT) was used to formulate the content of the three expert CDRs. This meeting was facilitated by an
independent researcher experienced in the NGT, which followed recommended principles for best practice
in developing consensus,41,42 consisting of the following steps:
l presentation of a summary of Delphi survey results
l facilitated group discussion of individual candidate variables
l initial rating round for inclusion of each variable
l facilitated discussion of rating results
l further rating and discussion rounds
l confirmation of variables with group consensus for inclusion in CDRs.
Online surveys were designed and implemented using the SmartSurvey web application (SmartSurvey Ltd,
Tewkesbury, UK). Data analysis was performed in Microsoft Excel® 2013 (Microsoft Corporation, Redmond,
WA, USA). Diagnostic accuracy metrics were calculated using R, version 3.3.2 (The R Foundation for
Statistical Computing, Vienna, Austria). Ethics approval was obtained from the University of Sheffield.
No financial incentives were offered and participants remained anonymous throughout the Delphi survey.
Results
The systematic literature review identified 45 potential variables for evaluation in the Delphi Survey,
comprising demographic, obstetric and medical characteristics; symptoms; clinical signs; and bedside
investigations.
All 20 experts invited to participate in the Delphi survey completed the first-round questionnaire. At this
stage, consensus was adjudged to have been reached on 12 out of the initial 45 variables (27%). Of these,
17 experts also participated in second and third rounds, during which consensus was obtained on a further
26 variables. At this stage, it was apparent that opinions diverged widely on the remaining seven variables
and had not been significantly influenced by feedback between rounds. Free-text responses indicated
that further convergence of opinion with additional rounds of surveying was unlikely to occur. It was
considered that further sampling would lead to declining response rates rather than more relevant findings
and the Delphi study was therefore terminated after round 3. Table 2 summarises the results of the
Delphi survey.
Twenty-four variables that were felt to be moderately or strongly predictive of PE were carried forward for
consideration in the consensus meetings. Two further variables from the Delphi survey were additionally
considered after the initial presentation of results at the request of the DiPEP clinical investigators: pleuritic
EXPERT CONSENSUS CLINICAL DECISION RULE STUDY
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chest pain (rated as weakly predictive) and active medical comorbidity (no consensus). During the initial
NGT meeting, consensus was subsequently achieved for the inclusion of 13 predictors in the final CDRs.
Variable weightings and the CDR cut-off point for each CDR (balanced, sensitive, specific) were agreed in
two subsequent facilitated roundtable meetings. The scope of the CDRs, in terms of which patients these
could be applied to, was also confirmed. The final CDRs developed are presented in Table 3.
Discussion
We have used expert consensus to develop three CDRs for the purpose of selecting pregnant or postpartum
women with a suspected PE for imaging. The primary rule is intended to achieve an appropriate balance
between sensitivity and specificity, whereas the sensitive and specific rules prioritise sensitivity and specificity,
respectively. These rules have been developed for testing in the DiPEP study and are not ready for clinical use.
To our knowledge, there have been no other CDRs developed specifically for this purpose. Wells’s PE
criteria, the Geneva score and the PERC rule were developed to assess the clinical probability of PE in the
general population with a suspected PE, but were not developed for pregnant or postpartum women.
Our consensus-derived rules share a number of criteria with these rules (haemoptysis, previous VTE, clinical
symptoms or signs of DVT, recent injury or surgery) and have adapted others by using pregnancy-specific
thresholds (heart rate, oxygen saturation). Our expert consensus group drew on pre-existing rules for the
general population, but adapted and added criteria to make the rules relevant to the pregnant population.
Consensus development provides a relatively quick and efficient way of developing a CDR, but has some
inevitable limitations. Experts should base their judgements on empirical data, but, as Chapter 1 has
highlighted, there are very limited data relating to the clinical prediction of PE in pregnancy. In the absence of
empirical evidence, experts may base their judgements on personal experience, which is known to be subject
TABLE 2 Consensus results from the Delphi survey
Consensus for strong
prediction of PE
Consensus for moderate
prediction of PE
Consensus for weak
prediction of PE
No consensus
reached
l Previous history of DVT/PE
l Clinical signs suggestive
of lower limb DVT
(e.g. unilateral swelling)
l Chest radiograph
showing alternative
non-PE diagnosis
l Recent significant injury
l Oxygen saturations of
< 95% on room air
l Active i.v. drug use
l Family history of VTE
l Tachycardia
l D-dimer level > 2× upper
limit of normal range
l The current pregnancy has
had medical or obstetric
complications
l Post partum vs. third
trimester vs. second
trimester vs. first trimester
l Unstructured clinical gestalt
is that PE is the most
likely diagnosis
l Raised BMI of > 30 kg/m2
l Prolonged bed rest
l Multiple pregnancy
l Low systolic blood pressure
for gestational age
l Increased respiratory rate
for gestational age
l Multiple pregnancy
l Taking VTE prophylaxis
l Haemoptysis
l Hyperemesis
l Lower leg pain/discomfort
l SOB at rest
l Syncope
l The patient is a
current smoker
l The patient has
varicose veins
l The patient is pregnant
rather than post partum
l The patient has had
previous pregnancies
l Previous pregnancies
have had medical or
obstetric complications
l Non-pleuritic chest pain
l Palpitations
l Diastolic blood pressure
lower than the
gestational age norm
l D-dimer level greater
than the threshold
for positivity
l Recent long-haul travel
l Aged > 35 years
l Pleuritic chest pain
l SOB on exertion
l Reduced PaCO2
l IVF conception
l ECG changes
l Productive cough
l Temperature of
> 38 °C
l Raised troponin
l Reduced PaO2
l Major comorbidity
i.v., intravenous; IVF, in vitro fertilisation; PaCO2, partial pressure of arterial carbon dioxide; SOB, shortness of breath.
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to cognitive biases, such as the availability heuristic and the Dunning–Kruger effect. These may lead to
overestimation of the importance of atypical but memorable observations, as well as overestimation of
diagnostic certainty.
The consensus methods used are intended to reduce the risk of domination by a single expert opinion,
but can have the opposite risk of discouraging legitimate questioning of commonly held beliefs. We
deliberately restricted the number of experts involved in the final phase of developing the rules to ensure
that this process was manageable. This carries the risk of supressing dissenting views in the interests of
achieving a practical output.
TABLE 3 Consensus-derived CDRs to guide advanced imaging decisions for PE in pregnancy and the
postpartum period
Included variables
Variable weightinga
Primary
CDR Sensitive CDR
Specific
CDR
Haemoptysis 3 1 4
Pleuritic chest pain 0 1 0
Previous VTE 3 1 4
Family history of VTE in first-degree relative 0 1 0
Hospital admission, surgery or significant injury within 90 days (excluding NVD
or caesarean section)
2 1 1
Obstetric complicationb 1 1 0
Active medical comorbiditiesc 2 1 1
Post partum or third trimester 1 1 0
Raised BMI of ≥ 30 kg/m2 1 1 0
Clinical symptoms or signs of DVTd 3 1 4
Oxygen saturation of < 94% on room air 3 1 3
Tachycardia of > 100 b.p.m. (in the first or second trimester, or post partum)/
tachycardia of > 110 b.p.m. (in third trimester)
2 1 2
Increased respiratory rate of > 24 breaths per minute 2 1 2
CDR cut-off point 3 1 4
b.p.m., beats per minute; NVD, normal vaginal delivery.
a The scoring systems for the primary and specific rules allow the three rules to be presented alongside each other.
In practice, these scores can be simplified by removing zero-scoring variables.
b Obstetric complications – apply once if any of the following are present: pre-eclampsia in current pregnancy assisted
reproductive technology/in vitro fertilisation (antenatal only), multiple pregnancy, caesarean section in labour, elective
caesarean section, mid-cavity or rotational operative delivery, prolonged labour (> 24 hours), postpartum haemorrhage
(> 1 litre or transfusion), preterm birth at < 37+0 weeks in current pregnancy, stillbirth in current pregnancy, hyperemesis,
ovarian hyperstimulation syndrome (first trimester only).
c Active medical comorbidities – apply once if any of the following are present: cancer, heart failure, systemic lupus
erythematosus, inflammatory polyarthropathy or inflammatory bowel disease, nephrotic syndrome, type 1 or type 2
diabetes mellitus with nephropathy, sickle cell disease.
d Patients presenting with symptoms and/or signs of DVT and suspicion of PE would initially undergo duplex ultrasound of
the leg(s). If positive, patients would be treated for DVT and presumed PE. Negative leg imaging does not rule out DVT
and these patients would still be considered to be at a higher risk of developing PE.
Note
The CDRs apply to pregnant or postpartum women presenting with symptoms that prompt consideration of PE (e.g. chest
pain, shortness of breath). The rule does not apply if critically ill and/or in need of resuscitation; a clear non-PE diagnosis is
identified by clinical assessment, including ECG, chest radiograph and blood tests when appropriate (e.g. chest infection);
or an uncommon but powerful VTE risk factor exists (e.g. thrombophilia, intravenous illicit drug misuse).
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Conclusion
We have developed three CDRs through expert consensus that need to be tested to determine their ability
to discriminate between pregnant or postpartum women with and without PE.
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Chapter 3 Case–control study
Aims and objectives
The case–control study was intended to compare participants with PE with control participants without
PE to allow for the estimation of the diagnostic accuracy of clinical features, CDRs and biomarkers, and
statistical derivation of a new CDR. To minimise bias, we tried to ensure that the case participants and
control participants were selected in a similar way (i.e. that case participants presented to hospital with
suspected PE were investigated accordingly). The postpartum period was defined as the 6 weeks (42 days)
at the end of a pregnancy beyond the first trimester. As noted in Chapter 1, the design could more
accurately be described as a prospective cohort study of women with a suspected PE augmented with a
retrospective cohort of women with a diagnosed PE, but, for the reasons previously outlined, we will use
the term case–control study.
Methods
Study population
Diagnosed PE: the UKOSS research platform was used to identify a sample of pregnant or postpartum
women who were diagnosed with PE in the UK after presentation with a suspected PE. We identified and
collected data from any woman diagnosed with PE at a hospital participating in the UKOSS platform
between 1 March 2015 and 30 September 2016.
Suspected PE: we recruited a sample of pregnant or postpartum women investigated for a suspected PE
across 11 participating sites. We anticipated that 98% of women in the sample would have no confirmed
diagnosis of PE and would constitute the control group. Those with a diagnosis of PE confirmed would be
analysed with the patients with PE.
Inclusion/exclusion criteria
Diagnosed PE: we included women with PE if they met any of the following definitions:
1. pulmonary embolism confirmed using imaging (angiography, CT, magnetic resonance imaging or VQ
scan showing a high probability of PE)
2. pulmonary embolism confirmed at surgery or post mortem
3. clinical diagnosis of PE resulting in a course of anticoagulation therapy for > 1 week.
Women meeting criterion 1 or 2 were included as patients with PE in the primary analysis. Women with a
clinical diagnosis of PE (criterion 3) were excluded from the primary analysis, but were included as patients
with PE in the secondary analysis. This was because of the risk of incorporation bias if the clinical reference
standard diagnosis of PE was based on the clinical variables or biomarkers being used as index tests.
We excluded women who did not present with a suspected PE prior to diagnosis (i.e. with PE identified as
an incidental finding). We collected data from women who required life support at presentation (chest
compressions or assisted ventilation) to allow for the estimation of the incidence of PE in pregnancy,
but did not include these women in the analyses in this study.
Suspected PE: we included any pregnant or postpartum woman presenting to the participating hospitals
who was considered to require diagnostic imaging for a suspected PE. Women were recruited once the
clinician had decided that imaging would be required. However, not all women received lung imaging;
in a proportion of patients, the decision that imaging was required was reversed by a more senior clinician,
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and some women received imaging only for DVT (e.g. venous ultrasound). Women who had PE ruled out
clinically (i.e. without diagnostic imaging of the lungs for PE) were excluded from the primary analysis, but
included in the secondary analysis. This was because of the risk of bias if the PE was missed as a result of a
lack of adequate imaging and the decision not to undertake imaging was based on the clinical variables or
biomarkers that constituted the index tests.
We excluded women who needed life support on presentation to hospital (chest compressions or assisted
ventilation), women who had been diagnosed with PE earlier in the current pregnancy, women who were
unable or unwilling to provide informed consent, women aged < 16 years and women previously recruited
to the study. The form used for screening is shown in Report Supplementary Material 1 (the suspected PE
screening form).
Setting/context
Diagnosed PE
UKOSS collects data from all UK hospitals with a consultant-led maternity unit. Patients for this study
presented through a variety of routes, depending on local practice, but were ultimately the responsibility
of the obstetric services, and thus women who had PE at any stage in gestation were identified, provided
that their pregnancy was ongoing. Postpartum women were identified if they were still under obstetric
care, but inevitably this meant that patient identification became less reliable towards the end of the
postpartum period.
Suspected PE
Pregnant and postpartum women with a suspected PE are investigated in secondary care, but may follow
a variety of different pathways, depending on local practice. At each hospital, patient recruitment was
targeted at the location at which the decision to undertake diagnostic imaging was made – this included
the emergency department, the maternity unit or both.
Sampling
Diagnosed PE
Nominated clinicians in each consultant-led maternity unit in the UK were sent a card each month and
asked to report all patients with antenatal or postnatal PE, thus covering the entire cohort of UK births.
In addition, the ascertainment of any maternal deaths from PE occurring during the study period was
checked through MBRRACE-UK (Mothers and Babies: Reducing Risk through Audits and Confidential
Enquiries across the UK), the collaboration responsible for the UK Confidential Enquiries into Maternal
Death. When a patient was identified, the UKOSS clinician was contacted and asked to complete a data
collection form if appropriate.
It was not practical to obtain consent for data collection from individual women with a diagnosed PE.
The Confidentiality Advisory Group of the Health Research Authority and equivalent bodies in the devolved
nations consider that organisations seeking to use NHS information for research purposes without consent
should seek anonymised or pseudonymised data only, and not any personally identifiable information.
Accordingly, names, addresses, postcodes, dates of birth and NHS or hospital numbers were not collected
in the UKOSS research platform.
Suspected PE
Clinicians in the participating hospitals prospectively identified pregnant or postpartum women with a
suspected PE considered to require diagnostic imaging. They contacted the research nurse/midwife or
recruiting clinician, who provided women with information about the study, and checked the eligibility
criteria. Informed consent to participate was sought prior to discharge, which at some hospitals included
consenting women who returned for outpatient appointments for diagnostic imaging.
CASE–CONTROL STUDY
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Data collection and follow-up
Diagnosed PE
UKOSS clinicians who reported a patient were asked to complete a data collection form detailing the
clinical variables, diagnostic test results, management and outcomes (see Report Supplementary Material 2,
the diagnosed PE data collection form). Up to five reminders were sent if completed forms were not
returned. On receipt of the data collection forms, patients were checked to confirm that they met the
patient definition (see Inclusion/exclusion criteria). Duplicate reports were identified by comparing the
woman’s year of birth, hospital, the date of a suspected PE and the expected date of delivery, or the date
of birth for postpartum women.
Suspected PE
The research nurse/midwife completed a data collection form incorporating clinical variables, diagnostic test
results and management, using information from patient records (see Report Supplementary Material 3,
the suspected PE data collection form). Participants provided a blood sample and underwent diagnostic
imaging in accordance with local protocols. Ideally, the research nurse/midwife would collect clinical data
prior to diagnostic imaging being performed and would thus be blinded to the results of the diagnostic
imaging. However, some patients were recruited after diagnostic imaging had been performed. For these
patients, we asked the research nurse/midwife to record whether or not they were aware of the results of
the diagnostic imaging when they collected clinical data.
At 30 days after recruitment, the research nurse/midwife reviewed hospital records and recorded details
of any adverse events and the results of any additional diagnostic investigations for PE. When the research
nurse/midwife was aware of follow-up care outside the hospital NHS trust, attempts were made to
complete follow-up data using hospital records from the relevant location. All participants who provided
contact details, except for those who had died or withdrawn from the study, were sent a questionnaire
by mail, e-mail or telephone to record any additional adverse events, details of the health care received,
health utility and standardised quality of life using the EuroQol-5 Dimensions, five-level version [(EQ-5D-5L),
www.euroqol.org/, accessed 13 June 2017]. Participants received up to three reminders to complete the
30-day questionnaire. One of the two reminders used an alternative method of contact in accordance with
their stated preference (e.g. telephone or e-mail if there was no response to posted mail). When insufficient
information or no information was obtained on the data collection form, the research nurse/midwife follow-up
or the patient follow-up questionnaire, the woman’s general practitioner (GP) was contacted to rule out serious
adverse events of additional diagnostic investigations for PE using primary care records.
Women recruited with a suspected PE who were subsequently diagnosed with PE were cross-checked with
the UKOSS patients to avoid duplication. If duplication was found, data collected by the research nurse/
midwife were used.
Non-recruited women with suspected PE: women presenting to the participating hospitals with suspected
PE who were eligible but not approached to request participation, were retrospectively identified from
hospital systems, radiology records and communication between clinicians (see Report Supplementary
Material 4, non-recruited suspected PE screening form). The research nurse/midwife then extracted
anonymised data from the hospital records. The anonymised data included, when possible, the clinical
variables and the imaging, treatment, and follow-up data used to diagnose PE (see Report Supplementary
Material 5, non-recruited suspected PE data collection form). No blood sample was taken and no follow-up
questionnaire was administered, and any data not available in the case notes were recorded as missing.
These data were used to explore whether or not the recruited sample was representative.
Sample size
The sample size for the UKOSS data were inevitably determined by the incidence of PE during the data
collection period. Based on a previous similar study,27 we anticipated that we would identify 150 patients
with diagnosed PE over the 18 months of the study. We aimed to recruit 250 women with suspected PE
over the same time period, resulting in around 155 women with PE, and 245 women without PE in the
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control group, assuming that the prevalence of PE is 2% in those with a suspected PE. This would allow
for the estimation of sensitivity or specificity of 90% with a SE of around 2.5% and 2.0%, respectively.
Assuming that the ratio of women with PE to women without PE in the control group would be around
0.4, this sample size would be sufficient to identify an odds ratio of a clinical predictor of around 2, with
90% power and 5% two-sided significance.44
With a limited sample size, the complexity of any statistical model was limited in terms of the number of
predictor variables that could be included. This was addressed by selecting only those variables that were
felt to be clinically important in the model and by aiming for maximum parsimony in the final model. The
statistical analysis outlined in the study proposal stipulated modelling outcomes by splitting the cohort into
a training data set and a validation data set. This effectively reduces power, so, in developing the statistical
analysis plan, an alternative approach of leave-one-out cross-validation was planned instead.
Data management
Diagnosed PE data and suspected PE data were collected on study-specific case report forms (CRFs) and
entered onto a secure electronic data capture system at UKOSS and the Clinical Trials Research Unit
(CTRU) at the University of Sheffield. The prospective data were managed via the CTRU Prospect system
(epiGenesys, University of Sheffield, Sheffield, UK), which used inbuilt validation to promote high-quality
data and security management features to ensure data confidentiality. On completion of the study,
pseudonymised UKOSS data were encrypted and uploaded to the Prospect system. Physical data were
stored in accordance with good clinical practice and local standard operating procedures.
Ethics and research and development approvals
Ethics approval for the study was obtained from the London Brent Research Ethics Committee (reference
14/LO/1695). A feasibility assessment for each participating site was undertaken by the research team and
in accordance with local research governance procedures. Permission to undertake the research study was
granted and reviewed in response to project amendments.
Patient and public involvement
Four members of the public, representing interests in obstetric care and emergency medicine, were actively
involved in the oversight of the study via membership of the Study Steering Committee. Patient and public
involvement (PPI) representatives influenced the development of study documents and data collection,
shaped the dissemination strategy and commented on outputs. PPI representatives also engaged with
external organisations such as the Sheffield Emergency Care Forum and Thrombosis UK.
Analysis populations
The primary analysis population consisted of women recruited with a suspected PE and women identified
through UKOSS with a diagnosed PE. Women who presented to hospital needing life support were
excluded from the suspected PE sample and were used in the UKOSS sample only to estimate the overall
PE incidence. They were therefore excluded from all analyses reported in this study. We also excluded any
women from the UKOSS sample if it was not recorded whether or not they presented to hospital needing
life support, unless presenting physiological data showed that life support would not have been needed.
We planned a priori that the primary analysis should be limited to participants with diagnostic imaging,
surgery or post-mortem confirmation of PE or in whom PE had been ruled out by diagnostic imaging,
and thus included only patients without diagnostic imaging, surgery or post-mortem confirmation in the
secondary analyses. We also planned a priori to undertake the secondary analysis excluding isolated
subsegmental PE, as the identification of subsegmental PE on imaging may be unreliable and the need for
treatment may be uncertain.
We identified any duplicates between the UKOSS data set and the women with a suspected PE. If the
woman was recruited with a suspected PE, then the corresponding UKOSS data were removed from the
overall data set. If the woman was identified but not recruited with a suspected PE, then the UKOSS data
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were retained. The anonymised data relating to women’s presentation with a suspected PE were used in a
descriptive analysis of the non-recruited patients.
Reference standard classification
We planned that the classification of participants as having PE (PE present) or not having PE (PE absent)
should be based on the results of imaging, thromboembolic events and the evidence of treatment for PE,
regardless of whether or not participants were recruited with a suspected PE or identified as having a
diagnosed PE through UKOSS. Two independent assessors (SG and CNP), who were blind to the clinical
predictors and the blood results, used a structured process to classify the diagnostic imaging results, the
details of adverse events and the details of treatments given, and thus to classify all participants and
non-recruited participants as PE present (women with PE) or PE absent (control group participants). Details
of the structured process are provided in Appendix 1. Disagreements were resolved through adjudication
by a third assessor (FL). This process also classified how participants would be handled in the primary and
secondary analysis.
We structured the process of classification for primary and secondary analysis around the following principles:
Primary analysis –
l Pulmonary embolism was present if lung imaging was reported as showing PE or if venous imaging
showed DVT in the presence of symptoms indicating suspected PE (i.e. if the patient met the eligibility
criteria), if surgery or a post-mortem examination revealed PE or if the 30-day follow-up identified a
subsequent diagnosis of PE.
l Pulmonary embolism was absent if lung imaging was reported as negative for PE, unless the 30-day
follow-up identified subsequent PE.
l Pulmonary embolism was absent if lung imaging was non-diagnostic, no treatment was given for PE
(defined as therapeutic anticoagulation for at least 1 week) and no subsequent PE was identified on
follow-up.
l Women with clinically diagnosed PE were excluded (i.e. if lung imaging was non-diagnostic, but
treatment was given for PE).
l Women with clinically ruled-out PE were excluded (i.e. if lung imaging was not done).
The secondary analyses examined the following reclassifications –
l the inclusion of women with clinically diagnosed PE as PE present (i.e. women with no lung imaging or
non-diagnostic lung imaging who received treatment for PE)
l the inclusion of women with clinically ruled out PE as PE absent (i.e. women with no lung imaging who
did not receive treatment for PE)
l the exclusion of women with isolated subsegmental PE.
Clinical variable classification
Clinical variables that could be diagnostically useful were classified on the basis of a priori categorisation
as to whether the variable was present or absent. For most patients, this was on the basis of an expected
association between a variable and the presence or absence of PE. If the variable was present, then it was
expected that PE would be more likely to be present. Continuous variables were determined from the
expert opinion of DiPEP co-investigators, existing criteria used in the relevant decision tools,2 or widely
acknowledged physiological definitions (e.g. tachycardia) to give clinically meaningful classifications.
Table 4 outlines the classification.
Other previous medical problems and other problems in the current pregnancy were analysed in two ways
using the lists above. First, they were analysed using any other previous medical problem or problems
with the current pregnancy as the predictor of PE (lists 1 and 2). Then, they were limited to other previous
medical problems and problems in the current pregnancy that were known to be associated with an
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TABLE 4 Pulmonary embolism predictor variable classification
Clinical variables Present Absent
Aged > 35 years > 35 years ≤ 35 years
BMI of ≥ 30 kg/m2 ≥ 30 kg/m2 < 30 kg/m2
Ex-smoker (prior) Gave up smoking before pregnancy No
Ex-smoker (during) Gave up smoking during pregnancy No
Current smoker Current smoker No
Previous pregnancy of < 24 weeks’ gestation One or more None
Previous pregnancy of > 24 weeks’ gestation One or more None
Previous pregnancy problems Any from list 1a None from list 1a
History of VTE in first-degree relatives Yes No
History of varicose veins Yes No
History of i.v. drug use Yes No
Known history of thrombophilia Yes No
Surgery in the previous 4 weeks Yes No
Significant injury in the previous 4 weeks Yes No
Previous VTE Yes No
Other previous medical problem Any from list 2b None from list 2b
Other previous medical problem with risk of VTE Any from list 3c None from list 3c
Pregnant vs. post partum Post partum Pregnant
Trimester Second First
Trimester Third First
Multiple pregnancy Yes No
History of long-haul travel during this
pregnancy
Any within 1 month None within 1 month
Period of immobility/bed rest during this
pregnancy
Any within 1 month None within 1 month
Prior thrombotic event in this pregnancy Yes No
Other problem in current pregnancy Any from list 1a None from list 1a
Other problem in current pregnancy with risk
of VTE
Any from list 4d None from list 4d
Pleuritic chest pain Yes No
Other (non-pleuritic) chest pain Yes No
SOB on exertion Yes No
SOB at rest Yes No
Haemoptysis Yes No
Other productive cough Yes No
Syncope Yes No
Palpitations Yes No
Other symptoms Yes No
Tachycardia Heart rate of > 100 b.p.m. (in first or second
trimester, or post partum) or > 110 b.p.m.
(in third trimester)
Other or not recorded
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increased risk of VTE, based on the outcome of developing the expert consensus-derived CDRs. Problems
specifically tested as a separate predictor (e.g. previous thrombotic event) were not included.
The following ECG abnormalities were classified as being PE related: SI QIII TIII pattern, complete or
incomplete right bundle branch block, right axis deviation, simultaneous T-wave inversions in the inferior
(II, III, aVF) and right precordial leads (V1–3), right atrial enlargement (peaked P wave in lead II of > 2 mm
in height), clockwise rotation (shift of the R/S transition point towards V6, persistent S wave in V6) or atrial
tachyarrhythmia (atrial fibrillation, flutter or tachycardia).
Chest radiographs were classified by reviewing the radiology report produced as part of clinical care. If the
report mentioned the PE or pulmonary infarction in describing radiographic changes or identified potentially
PE-related findings (such as atelectasis) without providing an alternative explanation for the finding, then we
classified it as referring to a PE-related abnormality. All other abnormal radiographs were classified as having
other abnormality.
The diagnostic impression was reviewed by one of the investigators (SG) and classified by whether or
not PE was at least as likely as any other diagnosis, based on with the criterion used in Wells’s PE score.3
TABLE 4 Pulmonary embolism predictor variable classification (continued )
Clinical variables Present Absent
Tachypnoea Respiratory rate of > 24 breaths per minute Other or not recorded
Hypoxia SaO2 on room air of < 94% Other or not recorded
Low systolic BP Systolic BP of < 90mmHg Other or not recorded
Low diastolic BP Diastolic BP of < 50mmHg Other or not recorded
Fever Temperature of > 37.5 °C Other or not recorded
Clinical signs of DVT Yes No or not recorded
PE-related ECG abnormality Yes Other
PE-related chest radiograph abnormality Yes Other
Other chest radiograph abnormality Yes Other
Diagnostic impression PE at least as likely as any other diagnosis Other
D-dimer Above the gestational age-specific threshold
(see Clinical variable classification)
Below gestational
age-specific threshold
BP, blood pressure; b.p.m., beats per minute; i.v., intravenous; SaO2, peripheral oxygen saturation; SOB, shortness of breath.
a List 1: previous or current pregnancy problems (other than VTE) – three or more miscarriages, amniocentesis, amniotic fluid
embolism, baby with a major congenital abnormality, dehydration requiring admission, eclampsia, gestational diabetes
mellitus, haemorrhage, hyperemesis requiring admission, infant requiring intensive care, large-for-gestational-age infant,
neonatal death, ovarian hyperstimulation syndrome, placenta praevia, postpartum haemorrhage requiring transfusion,
pre-eclampsia (hypertension and proteinuria), premature rupture of membranes, preterm birth or mid-trimester loss,
puerperal psychosis, significant placental abruption, severe infection (e.g. pyelonephritis, small-for-gestational-age infant,
stillbirth, surgical procedure in pregnancy.
b List 2: previous medical problems – autoimmune diseases, cancer, cardiac disease (congenital or acquired), diabetes
mellitus, endocrine disorders (e.g. hypothyroidism or hyperthyroidism), epilepsy, essential hypertension, gross varicose
veins, haematological disorders (e.g. sickle cell disease), hypertension, inflammatory disorders (e.g. inflammatory bowel
disease), malignancy within 6 months, myeloproliferative disorders (e.g. essential thrombocythaemia), polycythaemia
vera, other medical disorders (e.g. nephrotic syndrome, cardiac disease, paraplegia, psychiatric disorders, renal disease).
c List 3: previous VTE-related medical problems – cancer, heart failure; systemic lupus erythematosus, inflammatory
polyarthropathy or inflammatory bowel disease; nephrotic syndrome; type 1 or type 2 diabetes mellitus with
nephropathy; sickle cell disease.
d List 4: current VTE-related pregnancy problems – assisted reproductive technology/in vitro fertilisation (antenatal only),
multiple pregnancy, caesarean section in labour, elective caesarean section, mid-cavity or rotational operative delivery,
prolonged labour (> 24 hours), postpartum haemorrhage (> 1 litre or transfusion), preterm birth of < 37+0 weeks in
current pregnancy, stillbirth in current pregnancy, hyperemesis, ovarian hyperstimulation syndrome (first trimester only).
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This was done at two levels: (1) a strict judgement in which only diagnostic impressions that clearly stated
that PE was at least as likely as any other diagnosis were included and (2) a permissive judgement in which
any diagnostic impression that suggested that PE was as least as likely as any other diagnosis was included.
D-dimer measurements were recorded as part of routine care in a proportion of women with suspected PE
and women with diagnosed PE in the UKOSS cohort. The biochemical analysis was undertaken in many
different hospitals, using different assays with different diagnostic thresholds. Furthermore, we expected
specificity to decline with gestational age. We therefore planned to test a threshold for positivity for
D-dimer that varied with gestational age and was defined in relation to the threshold used for that assay
at the relevant hospital rather than as an absolute value. We used the standard threshold during the first
trimester, 1.5 times the standard threshold for the second trimester and two times the standard threshold
for the third trimester and post partum. This was based on data showing how D-dimer levels increase
during pregnancy45 and evidence that a higher threshold may improve specificity for diagnosing VTE in
pregnancy without sacrificing sensitivity.6
Missing data
The process for classifying the reference standard (PE present or absent) described above outlines how
data relating to imaging, follow-up and treatment are handled. In general, if data were missing, it was
assumed that imaging was not performed, treatment was not given or follow-up was negative. However,
all data were presented to the independent assessors so that they could take the presence or absence of
data into account when making their judgement.
For the clinical variables, there was scope for missing data if the attending clinician failed to measure or
record the data, or if the UKOSS clinician or research nurse/midwife was unable to access the necessary
hospital records. Analyses involving multiple clinical variables (i.e. multivariable regression and analysis of
decision rules) have to either impute missing variables or exclude every patient with a missing variable. In
these analyses, we included patients with small numbers of missing data, with missing variables imputed
as being normal or negative, and excluded patients with large numbers of missing data (i.e. if any of the
following criteria were met):
l more than one of heart rate, respiratory rate and oxygen saturation were missing
l more than half of the variables relating to previous medical history were missing
l more than half of the variables relating to the current pregnancy were missing.
Our rationale for this approach was that if large numbers of data were missing, then any assumption about
the pattern of missing data would be speculative and it would be best to exclude the patient, whereas, if
only a few variables were missing, it would be more likely that these were not recorded because they were
expected to be normal or negative. Imputing missing data as normal or negative would tend to overestimate
specificity and underestimate sensitivity. We felt that this represented a conservative assumption that would
accord with clinician willingness to accept a degree of overinvestigation and unwillingness to accept the risk
of missed PE. We felt that imputing abnormal or positive values when variables were missing, especially in
validating CDRs, would be met with scepticism by the clinical users of our findings and would undermine the
clinical credibility of these findings.
Planned analyses
Demographic and baseline characteristics were presented descriptively for the cohorts with diagnosed PE
and suspected PE, and the eligible but non-recruited patients with suspected PE. Demographics, baseline
characteristics and prevalence of PE diagnosis were then compared between the recruited women
and the non-recruited women with suspected PE to explore whether or not those recruited were a
representative cohort.
The cohort with diagnosed PE and the recruited cohort with suspected PE were then combined to form
the main data set for analysis. The primary analysis was limited to women with PE confirmed or ruled out
CASE–CONTROL STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
by imaging, surgery or post-mortem examination. Secondary analyses examined the effect of (1) including
women with clinically diagnosed PE, (2) including women with clinically ruled-out PE and (3) excluding
women with subsegmental PE as outlined above.
Clinical variables were compared between women with PE and those without PE. Univariable logistic regression
was then used to determine the association between each variable and the presence or absence of PE.
Summaries of the responses to the assessment questionnaires were tabulated for each time point.
The accuracy of each index test was assessed by reporting and comparing the sensitivity and specificity.
The combined sensitivity and specificity was assessed by plotting receiver operating characteristic
(ROC) curves and quantified by the area under the curve (AUC). By virtue of the case–control design
oversampling the proportion of patients with PE, no attempt was made to estimate the positive and
negative predictive values.
We retrospectively applied each of the decision rules derived by expert consensus (see Chapter 2) and the
following existing decision rules to the data to estimate diagnostic performance:
l the PERC rule5
l the Wells’s score3
l the revised Geneva score.4
These rules were not developed for use in the pregnant population, so we removed criteria that were
not relevant to the pregnant population and adapted criteria when appropriate to be relevant to the
pregnant population. We therefore removed exogenous oestrogen from the PERC rule and used the
thresholds developed for our analysis of clinical variables to dichotomise age, oxygen saturation and heart
rate (see Table 4). The need to design a CRF that would be usable for both prospective and retrospective
data collection and that would address the multiple study objectives meant that criteria used in each rule
did not always map precisely onto variables in the CRF. Furthermore, data for some of the variables were
missing. Appendix 2 outlines how the criteria in each rule were applied to the study data.
The diagnostic performance of CDRs is normally presented as the proportion in each risk stratum with the
outcome of interest (in this case PE). This is similar to reporting positive and negative predictive values for a
diagnostic test. This approach would be misleading in the DiPEP analysis, because the prevalence of PE in
the analysis cohort has been deliberately inflated using the UKOSS data to increase the precision of estimates
of sensitivity. Positive and negative predictive values are dependent on sensitivity, so the proportion of PE in
each stratum would be much higher than if the rule was used in a typical clinical cohort with low prevalence.
We therefore assessed the accuracy of each index test by calculating sensitivity and specificity at the usual or
recommended decision-making threshold, plotting ROC curves and quantifying the AUC. The consensus-derived
rules each specified a threshold for the rule being positive or negative. The PERC score was considered
positive if any criterion was positive. The Wells’s criteria score was considered to be positive if the score
was ≥ 4 points (PE likely). The simplified revised Geneva score was considered to be positive if the score
was ≥ 4 points (moderate or high risk).
D-dimer (as measured in the hospital laboratory and recorded in the clinical notes) was analysed as a
separate index diagnostic test, rather than as one of the clinical variables, and was not included in
the CDRs, multivariable analysis or recursive partitioning. The diagnostic accuracy was assessed by
calculating the sensitivity and specificity at the hospital laboratory threshold and the pregnancy-specific
thresholds outlined previously. We did not use ROC analysis for D-dimer because of the complexity of
having to use different thresholds for different assays across the multiple hospitals contributing data to
the study.
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Methods of statistical modelling
Three statistical modelling approaches were used in the development of new decision rules:
1. Logistic regression.
Univariable logistic regression analyses were undertaken to identify associations between clinical features
and diagnosis of PE.
2. The least absolute shrinkage and selection operator (LASSO).
The LASSO regression modelling approach was used to assess the predictor variables and estimate the effect
of each variable on the outcome.46–48 This method is also based on multivariable logistic regression modelling,
but addresses some of the problems of overfitting in the presence of multiple correlated covariates. The LASSO
adaptation of logistic regression applies a penalisation against higher-dimension models, thereby helping
to protect against coefficients being spuriously inflated.49 We included all clinical variables in the analysis,
regardless of their univariable association, but did not include receipt of thromboprophylaxis as a clinical
variable. Thromboprophylaxis is targeted at women who are at risk of VTE and is intended to prevent PE.
It is therefore likely to have a complex and inconsistent association with PE.
3. Recursive partitioning.
Recursive partitioning50 is a different approach which is used to create decision tree models. Rather than
estimating a formula linking outcome to a combination of covariates, recursive partitioning attempts to
identify subgroups with higher incidences of PE based on their characteristics, the aim being to derive a
rule with optimal sensitivity (ideally of > 95%). This had the advantage that continuous variables did not
need to be dichotomised beforehand, as the partitioning algorithm not only determines which subset of
variables provides the optimal classification, but also the cut-off points within predictor variables. As is
standard practice when performing recursive partitioning, cross-validation is employed at each partition to
ensure that fully fitted trees were pruned based on a function of the complexity parameter that minimises
the cross-validation error in order to avoid overfitting.
We intended that clinicians would review the derived models to ensure clinical credibility. We planned
to purge variables that were considered to be inappropriate (e.g. if it was something that could not in
practice be assessed) and then refit the models and recalculate the coefficients of the remaining covariates.
Clinical opinion would then be sought to weight/round the coefficients into simple decision rules and
decide upon a threshold for decision-making.
In accordance with the principles of reproducible research, all analyses were performed using a literate
programming approach, which allowed the recreation of tables and figures at will by anyone experienced
in using the software. The scripts were version controlled using the Git version 2.13 [(2017) Github Inc.,
San Francisco, CA, USA] control system and self-documenting. The statistical programming language R
was used to undertake the statistical analysis.
Results
Women with diagnosed pulmonary embolism
A total of 224 women were identified through the UKOSS between 1 March 2015 and 30 September 2016.
We excluded 13 women because they were recorded as presenting with life-threatening features and
a further eight women because presentation with life-threatening features was not recorded and the
absence of life-threatening features could not be inferred from physiological data. We identified five
women who had also been recruited with suspected PE (their data were removed from the UKOSS data
set) and three whose characteristics matched women in the eligible but non-recruited data set (their data
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were retained in the UKOSS data set). Thus, we included data from 198 women with diagnosed PE in the
study analysis.
Women with suspected pulmonary embolism
We originally planned to recruit across eight sites over 18 months at a rate of two per site per month to
achieve a sample size of 250 women. However, we realised after developing the detailed statistical analysis
plan and examining initial data that the exclusion of those with clinically diagnosed or clinically ruled-out
PE from the primary analysis would potentially leave the primary analysis underpowered. We therefore
increased the number of participating sites to 11 to ensure that the planned sample size of 250 women
would be achieved for the primary analysis.
A total of 324 women were recruited across 11 participating sites between 15 February 2015 and
31 August 2016. The result of diagnostic imaging for PE was known by the research nurse/midwife at the
time of consent for 46 out of 324 women (14%). A further 35 were eligible for recruitment but declined
to participate and 95 were not asked to participate despite being eligible, usually because of the lack of
availability of an appropriate person to undertake recruitment. Non-identifiable data were collected from
this latter group of women, who formed the cohort of eligible but non-recruited women. Appendix 3
provides details of the recruitment process and the flow of participants through the study. The mean
monthly recruitment rate per site was 1.7 women per month per site across the study.
Reference standard classification
Full details of the classification process are provided in Appendix 1. The 198 patients in the UKOSS data set
consisted of 163 women with PE confirmed by imaging or post-mortem examination (160 by imaging,
including seven women with subsegmental PE, two by post-mortem examination alone and one by
imaging and post-mortem examination) and 35 women with clinically diagnosed PE (29 with equivocal
imaging and six with no imaging recorded; all treated). Thus, 163 women were included as having PE
in the primary analysis, 198 women were included in the secondary analysis including those with
clinically diagnosed PE, and 156 women were included in the secondary analysis excluding those with
subsegmental PE.
The 324 women recruited with suspected PE consisted of 18 women with PE confirmed by imaging
(including one with subsegmental PE), five women with clinically diagnosed PE (three with equivocal
imaging and two with no lung imaging; all treated), 259 women with PE ruled out after imaging (254 with
negative lung imaging and five untreated after equivocal lung imaging) and 42 with PE clinically ruled out
without lung imaging (none treated). Thus, 18 women with PE and 259 without PE were included in the
primary analysis, 23 women with PE and 259 women without PE were included in the secondary analysis
including clinically diagnosed PE, 18 women with PE and 301 women without PE were included in the
secondary analysis including clinically ruled-out PE, and 17 women with PE and 259 women without PE
were included in the secondary analysis excluding subsegmental PE. The prevalence of PE was therefore
7.1% (23/324) across all women with suspected PE and 6.5% (18/277) when women with clinically
diagnosed or ruled-out PE were excluded.
The 95 eligible but non-recruited women with suspected PE consisted of six women with PE confirmed
by imaging (including three with subsegmental PE), five women with clinically diagnosed PE (four with
equivocal lung imaging and one with no lung imaging; all treated), 73 women with PE ruled out with lung
imaging (71 with negative imaging and two untreated after equivocal imaging) and 11 women with PE
clinically ruled out without lung imaging (none treated). The prevalence of PE was therefore 11.6% (11/95)
across all non-recruited women and 7.6% (6/79) when women with clinically diagnosed or ruled-out PE
were excluded.
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The total numbers for the analysis were therefore:
l primary analysis – 181 women with PE, 259 women without
l secondary analysis including clinically diagnosed PE – 221 women with PE, 259 women without
l secondary analysis including clinically ruled-out PE – 181 women with PE, 301 women without
l secondary analysis excluding subsegmental PE – 173 women with PE, 259 women without.
Predictor variable completeness
Full details of predictor variable completeness are provided in Appendix 4. Missing data rates were
generally higher in the women with diagnosed PE than in women with suspected PE. Only previous
pregnancy problems, temperature and D-dimer were missing in > 5% in the suspected PE cohort, whereas
employment, previous pregnancy problems, all physiological variables, ECG, likely diagnosis and D-dimer
were missing in > 5% of the diagnosed PE cohort.
All seven physiological variables were recorded in 141 out of 198 women (71.2%) with diagnosed PE,
whereas 44 out of 198 women (22.2%) had between one and three variables missing and 13 out of
198 women (6.6%) had four or more missing. The corresponding figures were 286 out of 324 (88.3%),
37 out of 324 (11.4%) and 1 out of 324 (0.3%) for recruited women with suspected PE, and 49 out of
95 (51.6%), 44 out of 95 (46.3%) and 2 out of 95 (2.1%) for non-recruited women with suspected PE.
Previous medical history data were complete for 190 out of 198 (96.0%) women with diagnosed PE,
323 out of 324 (99.7%) recruited women with PE and 88 out of 95 (92.6%) non-recruited women with
suspected PE. Only 1 woman out of 198 women with diagnosed PE (0.5%) and 2 out of 95 non-recruited
women with suspected PE (2.1%) had more than half of their data missing for this category.
Data relating to the current pregnancy were complete for 189 out of 198 women with diagnosed PE
(95.5%), 324 out of 324 recruited women with suspected PE (100%) and 90 out of 95 non-recruited
women with suspected PE (94.7%). Only 4 out of 198 women with diagnosed PE (2.0%) and 3 out of
95 non-recruited women with PE (3.2%) had more than half of their data missing in this category.
Overall, 15 out of 198 women with diagnosed PE (7.6%), 2 out of 324 recruited women with suspected
PE (0.6%) and 2 out of 95 non-recruited women with suspected PE (2.1%) were excluded from the
multivariable analysis and the analysis of CDRs, as they met our criteria for exclusion on the basis of having
too many missing data.
Characteristics of the cohorts
Table 5 shows the characteristics of the women with diagnosed PE, the women with suspected PE and the
non-recruited women. The mean age was 29.3 years for the women with suspected PE and 30.1 years for
women with diagnosed PE. The mean age for mothers of live births in England and Wales was 30.3 years
in 2015.51 Most women were white British, but there were significant minorities of Asian Pakistani and
Asian Bangladeshi women in the suspected PE cohort, reflecting the minority ethnic populations of the
participating site catchment areas. The incidence of both suspected and diagnosed PE increased from the
first trimester to the third trimester.
Table 6 compares the characteristics of the recruited women and the non-recruited women with suspected
PE. There were no marked differences between the recruited women and the non-recruited women. In
December 2016, the mean age at booking of pregnant women in the UK was 29.6 years and 46% were
classified as being overweight or obese (BMI of > 25 kg/m2), so both groups were similar to the general UK
pregnant population.52
Follow-up of suspected pulmonary embolism cohort
There were no withdrawals from the prospective data collection and hospital records were viewed at the
30-day follow-up point for all participants. A questionnaire was sent to 321 out of 324 participants (99%)
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TABLE 5 Characteristics of the cohorts
Characteristic
Cohort
Women with diagnosed
PE (N= 198)
Recruited women with
suspected PE (N= 324)
Non-recruited women with
suspected PE (N= 95)
Mean age (years) 30.1 29.3 30.0
Ethnic group, n (%)
White British 151 (76.3) 204 (63.0) 50 (52.6)
White Irish 4 (2.0) – –
White other 9 (4.5) 18 (5.6) 5 (5.3)
Mixed white and black
Caribbean
– 3 (0.9) –
Mixed white and black
African
– 2 (0.6) –
Mixed white and Asian – 2 (0.6) –
Mixed other – 1 (0.3) –
Asian Indian 4 (2.0) 6 (1.9) 4 (4.2)
Asian Pakistani 7 (3.5) 36 (11.1) 15 (15.8)
Asian Bangladeshi 1 (0.5) 19 (5.9) 3 (3.2)
Asian other 3 (1.5) 5 (1.5) 5 (5.3)
Black Caribbean 4 (2.0) 5 (1.5) 2 (2.1)
Black African 9 (4.5) 17 (5.2) 6 (6.3)
Black other – 4 (1.2) 1 (1.1)
Chinese – – –
Other 3 (1.5) 2 (0.6) 2 (2.1)
Missing 3 (1.5) – 2 (2.1)
Marital status, n (%)
Cohabiting 67 (33.8) 87 (26.9) 29 (30.5)
Married 93 (47.0) 171 (52.8) 46 (48.4)
Single 35 (17.7) 65 (20.0) 19 (20.0)
Missing 3 (1.5) 1 (0.3) 1 (1.1)
Employment, n (%)
Unemployed 74 (37.4) 127 (39.2) 46 (48.4)
Employed 111 (56.0) 195 (60.2) 33 (34.7)
Missing 13 (6.6) 2 (0.6) 16 (16.8)
Previous pregnancies lasting for > 24 weeks’ gestation, n (%)
None 59 (29.8) 115 (35.5) 30 (31.6)
≥ 1 136 (68.7) 209 (64.5) 63 (66.3)
Missing 3 (1.5) – 2 (2.1)
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and 265 out of 324 participants (82%) received at least one reminder to return the questionnaire.
Questionnaires were returned by 135 out of 324 participants (41%) with a mean response time of
52.4 days. There was insufficient follow-up information to rule out a VTE event for 16 out of 324 women
(4.9%), which resulted in contact with the GP by local researchers, and 14 out of 16 questionnaires were
returned by the GP.
Table 7 summarises the EQ-5D-5L data at the 30-day follow-up point from the 136 participants who
completed and returned the questionnaire. Most women were in good health at 30 days, although a
substantial proportion had slight problems with mobility, usual activities, anxiety/depression and pain/
discomfort, and around 15% had moderate problems with usual activities or pain/discomfort.
TABLE 5 Characteristics of the cohorts (continued )
Characteristic
Cohort
Women with diagnosed
PE (N= 198)
Recruited women with
suspected PE (N= 324)
Non-recruited women with
suspected PE (N= 95)
Previous pregnancies lasting for < 24 weeks’ gestation, n (%)
None 116 (58.6) 199 (61.4) 62 (65.3)
1 or more 74 (37.3) 125 (38.6) 27 (28.4)
Missing 8 (4.0) – 6 (6.3)
Current pregnancy, n (%)
First trimester 15 (7.6) 21 (6.5) 7 (7.4)
Second trimester 43 (21.7) 110 (34.0) 18 (18.9)
Third trimester 70 (35.4) 138 (42.6) 34 (35.8)
Post partum 60 (30.3) 55 (17.0) 35 (36.8)
Missing 10 (5.1) – 1 (1.1)
–, no data.
TABLE 6 Characteristics of recruited women and non-recruited women with a suspected PE
Characteristic
Cohort
Recruited women with
suspected PE (N= 324)
Non-recruited women with
suspected PE (N= 95)
Mean age (years) 29.3 30.0
Mean BMI (kg/m2) 28.0 28.7
Multiple pregnancy, n (%) 12 (3.7) 3 (3.2)
Receiving thromboprophylaxis, n (%) 89 (27.5) 29 (30.5)
Mean heart rate (b.p.m.) 95.8 96.2
Mean respiratory rate (breaths per minute) 18.7 18.7
Mean oxygen saturation (%) 97.7 97.8
Mean systolic BP (mmHg) 122 126
Mean diastolic BP (mmHg) 73 75
Mean temperature (°C) 36.6 36.5
PE in the primary analysis, n/N (%) 18/277 (6.5) 6/79 (7.6)
BP, blood pressure; b.p.m., beats per minute.
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Characteristics of women with and without pulmonary embolism
Table 8 compares the characteristics of women with and without PE in the primary analysis data set.
Women with PE were more likely to be older, to be post partum, to have given up smoking during the
current pregnancy, to have had a previous pregnancy lasting for > 24 weeks’ gestation, to have had
previous pregnancy problems, to have had surgery in the previous 4 weeks, to have a history of VTE, to
have a problem with their current pregnancy or to have received thromboprophylaxis. They were less likely
to have a family history of VTE, varicose veins, multiple pregnancy or recent long-haul travel.
TABLE 7 The EQ-5D-5L results at the 30-day follow-up point
Dimension
Problems and severity, n (%)
None Slight Moderate Severe Extreme
Mobility 92 (67.6) 33 (24.3) 9 (6.6) 1 (0.7) 1 (0.7)
Self-care 126 (92.6) 8 (5.9) 2 (1.5) 0 (0) 0 (0)
Usual activity 79 (58.0) 36 (26.5) 19 (14.0) 2 (1.5) 0 (0)
Pain/discomfort 59 (43.4) 51 (37.5) 21 (15.4) 4 (2.9) 1 (0.7)
Anxiety/depression 99 (72.8) 28 (20.6) 5 (3.7) 4 (2.9) 0 (0)
TABLE 8 Characteristics of women with and without PE in the primary analysis data set
Predictor
Cohort, n (%)
Women without PE Women with PE
Aged > 35 years 40 (15.4) 37 (20.4)
BMI of ≥ 30 kg/m2 85 (32.8) 60 (34.5)
Smoking status
Never 171 (66.0) 116 (64.1)
Gave up prior to pregnancy 39 (15.1) 28 (15.5)
Gave up during pregnancy 19 (7.3) 23 (12.7)
Current 30 (11.6) 14 (7.7)
Previous pregnancies
One or more previous pregnancy lasting for < 24 weeks’ gestation 97 (37.5) 68 (37.6)
One or more previous pregnancy lasting for > 24 weeks’ gestation 165 (63.7) 126 (69.6)
Previous pregnancy problems 70 (27.0) 55 (30.4)
Previous medical problems
Family history of VTE 46 (17.8) 24 (13.3)
History of varicose veins 19 (7.3) 5 (2.8)
History of i.v. drug use 1 (0.4) 1 (0.6)
Known thrombophilia 7 (2.7) 4 (2.2)
Surgery in the previous 4 weeks 21 (8.1) 35 (19.3)
Significant injury in the previous 4 weeks 3 (1.2) 2 (1.1)
Previous VTE 15 (5.8) 19 (10.5)
Other previous medical problem 110 (42.5) 75 (41.4)
Other previous medical problem (VTE related) 6 (2.3) 4 (2.2)
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TABLE 8 Characteristics of women with and without PE in the primary analysis data set (continued )
Predictor
Cohort, n (%)
Women without PE Women with PE
Current pregnancy
First trimester 20 (7.7) 15 (8.3)
Second trimester 79 (30.5) 37 (20.4)
Third trimester 116 (44.8) 60 (33.1)
Post partum 44 (17.0) 63 (34.8)
Multiple pregnancy 12 (4.6) 4 (2.2)
Long-haul travel during pregnancy 21 (8.1) 2 (1.1)
≥ 3 days of immobility/bed rest during pregnancy 21 (8.1) 14 (7.7)
Received thromboprophylaxis 70 (27.0) 88 (48.6)
Previous thrombotic event during this pregnancy 3 (1.2) 5 (2.8)
Other problems with this pregnancy 73 (28.2) 74 (40.9)
Other problems with this pregnancy (VTE related) 19 (7.3) 15 (8.3)
Presenting features
Presenting feature: pleuritic chest pain 137 (52.9) 94 (51.9)
Presenting feature: non-pleuritic chest pain 47 (18.1) 38 (21.0)
Presenting feature: SOB at rest 157 (60.6) 97 (53.6)
Presenting feature: SOB on exertion 125 (48.3) 93 (51.4)
Presenting feature: haemoptysis 10 (3.9) 13 (7.2)
Presenting feature: productive cough 23 (8.9) 16 (8.8)
Presenting feature: syncope 7 (2.7) 9 (5.0)
Presenting feature: palpitations 30 (11.6) 24 (13.3)
Presenting feature: other 90 (34.7) 62 (34.3)
Temperature of > 37.5 °C 7 (2.7) 14 (7.7)
Diastolic BP of < 50mmHg 2 (0.8) 4 (2.2)
Systolic BP of < 90mmHg 1 (0.4) 3 (1.7)
Oxygen saturation of < 94% on room air 10 (3.9) 27 (14.9)
Respiratory rate of > 24 breaths per minute 25 (9.7) 18 (9.9)
Heart rate of > 100 b.p.m. (in first or second trimester, or post partum) or
of > 110 b.p.m. (in third trimester)
72 (27.8) 55 (30.4)
Clinical signs of DVT 23 (8.9) 23 (12.7)
PE-related ECG abnormality 8 (3.1) 4 (2.2)
PE-related chest radiograph abnormality 1 (0.4) 9 (5.0)
Other chest radiograph abnormality 18 (6.9) 30 (16.6)
Normal chest radiograph 221 (85.3)a 108 (59.7)a
PE most likely diagnosis (permissive) 202 (78.0) 144 (79.6)
PE most likely diagnosis (strict) 34 (13.1) 99 (54.7)
BP, blood pressure; b.p.m., beats per minute; i.v., intravenous; SOB, shortness of breath.
a Thirty-six women with PE (19.9%) and 19 women without PE (7.3%) had no chest radiograph report available.
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In terms of presenting characteristics, women with PE were more likely to have reported haemoptysis or
syncope and less likely to have reported shortness of breath on exertion. There were only small differences
in the proportion of women reporting pleuritic or non-pleuritic chest pain, shortness of breath at rest, cough,
palpitations or other symptoms. Women with PE were more likely to have an elevated temperature or low
peripheral oxygen saturation. There were only small differences in the proportion of women with a high
heart rate or respiratory rate, and very few women had a low blood pressure. Women with PE were more
likely to have an abnormal chest radiograph than those without PE, regardless of whether or not the
abnormality was considered to be PE related. Women with PE were more likely to have an overall diagnostic
impression suggesting PE, but only when a strict interpretation rather than a permissive interpretation
was used.
Table 9 compares the mean age, BMI and physiological measurements between women with and without PE
in the primary analysis data set. The distributions of these measures are shown in the figures in Appendix 5.
Women with PE were slightly older, had a slightly higher mean BMI and mean heart rate and had a slightly
lower mean oxygen saturation. There was little difference between women with and without PE, in terms of
both the mean and the distribution. Many women with PE had normal physiological measurements and
many without PE had abnormal physiological measurements.
Table 10 shows the results of the univariable logistic regression using the primary analysis data set. The
only clinical features significantly associated with a diagnosis of PE (p < 0.05) were number of previous
pregnancies lasting beyond 24 weeks’ gestation, surgery in the previous 4 weeks (including caesarean
section), no history of varicose veins, no long-haul travel during pregnancy, higher temperature, lower
oxygen saturation, overall diagnostic impression suggesting PE (strict interpretation) and chest radiograph
abnormality (both PE related and non-PE related). Women who had received thromboprophylaxis were
significantly more likely to have a diagnosis of PE.
Some of these associations suggest that known risk factors for PE are associated with a diagnosis of no PE.
This may be explained by women having a lower threshold for seeking medical attention or clinicians having
a lower threshold for investigation in the presence of known risk factors. Whatever the explanation, these
counter-intuitive associations are unlikely to be useful in diagnostic decision-making, as they will not be
clinically credible and any diagnostic value is likely to depend on implicit selection processes during
presentation that may vary between settings.
TABLE 9 Comparison of physiological measurements between women with and without PE
Measurement
Cohort, mean (SD)
Women without PE Women with PE
Age (years) 29.4 (5.9) 30.2 (6.2)
BMI (kg/m2) 28.0 (6.5) 28.7 (7.6)
Heart rate (b.p.m.) 95.5 (17.7) 98.3 (19.7)
Respiratory rate (breaths per minute) 19.0 (4.4) 19.0 (5.0)
Oxygen saturation (%) 97.8 (1.8) 96.5 (4.4)
Systolic BP (mmHg) 123 (15.7) 121 (17.0)
Diastolic BP (mmHg) 72.9 (11.7) 74.2 (12.3)
Temperature (°C) 36.6 (0.8) 36.8 (0.6)
BP, blood pressure; b.p.m., beats per minute; SD, standard deviation.
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TABLE 10 Odds ratios, 95% CIs and p-values for univariable regression
Term Odds ratio 95% CI p-value
Age (continuous) 1.02 0.99 to 1.05 0.179
Age > 35 years 1.41 0.86 to 2.31 0.176
BMI (kg/m2) (continuous) 1.01 0.99 to 1.04 0.372
BMI of ≥ 30 kg/m2 1.01 0.68 to 1.52 0.942
Ex-smoker (prior) 1.06 0.61 to 1.81 0.837
Ex-smoker (during) 1.78 0.93 to 3.46 0.082
Current smoker 0.69 0.34 to 1.33 0.279
Number of previous pregnancies lasting for < 24 weeks’ gestation (continuous) 1.05 0.91 to 1.23 0.509
≥ 1 pregnancy lasting for < 24 weeks’ gestation 1.00 0.68 to 1.49 0.98
Number of previous pregnancies lasting for > 24 weeks’ gestation (continuous) 1.20 1.04 to 1.30 0.017
≥ 1 pregnancy lasting for > 24 weeks’ gestation 1.30 0.87 to 1.97 0.198
Previous pregnancy problems 1.18 0.77 to 1.79 0.442
Family VTE 0.71 0.41 to 1.20 0.205
History of varicose veins 0.36 0.12 to 0.91 0.045
History of i.v. drug use 1.43 0.06 to 36.4 0.8
Known thrombophilia 0.81 0.21 to 2.74 0.745
Surgery in previous 4 weeks (including caesarean section) 2.72 1.53 to 4.92 0.001
Injury in the previous 4 weeks 0.95 0.12 to 5.81 0.959
Previous VTE 1.91 0.95 to 3.92 0.073
Other previous medical problem 0.96 0.65 to 1.41 0.829
Other previous medical problem (VTE related) 1.02 0.26 to 3.62 0.978
Second trimester 0.62 0.29 to 1.37 0.234
Third trimester 0.69 0.33 to 1.46 0.324
Post partum 1.91 0.89 to 4.19 0.101
Multiple pregnancy 0.47 0.13 to 1.36 0.191
Long-haul travel during pregnancy 0.13 0.02 to 0.44 0.006
≥ 3 or more days of immobility/bed rest during pregnancy 0.95 0.46 to 1.91 0.887
Received thromboprophylaxis 2.56 1.72 to 3.82 < 0.001
Previous thrombotic event this pregnancy 2.44 0.59 to 12.0 0.226
Other problem with this pregnancy 1.46 0.97 to 2.20 0.067
Other problem with this pregnancy (VTE related) 1.14 0.56 to 2.31 0.713
Presenting: pleuritic chest pain 0.96 0.66 to 1.41 0.842
Presenting: non-pleuritic chest pain 1.20 0.74 to 1.93 0.457
Presenting: SOB (exertion) 1.13 0.77 to 1.66 0.52
Presenting: SOB (rest) 0.75 0.51 to 1.10 0.142
Presenting: haemoptysis 1.93 0.83 to 4.61 0.129
Presenting: cough 1.00 0.50 to 1.93 0.988
Presenting: syncope 1.88 0.69 to 5.36 0.218
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Diagnostic accuracy of clinical decision rules
Table 11 reports the diagnostic accuracy of each CDR and Figure 1 shows the ROC curve. The sensitivity and
specificity are reported for the recommended or usual threshold for decision-making (i.e. any score vs. zero
for the PERC score, PE likely vs. unlikely for Wells’s criteria and low risk vs. moderate or high risk for the
Geneva score). The ROC figure and the area under the ROC (AUROC) curve relate to the performance of the
rule across the range of values, rather than just using the recommended or usual threshold.
The diagnostic accuracy of the rules was generally poor. The consensus rules were derived specifically for
pregnant and postpartum women and were intended to identify a low-risk group of women who could
be discharged without imaging, but performed little better than chance. The sensitive rule had good
sensitivity (95%) but very poor specificity (4%), showing that sensitivity was achieved only by setting a
very low threshold for positivity.
The existing CDRs were developed for the general population with suspected PE. We adapted the relevant
criteria to make them appropriate for a pregnant population, but did not otherwise alter the rules. Wells’s
criteria may have some modest diagnostic value if the criterion ‘PE is the most likely diagnosis or equally
likely’ is applied in a strict way (i.e. it is only positive if PE is clearly considered to be the most likely or
equally most likely diagnosis). The other rules performed little better than chance.
TABLE 10 Odds ratios, 95% CIs and p-values for univariable regression (continued )
Term Odds ratio 95% CI p-value
Presenting: palpitations 1.17 0.65 to 2.07 0.598
Presenting: other 0.98 0.65 to 1.46 0.914
Temperature of > 37.5 °C 3.02 1.23 to 8.11 0.02
Temperature (continuous) 1.75 1.22 to 2.57 0.003
Diastolic BP of < 50 mmHg 2.90 0.56 to 21.1 0.221
Diastolic BP (continuous) 1.01 0.99 to 1.03 0.256
Systolic BP of < 90mmHg 4.35 0.55 to 88.3 0.205
Systolic BP (continuous) 0.99 0.98 to 1.01 0.322
Oxygen saturation of < 94% 4.37 2.12 to 9.71 < 0.001
Oxygen saturation (continuous) 0.85 0.78 to 0.92 < 0.001
Respiratory rate of > 24 breaths per minute 1.03 0.54 to 1.95 0.919
Respiratory rate (continuous) 1.00 0.96 to 1.04 0.948
Heart rate of > 100 b.p.m. (110 b.p.m. in third trimester) 1.13 0.75 to 1.72 0.556
Heart rate (continuous) 1.01 0.99 to 1.02 0.126
Clinical signs of DVT 1.49 0.81 to 2.77 0.199
PE-related ECG abnormality 0.71 0.19 to 2.29 0.579
PE-related chest radiograph abnormality 15.2 2.82 to 282.0 0.01
Other chest radiograph abnormality 2.82 1.53 to 5.33 0.001
PE is most likely diagnosis or equally likely (permissive) 1.48 0.85 to 2.62 0.174
PE is most likely diagnosis or equally likely (strict) 9.15 5.70 to 15.0 < 0.001
BP, blood pressure; b.p.m., beats per minute; i.v., intravenous; SOB, shortness of breath.
CIs were calculated using methods outlined by Harrell53 and Dobson and Barnett.54
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TABLE 11 Diagnostic accuracy of the CDRs
Decision rule
Diagnostic accuracy
AUROC using full range
of score values (95% CI)
Sensitivity at usual or
recommended threshold
(95% CI), n/N
Specificity at usual or
recommended threshold
(95% CI), n/N
Primary consensus 0.626 (0.572 to 0.681) 0.609 (0.532 to 0.683), 103/169 0.585 (0.523 to 0.646), 151/258
Sensitive consensus 0.620 (0.566 to 0.675) 0.959 (0.917 to 0.983), 162/169 0.035 (0.016 to 0.065), 9/258
Specific consensus 0.589 (0.537 to 0.642) 0.361 (0.289 to 0.438), 61/169 0.783 (0.728 to 0.832), 202/258
PERC score 0.621 (0.570 to 0.672) 0.675 (0.598 to 0.745), 114/169 0.519 (0.457 to 0.582), 134/258
Simplified revised
Geneva score
0.579 (0.526 to 0.632) 0.444 (0.368 to 0.522), 75/169 0.636 (0.574 to 0.694), 164/258
Wells’s score
(permissive)a
0.577 (0.522 to 0.632) 0.490 (0.410 to 0.571), 77/157 0.617 (0.553 to 0.678), 153/248
Wells’s score (strict)a 0.732 (0.682 to 0.782) 0.376 (0.300 to 0.457), 59/157 0.895 (0.850 to 0.930), 222/248
AUROC, area under the receiver operating characteristic.
a Wells’s criteria scores were tested using a liberal (permissive) interpretation of clinical diagnosis text to determine
whether PE was the most likely or equally most likely diagnosis and a more strict interpretation.
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FIGURE 1 Receiver operating characteristic curves for CDRs.
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Appendix 6 provides figures showing how each rule performed across the range of scores. These show
that a non-negligible proportion of women with PE were categorised in the lowest risk stratum of all of
the scores. Only the sensitive consensus rule and Wells’s score (permissive application) had < 5% of
women with PE in the lowest stratum and both of these methods categorised too few women without PE
in the lowest risk category to be clinically useful (i.e. using the rule would not make a practically important
difference to patient management).
Wells’s score and the simplified revised Geneva score are usually used to select low-risk patients for
biomarker testing, whereas the PERC score is intended to allow discharge without testing if it is negative.
Our analysis showed that a substantial proportion of women with PE have a negative PERC score. In
applying the PERC score, we did not apply the criterion of exogenous oestrogen. If being pregnant or post
partum were considered to carry the same risk as exogenous oestrogen, then the PERC score would be
positive in all pregnant and postpartum women.
Appendix 7 shows the coefficients from logistic regression for each of the elements of each rule. This gives
an indication of the contribution that each element makes to the diagnostic performance of the rule.
The consensus-derived rules included elements that the experts thought would be useful, but added little
diagnostic value (pleuritic chest pain, injury, medical comorbidities, raised BMI, tachycardia and tachypnoea)
and two elements (being in the third trimester, family history of VTE) that had weak associations with the
absence of PE. The existing rules had similar problems related to the inclusion of elements with little diagnostic
value, but Wells’s score benefited from the inclusion of the criterion ‘PE is the most likely diagnosis or equally
likely’ when this criterion was recorded as positive only if the diagnostic impression clearly indicated a positive
diagnosis of PE rather than mentioning it as a possibility.
D-dimer analysis (using measurements from routine care)
D-dimer measurements were recorded as part of routine care for 44 out of 198 women with diagnosed
PE (22%) and 156 out of 324 women with suspected PE (48%). After the exclusion of 22 women with
clinically diagnosed or ruled-out PE, the primary analysis data set for those with routine care D-dimer
measurements consisted of 53 women with PE and 125 women without PE.
We have not reported absolute D-dimer values because the measurements were made using a variety of
assays with different thresholds for positivity. Instead, we simply report the sensitivity and specificity of
D-dimer measurements using the threshold specified by the hospital laboratory (the conventional threshold)
and the pregnancy-specific thresholds we defined a priori (conventional threshold in the first trimester, 1.5×
the conventional threshold in the second trimester and 2× the conventional threshold in the third trimester).
Ten women with PE did not have a hospital laboratory threshold reported and thus could not be included in
the analysis, which therefore involved 43 women with PE and 125 women without PE.
Using the hospital laboratory threshold, the sensitivity (n/N) of D-dimer was 88.4% (38/43, 95% CI 74.1%
to 95.6%) and the specificity was 8.8% (11/125, 95% CI 4.7% to 15.6%). Using the gestation-specific
threshold, the sensitivity (n/N) of D-dimer was 69.8% (30/43, 95% CI 53.7% to 82.3%) and the specificity
was 32.8% (41/125, 95% CI 24.8% to 41.9%).
Multivariable analysis
Details of the multivariable analysis are reported in Appendix 8. Leave-one-out cross-validation was
utilised internally at each step of the fitting of the LASSO to shrink the point estimate and inform the next
iteration. Optimal values for the parameter lambda were identified as the minimum value or the value
corresponding to 1 × the SE of the point estimate of the mean squared error. Models were derived for
each of these values and the diagnostic parameters were calculated. Figure 2 shows the ROC curve and
Table 12 reports the coefficients for each predictor that contributed significantly to the model and the
diagnostic parameters for the model.
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FIGURE 2 Receiver operating characteristic curves for the multivariable models.
TABLE 12 Coefficients for each term and diagnostic parameters for the multivariable models
Term or diagnostic parameter 1 × SE model Minimum value model
(Intercept) 1.915 –3.987
Previous VTE 0.000 0.256
Long-haul travel during pregnancy –0.428 –1.225
Multiple pregnancy 0.000 –0.402
Oxygen saturation (continuous) –0.041 –0.065
Surgery in previous 4 weeks 0.028 0.299
Temperature (continuous) 0.037 0.273
PE-related chest radiograph abnormality 0.413 0.660
AUC (95% CI) 0.668 (0.607 to 0.729) 0.724 (0.669 to 0.779)
Sensitivity, % (95% CI) 1.00 (0.971 to 1.000) 0.831 (0.753 to 0.892)
Specificity, % (95% CI) 0.077 (0.046 to 0.119) 0.391 (0.328 to 0.456)
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The analysis suggests that there is little potential for an accurate and usable CDR. The most accurate
model used previous VTE, long-haul travel during pregnancy, multiple pregnancy, oxygen saturation
(as a continuous variable), surgery in the previous 4 weeks, temperature (as a continuous variable) and
PE-related chest radiograph abnormality to predict PE with an AUC of 0.724 (95% CI 0.669 to 0.779). The
ROC curve shows that the specificity would have to be as low as 20% to achieve a level of sensitivity that
is acceptable to allow imaging to be avoided (> 95%). This estimate would need to be validated in a new
cohort and statistical shrinkage would probably result in worse accuracy. Furthermore, the model includes
variables with a counter-intuitive negative association with PE (history of long-haul travel and multiple
pregnancy) that may be dependent on referral processes and would therefore vary between settings and
over time, if referral processes changed.
In view of the poor accuracy of the model in the derivation cohort, we did not proceed to internal
validation or attempting to make the model more clinically credible or usable.
Recursive partitioning
Recursive partitioning resulted in a range of models of increasing complexity, accuracy and risk of
overfitting. Details are reported in Appendix 9. The optimal model is shown in Figure 3; it uses BMI,
oxygen saturation, heart rate and trimester to categorise women. The percentages show how the study
population is split by the partitioning process. The proportions are the proportion of PE in each subgroup.
The high proportion of PE in each subgroup reflects the case–control design. The prevalence of PE in the
suspected PE group was 6.5%, so the proportion of women with PE in each group is around six times
higher than would be expected in a typical population with suspected PE.
Figure 4 shows the ROC curve for the model. The AUC was 0.657 (95% CI 0.611 to 0.703) and the threshold
that provided a sensitivity of > 95% had a corresponding specificity of 5%. More complex models with more
variables had higher accuracy (see Appendix 9), but with an increasing risk of overfitting. Therefore, although
some of the very complex models had apparently acceptable accuracy, statistical shrinkage in the validation
analysis would be highly likely to result in unacceptable accuracy in a validation cohort. Highly complex
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FIGURE 3 Dendrogram of the optimal recursive partitioning model. b.p.m., beats per minute.
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models would be difficult to use in clinical practice without appropriate software and, being based on
variables with weak associations with PE diagnosis, would lack clinical credibility.
Secondary analysis
The results of the secondary analysis are summarised in Appendix 10. There were no meaningful
differences between the results of the primary analysis and the secondary analysis.
Feasibility of a prospective cohort study
We aimed to use the recruitment data for women with suspected PE to determine the feasibility of using a
prospective cohort design to validate a new CDR or biomarker. The study recruited women with suspected
PE at a rate of 1.7 women per site per month and a prevalence of 23 out of 324 women with PE (7.1%).
This suggests that a prospective cohort study involving 50 sites (more than one-quarter of all potential sites
in the UK) recruiting for 2 years could achieve a sample size of 2040, including 145 women with PE.
Discussion
Main findings
Our analysis showed that clinical variables have little diagnostic value in the assessment of pregnant and
postpartum women with suspected PE. There was very little difference in physiological measures between
women with PE and those without PE. Many women with PE had entirely normal physiology while many
without PE had abnormal physiology. Higher temperature and lower oxygen saturation were associated
with PE, but the association was too weak to be clinically useful. Recent surgery (almost entirely caesarean
section) was associated with an increased risk of developing PE, whereas older age, giving up smoking
during pregnancy, higher heart rate (measured as a continuous variable), absence of shortness of breath
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FIGURE 4 The ROC curve for the optimal recursive partitioning model. CP, complexity parameter.
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at rest, haemoptysis, previous thrombosis, being post partum, having a single pregnancy and having
obstetric problems during pregnancy showed weak associations with PE.
Important negative findings were that presenting features, with the exception of haemoptysis and possibly
syncope, had little diagnostic value. Risk factors for VTE, with the exception of obstetric problems and a
past history of VTE, also had little diagnostic value. Some risk factors (recent long-haul travel, varicose veins
and possibly multiple pregnancy and family history of VTE) were more common in women presenting with
suspected PE but in whom the diagnosis was not confirmed, than in women in whom the diagnosis of
PE was confirmed. This is likely to reflect selection processes, whereby women with symptoms suggestive
of PE and known risk factors are more likely to present, be referred and be investigated than those
without risk factors.
There were some counter-intuitive findings, most notably that abnormal chest radiograph appearances (even
those not considered to be related to PE) were associated with an increased risk of PE. Diagnostic guidelines
for suspected PE in pregnancy2 advise a chest radiograph on the basis of identifying alternative causes and
determining whether to use CTPA or VQ scanning. Our findings suggest that an abnormal chest radiograph
increases rather than decreases the probability of PE.
Given the poor discriminant value of the clinical predictors, it is not surprising that CDRs also had poor
discriminant value, with only Wells’s criteria (with a strict interpretation of PE likelihood) having an AUC
that was > 0.7. Critically for clinical practice, none of the rules was able to identify a meaningfully sized
low-risk group that could be selected for discharge without imaging.
The same problems arose when we attempted to derive a diagnostic model for PE using multivariable analysis
and recursive partitioning. The models and decision trees we derived had poor accuracy, were unable to achieve
clinically useful specificity at acceptable sensitivity and included variables with counter-intuitive associations with
PE that lacked clinical credibility. The poor performance of these models in the derivation cohort suggests that
attempts at validation are not worthwhile. Our findings suggest that CDRs have no useful value in selecting
pregnant and postpartum women with suspected PE for imaging.
Comparison with previous studies
Our systematic review identified few studies evaluating clinical variables or CDRs for diagnosing PE in
pregnancy and post partum, and those we identified included few women with PE. Previous studies
reporting a lack of association between presenting features or physiological measurements and a diagnosis
of PE12,15,18 may be explained by a lack of statistical power. The DiPEP study was powered to detect clinically
important associations. Our findings should therefore convincingly refute the suggestion that clinical features
are diagnostically useful for PE in pregnancy and post partum (in the setting of secondary care at least).
Previous studies suggested that Wells’s PE criteria may be useful in pregnant or postpartum women.8,17
Our findings suggest that Wells’s PE criteria may have some modest diagnostic value when adapted for the
pregnant population and applied with a strict interpretation of the likelihood of PE, but this is unlikely to
be clinically useful. The discordance between our study and previous studies may be explained by random
error, owing to the small numbers in previous studies or differences in study design.
Strengths and limitations
The DiPEP study is the largest study ever undertaken to evaluate the diagnostic accuracy of clinical
predictors and biomarkers for pregnant and postpartum women with suspected PE. In terms of the number
of women with PE, it is many times larger than any previous study. This provided us with much greater
power to detect associations with PE and allowed us to estimate diagnostic sensitivity with much greater
precision. The women with suspected PE were a relatively unselected cohort presenting to a representative
group of hospitals, involving both maternity units and emergency departments. The women with diagnosed
PE were identified across all UK hospitals and, therefore, were likely to be a representative sample. Data
completion rates were generally good and follow-up ensured that the risk of misclassification of women
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with PE as having no PE was minimised. The primary analysis was limited to women with imaging
confirmation to reduce the risk of misclassification, whereas the secondary analysis including women with
clinically diagnosed or ruled-out PE explored the applicability of findings to a wider cohort.
The large number of women in the study with PE was achieved by using a case–control design, which
has some inevitable limitations. Strictly speaking, the design was a cohort design in which the cohort was
augmented by the inclusion of additional patients with PE. However, it shares potential limitations with the
case–control design. Patients may be selected and represent the more severe end of the spectrum with the
disease, whereas control patients may not be typical of those investigated without the disease and may
not have conditions that lead to a false-positive diagnosis. We reduced these risks by including all women
with diagnosed PE as participants and then excluding those requiring immediate resuscitations (or who
we could not verify had not required immediate resuscitation), so that they would be representative of
women diagnosed with PE and presenting with suspected PE. Women in the control group were not
healthy control participants, but women presenting with suspected PE who underwent investigation.
Crucially, it should be noted that the bias associated with the case–control design tends to inflate the
estimates of sensitivity and specificity. This means that our findings of poor discriminant value for clinical
predictors and CDRs are unlikely to be undermined by the risk of bias.
A more significant risk of bias may relate to differences in data collection methods between women with
diagnosed PE and women with suspected PE. Data from the former group were retrospectively recorded
by UKOSS clinicians using the hospitals records, whereas data from the latter group could be collected by
the research nurse/midwife directly questioning patients. We encouraged the research nurse/midwife to
rely on hospital records rather than patient interview to collect predictor variables, but we cannot be sure
that they did not rely on patient interview. Furthermore, to reduce potential screening and data collection
bias, the immediate collection of prospective data would be preferable. Missing data rates were higher
for the UKOSS data, which suggests that the identification of clinical predictors from the women with
suspected PE may have been more rigorous. This potential bias offers an alternative explanation to the
one considered above for the counter-intuitive findings that some risk factors for developing VTE
(long-haul travel, varicose veins) were associated with an absence of PE. It does not explain the negative
associations with easily identifiable predictors, such as multiple pregnancy, or the limited predictive value
of physiological variables.
Crucially, it should be noted that the participants in our study had all been through some sort of selection
process, either by virtue of deciding to self-present to emergency or maternity services, or by referral by a
health professional. This process is likely to have been based on many of the clinical variables that we
examined in our analysis. It is therefore possible that the diagnostic value of clinical variables is ‘used up’
during the referral process. For example, if women with risk factors for VTE or abnormal physiology are
more likely to self-present or be referred, then these factors will have less diagnostic value than if those
presenting are a random or unselected sample of women suffering symptoms compatible with PE during
pregnancy or post partum.
This does not undermine the relevance of our findings to secondary care, as clinicians working in
emergency departments and maternity units will see similarly selected patients, but does mean that we
should be cautious about extrapolating our findings to primary care and other settings outside hospital.
Clinical variables may be being used to select women for hospital attendance, which explains their lack
of value in a hospital cohort.
It is also important to recognise that our findings do not challenge existing knowledge on what constitutes
risk factors for VTE in pregnancy. The DiPEP study was designed to determine the diagnostic value of
clinical features (including the risk factors for developing VTE) in women with suspected PE in pregnancy
and post partum. It was not designed to determine whether or not these features are risk factors for
developing VTE. Previous studies comparing women who develop VTE in pregnancy with those who do
not have already answered this question.27–29,55
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Conclusions
Clinical features have limited diagnostic value for PE in pregnant and postpartum women and CDRs are
unlikely to have a useful role in selecting women for imaging. We were unable to derive a new decision
rule with sufficient diagnostic accuracy and clinical credibility and utility to justify further validation.
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Chapter 4 Biomarker study
Introduction
As outlined in Chapter 1, a number of biomarkers have a potential role in selecting pregnant or postpartum
women for diagnostic imaging, but only D-dimer measurement is currently used in routine clinical practice,
with troponin and BNP being used to grade the extent of PE. D-dimer measurements recorded in clinical
practice were collected and analysed as part of the case–control study, but we anticipated that the analysis
of these data would be limited by missing data, as current guidance2 advises against using the D-dimer
measurement, and by the use of different assays with different thresholds for positivity at different
hospitals. We therefore planned to analyse the D-dimer measurement along with a number of other
biomarkers, using blood samples obtained from women with suspected PE and women presenting to the
prospectively recruiting sites with diagnosed DVT.
Aims and objectives
The aim of the biomarker study was to explore the potential diagnostic value of classical and alternative
biomarkers for PE in pregnant and postpartum women.
Methods
The prospective identification of a cohort of pregnant or postpartum women with suspected PE for the
case–control study offered the opportunity to collect blood samples for biomarker evaluation for at least a
proportion of the study population. This allowed us to evaluate the potential alternative biomarkers and
undertake a more detailed analysis of the D-dimer measurement to determine whether or not a
pregnancy-specific threshold could optimise specificity without compromising sensitivity.
Patient consent was required to take additional blood samples so that the biomarker study could not include
women with diagnosed PE identified through UKOSS. We anticipated that only a small number of women
with suspected PE would actually have PE. This would provide very little power to estimate sensitivity with
any degree of precision. We therefore augmented the sample with pregnant or postpartum women who
had DVT diagnosed during the recruitment period at the participating hospitals, thus including all women
with diagnosed VTE. There are good pathophysiological reasons for expecting that biomarkers will have the
same sensitivity in PE and DVT, and empirical studies of D-dimer measurement have shown similar sensitivity
in DVT and PE.37
Target population
Suspected pulmonary embolism
Pregnant or postpartum women with suspected PE who consented to participate in the study were
asked to provide an additional blood sample. Details of the study population with suspected PE, the
inclusion and exclusion criteria, sampling, consent and the data collection procedures are described in
Chapter 3.
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Diagnosed deep-vein thrombosis
We also recruited any women identified with a DVT diagnosis confirmed by imaging (ultrasound, magnetic
resonance, CT or contrast venography) who were willing to provide an additional blood sample. The
recruitment of these women was limited to hospitals participating in the recruitment of women with
suspected PE. We excluded women with symptoms of suspected PE (who should be recruited as having
suspected PE), women who had been diagnosed with PE or DVT earlier in the current pregnancy, women
who were unable or unwilling to provide informed consent and women aged < 16 years. The screening
form and the data collection form are available in Report Supplementary Material 6 and 7.
Sample size
The incidence of DVT in pregnancy and post partum is around four times that of PE,28 so we anticipated
that we would recruit around 20 women with DVT. Thus, the sample for the biomarker substudy was
expected to include 245 women with suspected PE but negative diagnostic testing, five women with
diagnosed PE, and 20 women with diagnosed DVT (i.e. 25 women with confirmed VTE).
Blood sample collection, handling, storage and analysis
Serum and citrate blood samples were collected by a member of the clinical team or research nurse/
midwife using venepuncture technique, ideally while obtaining routine blood samples for standard clinical
assessment in diagnostic workup. Sample preparation was conducted by the research nurse/midwife or a
member of the hospital laboratory staff. The samples were centrifuged at 2000 g for 15 minutes at room
temperature within 4 hours of being obtained. Citrate samples were further processed to obtain platelet-
free plasma.
Plasma and serum samples were stored in aliquots labelled with the patient identification and the storage
box co-ordinates were recorded on paper and electronic study documentation, in accordance with local
protocols. The samples were stored in –70 °C freezers at each participating hospital (with the exception of
one location in which a –40 °C freezer was used) for the duration of the study, until all samples were
transported for analysis to Guy’s and St Thomas’ NHS Foundation Trust (GSTT), London, UK.
Biomarker analysis
The biomarkers selected for analysis are outlined in Table 13.
Analytic techniques
Citrated plasma was utilised for PT, APTT, Clauss fibrinogen, D-dimer (Innovance), D-dimer ELISA, thrombin
generation (TG), plasmin–antiplasmin, prothrombin fragment 1 + 2 (PF 1 + 2), and tissue factor. Serum was
utilised for troponin-1, BNP, MRProANP, and CRP assays.
Thrombin generation was measured by the Thrombinoscope (ThermoElectron Corporation, Cambridge, UK).
The samples were tested in batches to minimise variability. The frozen-plasma aliquots were placed in a
water bath (at 37 °C) to thaw for 5 minutes. Platelet-poor plasma (PPP)-reagent LOW (Diagnostica Stago UK
Ltd., Theale, UK) was used because of expected hypercoagulability; PPP-reagent LOW consists of 1 pM of
tissue factor with 4 µM of phospholipids. A measurement of 20 µl of PPP reagent was added to each TG
well together with 80 µl of platelet-free plasma and 20 µl of fluorogenic substrate and calcium. The fluorogenic
substrate consisted of amino-methyl-coumarin. The calibrator wells consisted of 80 µl of platelet-free plasma,
20 µl of calibrator and 20 µl of fluorogenic substrate and calcium. All of the reagents were from Diagnostica
Stago, Reading, UK. The analysis was conducted in an ELISA plate (Diagnostica Stago, Reading, UK) that
enables the thrombin formation to be followed in a Fluoroskan (Fluoroskan Ascent™, Thermo Scientific,
Loughborough, UK). The coefficient of variation was 2.2% to 3.2% intra-assay and 5.1% to 16.7% interassay
for lag time, endogenous thrombin potential, peak and time to peak.
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TABLE 13 Biomarkers selected for analysis
Biomarker Description Reference range
D-dimers (ELISA) A fibrin degradation product – a small protein fragment present in the
blood after a blood clot is degraded by fibrinolysis. Measured by ELISA
and a highly sensitive assay
0–400 ng/ml
D-dimers
(Innovance)
As above, but near patient testing and fast turn around time allows for
day- to-day use. This is a point-of-care test that is used by many routine
laboratories in the UK in 2016
0–1.13 mg/l
Plasmin–antiplasmin
level
An ELISA assay that measures the level of plasmin–antiplasmin
complexes and thus is a very sensitive assay of plasmin activation
150–800 µg/l
PF 1 + 2 A small molecule cleaved from prothrombin when thrombin is
generated. It is thus a sensitive marker of thrombin generation i.e.
coagulation turnover. It is an ELISA assay
200–1200 pmol/l
Thrombin
generation
Thrombin generation can be measured dynamically using the
endogenous thrombin potential (ETP), a term introduced by Hemker in
1986 that refers to the total amount of thrombin generated during
the test. Commonly measured variables when analysing thrombin
generation include the lag time, the time to peak thrombin generation,
the endogenous thrombin potential (ETP) – the area under the curve
Lag time: 0.9–3.4 minutes
ETP:
696–1533 nM×minutes
Peak: 103–475 nM
Time to peak:
1.4–7.7 minutes
PT A routine measure of the extrinsic pathway of coagulation, used to
determine the clotting tendency of blood
11.7–15.9 seconds
APTT A routine measure of the intrinsic and common coagulation pathways,
used to detect abnormalities in blood clotting
27–52 seconds
Clauss fibrinogen A functional measure of fibrinogen 2.03–4.11 g/l
Soluble tissue factor A marker of tissue factor activation – when tissue factor is upregulated,
part of the molecule may be cleaved and enters the systemic circulation
40–300 pg/ml
Troponin I Part of the troponin complex in cardiac muscle tissue, used to detect
myocardial damage resulting from myocardial ischaemia or noncardiac
causes such as PE
0.91–2.63 ng/ml
B-type natriuretic
peptide
A polypeptide secreted by the ventricles of the heart in response to
excessive stretching of heart muscle cells, used to measure heart strain
resulting from primary heart disease or noncardiac causes such as PE
107–523 pg/ml
C-reactive protein CRP is an acute-phase protein, the levels of which rise in response to
inflammation. Elevation of CRP has been shown to be associated with a
diagnosis of PE
0–3104 ng/ml
MRproANP MRproANP is an emerging measure of right ventricular strain which
occurs as a consequence of pulmonary embolism
0–954 pmol/l
PF 1 + 2, prothrombin fragment 1+ 2.
Adapted from Hunt et al.56 This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial License (CC BY-NC 4.0), which permits use, distribution and reproduction in any medium, provided the
original work is properly cited and is not used for commercial purposes.
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The PT, APTT, and Clauss fibrinogen were measured on the ACL300R (Werfen UK, Warrington, UK) using
PT High Sensitivity Plus reagent for the PT, HemosIL APPT Synthetic Phospholipids liquid for the APTT
(Werfen UK, Warrington, UK), and fibrinogen C for the Clauss fibrinogen. All reagents were purchased
from Werfen UK (Warrington, UK). The tests were measured in accordance with the manufacturer’s
instructions for the ACL300R analyser. The coefficient of variation was 3.2% to 3.5% intra-assay and
3.6% to 4.2% interassay for PT, APTT and Clauss fibrinogen.
The latex-based D-dimer was measured on the CA660 analyser from Sysmex UK (Milton Keynes, UK).
Innovance D-dimer reagent (Sysmex UK, Milton Keynes, UK) was used to measure the D-dimer in
accordance with the manufacturer’s instructions. The coefficient of variation was 6.0% intra-assay and
12% interassay for the Innovance D-dimer.
The Zymutest D-dimer ELISA assay (Quadratech Diagnostics Ltd, Epsom, UK) was used to measure the
D-dimers by ELISA. D-dimer was measured in accordance with the manufacturer’s instructions. The
coefficient of variation was 4.6% intra-assay and 10.8% interassay for the Zymutest D-dimer.
The plasmin–antiplasmin ELISA (Immunodiagnostics Systems Ltd, Boldon Colliery, UK) was used to measure
the plasmin–antiplasmin. The assay was measured in accordance with the manufacturer’s instructions. The
coefficient of variation was 4.2% intra-assay and 7.3% interassay for the plasmin–antiplasmin.
The fragment 1 + 2 Micro (Sysmex, Milton Keynes, UK) was used to measure the PF 1 + 2 in the citrated
plasmas. The PF 1 + 2 was measured in accordance with the manufacturer’s instructions. The coefficient of
variation was 6.0% intra-assay and 9.0% interassay for the PF 1 + 2.
The Immubind tissue factor (Invitech Ltd, Huntingdon, UK), was used to measure the tissue factor by
ELISA. The tissue factor was measured in accordance with the manufacturer’s instructions. The coefficient
of variation was 6.0% intra-assay and 5.0% interassay for the tissue factor.
The troponin-1 type 3 ELISA (Bio Techne, Abingdon-on-Thames, UK) was used to measure the troponin-1
levels. The troponin-1 levels were measured in accordance with the manufacturer’s instructions. The
coefficient of variation was 4.0% intra-assay and 4.6% interassay for the troponin-1 levels.
The BNP ELISA (Bio Techne, Abingdon-on-Thames, UK) was used to measure the BNP levels. The BNP levels
were measured in accordance with the manufacturer’s instructions. The coefficient of variation was 10%
intra-assay and 15% interassay for the BNP assay.
The human midregional pro-atrial natriuretic peptide ELISA (2B Scientific, Upper Heyford, UK) was used to
measure the MRProANP levels. The MRProANP levels were measured in accordance with the manufacturer’s
instructions. The coefficient of variation was 8% intra-assay and 10% interassay for the MRProANP levels.
The human CRP Quantikine assay (Bio Techne, Abingdon-on-Thames, UK) was used to measure the CRP
levels. The CRP levels were measured in accordance with the manufacturer’s instructions. The coefficient of
variation was 5.5% intra-assay and 6.5% interassay for the CRP assay.
Statistical analysis
The biomarker analysis included all women with suspected PE or diagnosed DVT who provided consent
and an analysable blood sample. Women with suspected PE were classified as having VTE if they were
classified as having PE in accordance with the method described in the case–control study. The primary
and secondary analyses were planned along the lines outlined in the case–control study. Women recruited
with diagnosed DVT were all classified as having VTE and included in the primary analysis.
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Blood samples were analysed at GSTT and the results of the analysis were sent to the Sheffield CTRU.
GSTT established normal ranges for the assays using 20 normal plasma/serum samples (depending on the
assay), with the 99th percentile used as the top of the normal range.
We calculated the AUC for each biomarker and the sensitivity and specificity at the upper limit of the
normal range. We then examined the ROC curve to determine whether or not there was an optimal
threshold for clinical practice, whereby sensitivity exceeds 95% but specificity still allows a meaningful
proportion of women without PE to have the diagnosis ruled out.
Results
The characteristics of the 324 recruited women with suspected PE are described in Chapter 3. Blood
samples were taken from 312 out of 324 women. The reasons for failure to take a blood sample were
inability to draw blood (n = 7), patient refused (n = 2), unavailability of blood-handling services (n = 1),
patient discharged before venepuncture (n = 1) and unknown (n = 1). Two samples were not labelled
correctly (one from a woman with PE clinically ruled out without imaging and one with PE ruled out by
negative imaging) and were therefore not analysed, leaving 310 samples for analysis.
We recruited 18 women with diagnosed DVT, nine of whom were recruited at Guy’s and St Thomas’
Hospital Maternity Unit (a specialist centre); the remaining nine women were recruited from Leeds
Teaching Hospitals Maternity Unit (n = 3), Queen Alexandra Hospital Portsmouth Maternity Unit (n = 3),
Royal Berkshire Hospital Maternity Unit (n = 2) and Bradford Royal Infirmary Maternity Unit (n = 1).
A further six were eligible for recruitment but declined to participate.
The women with diagnosed DVT had a mean age of 28.3 years, a mean BMI of 26.3 kg/m2 and were
from the following ethnic groups: white British (n = 9), black African (n = 2), black Caribbean (n = 1),
Asian Pakistani (n = 1), mixed white and black African (n = 1), mixed white and black Caribbean (n = 1),
other white (n = 1) and other ethnic group (n = 2). They included seven married, three single and eight
cohabiting women; 11 women were employed and seven were unemployed, and by gestational age, one
women was in the first trimester, one women was in the second trimester, nine women were in the third
trimester and seven women were post partum.
Adding the 18 samples from women with DVT to the 310 samples from women with suspected PE gave
328 samples for analysis. The 310 women recruited with suspected PE consisted of 18 women with PE
confirmed by imaging (including one women with subsegmental PE), five women with clinically diagnosed
PE (three with equivocal imaging and two with no imaging; all treated), 247 women with PE ruled out
after imaging (242 women with negative imaging and five untreated after equivocal imaging) and
40 women with PE clinically ruled out without imaging (none treated). Thus, 36 women with VTE and
247 women without VTE were included in the primary analysis; 41 women with VTE and 247 women
without VTE were included in the secondary analysis including clinically diagnosed PE; 36 women with VTE
and 287 women without VTE were included in the secondary analysis including clinically ruled-out PE;
and 35 women with PE and 247 women without PE were included in the secondary analysis excluding
subsegmental PE.
Table 14 compares the mean biomarker levels between women with and without VTE in the primary
analysis. D-dimer (both assays), TG (lag time and time to peak), Clauss fibrinogen and plasmin–antiplasmin
had significantly higher mean levels in women with VTE than in women without VTE. The mean levels of
the other biomarkers did not significantly differ between the groups.
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Appendix 11 provides further details for each biomarker, with a box-and-whisker plot showing the
distribution for women with DVT, women with PE and women with no PE, and those who were excluded
from the analysis. The distributions of all biomarkers overlapped substantially between women with and
without VTE.
Figures 5–7 show the ROC curves for the D-dimer, APTT, PF 1 + 2, PT and TG biomarkers, and for the
other biomarkers. It was not possible to identify a threshold for any biomarker that would optimise
sensitivity (> 98%) while maintaining meaningful specificity.
Table 15 reports the AUROC for the continuous biomarker and diagnostic parameters for the biomarkers
at the predefined threshold for positivity and the threshold that optimised sensitivity (> 95%) at the
expense of specificity. No biomarker had sufficient sensitivity to rule out VTE while achieving meaningful
specificity, with the possible exception of TG (lag time), with an AUC of 0.702, a sensitivity of 97% and a
specificity of 25% at the threshold that optimised sensitivity at the expense of specificity.
TABLE 14 Mean (standard deviation) biomarker levels for the patient groups in the primary analysis
Biomarker
Mean biomaker level (SD) in women with
p-valueNo VTE (N= 247) VTE (N= 36)
APTT (minutes) 39.7 (22.1) 41.4 (13.2) 0.660
Clauss fibrinogen 5.37 (1.69) 6.30 (2.73) 0.007
CRP level (pg/ml) 5348 (1705) 5603 (1646) 0.401
PT (minutes) 16.2 (5.4) 18.7 (13.2) 0.089
D-dimer (ELISA) 1247 (1474) 2401 (2642) 0.001
D-dimer (Innovance) 1.147 (1.269) 2.282 (3.388) 0.004
TG (lag time) 8.70 (4.84) 13.85 (8.30) < 0.001
TG (endogenous potential) 1217 (558) 1081 (561) 0.241
TG (time to peak) 14.8 (9.1) 21.5 (13.1) 0.001
TG (peak) 162 (116) 130 (124) 0.160
Plasmin–antiplasmin level 688 (251) 915 (647) 0.004
BNP level 372 (900) 385 (731) 0.932
MRproANP 603 (1016) 753 (1159) 0.415
Tissue factor (pg/ml) 291 (320) 488 (1067) 0.065
PF 1 + 2 (pmol/l) 623 (408) 550 (333) 0.298
Troponin level (ng/ml) 1.328 (2.458) 0.762 (0.968) 0.105
SD, standard deviation.
Adapted from Hunt et al.56 This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial License (CC BY-NC 4.0), which permits use, distribution and reproduction in any medium, provided the
original work is properly cited and is not used for commercial purposes.
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Analysis excluding women who had received anticoagulation treatment
Anticoagulation treatment with heparin is known to interfere with biomarker assays. Unfractionated
heparin will prolong the APTT and thrombin time and low-molecular-weight heparin (LMWH) may cause a
slight prolongation of the APTT. However, suppressing the activation of both Factor Xa and thrombin will
decrease all parameters of the TG assay and PF 1 + 2. Furthermore, decreasing the generation of thrombin,
which is a major stimulator of fibrinolysis, will reduce the D-dimer and plasmin–antiplasmin values.
We repeated the analysis, having excluded 240 out of 328 women who had received anticoagulation
treatment prior to blood sampling. The primary analysis involved only 66 women, of whom only four had
VTE, so the findings were limited by small numbers. Details of the findings are provided in Appendix 11.
The differences in mean biomarker levels observed in the main analysis between women with and without
PE disappeared or even reversed when those receiving anticoagulation treatment were removed, but this
probably reflects the small numbers. ROC analysis suggested that BNP (AUC 0.774, 95% CI 0.670 to 0.878),
PF 1 + 2 (0.795 pmol/l, 95% CI 0.644 to 0.947 pmol/l), TG lag time (0.735, 95% CI 0.531 to 0.940) and
troponin (0.742 ng/ml, 95% CI 0.453 to 1.000 ng/ml) may have some potential to rule out VTE with
acceptable sensitivity, but the CIs were wide and estimates would need to be validated in a larger cohort
with VTE.
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FIGURE 5 Receiver operating characteristic curves for D-dimer biomarkers. Adapted from Hunt et al.56 This is an
open access article under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0),
which permits use, distribution and reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.
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Discussion
We were unable to identify any biomarker that would provide clinically useful discrimination between
women with and without VTE. In the analysis involving all patients, Clauss fibrinogen, both D-dimer assays,
TG (lag time and time to peak) and plasmin–antiplasmin had significantly higher levels in those with VTE
than in those without. Other biomarker levels did not significantly differ between women with and
without VTE. The only biomarker with an AUC that was > 0.7 was TG (lag time), with an AUC of 0.702.
The ROC curves showed that there was no threshold for sensitivity and specificity that would be useful for
clinical decision-making, with the possible exception of TG (lag time), with a sensitivity of 97% and a
specificity of 25% at the threshold that optimised sensitivity at the expense of specificity.
Most of the women in the analysis (240/330) had received anticoagulation treatment prior to blood
sampling. As a consequence, most of the coagulation biomarkers were affected because all forms of
heparin used to treat these women (unfractionated and LMWH) suppress coagulation activation, and thus
TG and PF 1 + 2 are suppressed and APTT and thrombin time are prolonged. Furthermore, thrombin is a
major stimulator of fibrinolysis and, therefore, when thrombin is reduced, there is less increment in
plasmin–antiplasmin and D-dimer.
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FIGURE 6 Receiver operating characteristic curves for APTT, PF 1+ 2, PT and TG biomarkers. Adapted from Hunt
et al.56 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License
(CC BY-NC 4.0), which permits use, distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
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To address this issue, we repeated the analysis, excluding those who had received anticoagulation
treatment. Unfortunately, this reduced the sample size markedly and included only four women with VTE.
No biomarker showed any association with VTE, although this may reflect a lack of statistical power. BNP,
PF 1 + 2, TG (lag time) and troponin may have some potential to rule out VTE with acceptable sensitivity,
but the CIs are wide, being based on only four women with VTE. Further validation is therefore required in
a larger cohort of women with VTE.
We selected the biomarkers for analysis on the basis of previous evidence suggesting that they may be
diagnostically useful. Outside pregnancy, within secondary care, the D-dimer measurement has been
validated as a useful biomarker to aid in the diagnosis of PE. Indeed, it is chiefly used for its negative
predictive value in combination with a low Wells’s score to exclude PE.57 The previous data on the use of
D-dimer in pregnancy are of low quality, but some authors have suggested that D-dimer is increased in
women with PE during pregnancy.58 However, there are more substantial data showing that, in normal
pregnant women, D-dimer values increase continuously during pregnancy across all gestation periods and
that the ‘normal range’ outside pregnancy cannot be applied to pregnant women.21,59 Hedengran et al.59
also showed that the D-dimer values in individual healthy pregnant women fluctuated by > 50%, and thus
concluded that they may not be of value in the diagnosis of VTE during pregnancy.
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FIGURE 7 Receiver operating characteristic curves for the other biomarkers. Adapted from Hunt et al.56 This is an
open access article under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0),
which permits use, distribution and reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.
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TABLE 15 The AUROC, sensitivity and specificity for each biomarker
Biomarker
AUC
(95% CI)
At the predefined threshold, %
(95% CI)
At the threshold with optimal
sensitivity, % (95% CI)
Sensitivity Specificity Sensitivity Specificity
APTT (minutes) 0.669
(0.570 to 0.768)
0.088
(0.019 to 0.237)
0.914
(0.870 to 0.947)
0.971
(0.847 to 0.999)
0.086
(0.053 to 0.130)
BNP level 0.549
(0.453 to 0.645)
0.167
(0.064 to 0.328)
0.879
(0.831 to 0.917)
0.972
(0.855 to 0.999)
0.146
(0.104 to 0.196)
CRP level (pg/ml) 0.542
(0.445 to 0.639)
0.861
(0.705 to 0.953)
0.121
(0.083 to 0.169)
0.972
(0.855 to 0.999)
0.032
(0.014 to 0.063)
Clauss fibrinogen 0.589
(0.476 to 0.701)
0.778
(0.608 to 0.899)
0.228
(0.177 to 0.286)
0.972
(0.855 to 0.999)
0.066
(0.038 to 0.106)
D-dimer (ELISA) 0.668
(0.561 to 0.776)
0.861
(0.705 to 0.953)
0.196
(0.148 to 0.251)
0.972
(0.855 to 0.999)
0.037
(0.017 to 0.069)
D-dimer (Innovance) 0.651
(0.545 to 0.758)
0.528
(0.355 to 0.696)
0.727
(0.666 to 0.781)
0.972
(0.855 to 0.999)
0.078
(0.047 to 0.118)
MRproANP 0.524
(0.418 to 0.630)
0.278
(0.142 to 0.452)
0.785
(0.729 to 0.835)
0.972
(0.855 to 0.999)
0.097
(0.063 to 0.141)
PF 1 + 2 (pmol/l) 0.562
(0.462 to 0.661)
0.056
(0.007 to 0.187)
0.935
(0.896 to 0.962)
0.972
(0.855 to 0.999)
0.045
(0.023 to 0.079)
Plasmin–antiplasmin level 0.639
(0.536 to 0.742)
0.472
(0.304 to 0.645)
0.763
(0.705 to 0.815)
0.972
(0.855 to 0.999)
0.041
(0.020 to 0.074)
PT (minutes) 0.613
(0.508 to 0.718)
0.486
(0.314 to 0.660)
0.730
(0.669 to 0.785)
0.971
(0.851 to 0.999)
0.084
(0.052 to 0.127)
TG (lag time) 0.702
(0.598 to 0.806)
1.000
(0.888 to 1.000a)
0.000
(0.000 to 0.017a)
0.968
(0.833 to 0.999)
0.251
(0.195 to 0.314)
TG (endogenous potential) 0.559
(0.437 to 0.681)
0.231
(0.090 to 0.436)
0.706
(0.638 to 0.767)
0.962
(0.804 to 0.999)
0.069
(0.038 to 0.112)
TG (peak) 0.596
(0.478 to 0.715)
0.000
(0.000 to 0.097)
0.996
(0.977 to 1.000)
0.968
(0.833 to 0.999)
0.059
(0.032 to 0.099)
TG (time to peak) 0.655
(0.541 to 0.769)
1.000
(0.888 to 1.000)
0.110
(0.071 to 0.159)
1.000
(0.888 to 1.000)
0.114
(0.075 to 0.164)
Tissue factor (pg/ml) 0.531
(0.424 to 0.638)
0.222
(0.101 to 0.392)
0.771
(0.714 to 0.822)
0.972
(0.855 to 0.999)
0.037
(0.017 to 0.069)
Troponin level (ng/ml) 0.597
(0.499 to 0.695)
0.056
(0.007 to 0.187)
0.887
(0.840 to 0.923)
0.972
(0.855 to 0.999)
0.085
(0.053 to 0.127)
a All participants had abnormally high lag time, giving a sensitivity of 1 and a specificity of 0. CIs are one-sided 97.5%
binomial intervals.
Adapted from Hunt et al.56 This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial License (CC BY-NC 4.0), which permits use, distribution and reproduction in any medium, provided the
original work is properly cited and is not used for commercial purposes.
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During clot formation there is activation of coagulation and, therefore, we did look at markers that
measured this, which measured simple coagulation tests, PF 1 + 2 and TG. In actuality, these have been
poorly studied in diagnosing VTE outside pregnancy because the D-dimer assay has long been well
established, can be done cheaply and, most importantly, is validated in the non-pregnant setting. Whether
or not any of these markers might have an ancillary role in the diagnosis of VTE both inside and outside
pregnancy remains uncertain because of the effects of anticoagulation.
This analysis has a number of limitations. We were unable to obtain blood samples from the UKOSS cohort
with diagnosed PE and so we had to supplement the anticipated low prevalence of PE among women
with suspected PE by including women with diagnosed DVT. Women with DVT are likely to have a lower
thrombotic load than women with PE and are less likely to have cardiac strain, so biomarkers may be less
sensitive for DVT than for PE. Most of the blood samples were taken after anticoagulation treatment was
given, which we considered (especially from the effect on TG) to have interfered with the biomarker assays
and reduced their diagnostic value. This is an inevitable consequence of the current guidance33 stating
that patients with suspected PE should be given anticoagulation treatment while awaiting diagnostic
testing if any delay is anticipated. We repeated the analysis, having excluded women who had received
anticoagulation treatment, but this resulted in a small sample size with little statistical power to draw
reliable conclusions.
Conclusion
Our analysis suggests that there are currently no biomarkers that can be recommended for clinical use
as a way of selecting women with suspected PE in pregnancy or post partum for imaging. The findings for
D-dimer in particular suggest that it should not be recommended for use in the diagnostic work-up of PE
in pregnancy.
Future research would ideally test biomarkers on a large cohort including a substantial number of women
with VTE and would involve blood-sampling before anticoagulation treatment is given. This will be very
difficult to achieve, owing to the need to give anticoagulation treatment as soon as the suspicion of VTE is
raised. Unless consent is obtained very quickly from such women, it would not be ethical to pursue this.
Our study is reflective of this, as we were able to recruit only four women with VTE who had not received
anticoagulation treatment before blood sampling, despite recruiting from 11 sites over 18 months.
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Chapter 5 Decision-analysis modelling
Introduction
An economic model evaluated the cost-effectiveness of using a CDR in pregnant women with suspected
PE. In the model, 10 strategies were tested: (1) scanning all pregnant women with suspected PE (current
recommended care), (2–4) applying the three expert-derived clinical consensus decision rules (primary,
sensitive and specific), (5) applying a permissive interpretation of Wells’s decision rule (Wells’s permissive),
(6) applying a strict interpretation of Wells’s decision rule (Wells’s strict), (7) applying the PERC decision
rule, (8) applying the simplified Geneva decision rule, (9) scanning no women, but treating all (SNTA) and
(10) scanning no women and treating no women (SNTN). The sensitivity and specificity of these strategies
were estimated using the primary data. Sensitivities and specificities of strategies based on CDRs were
estimated from the women with PE confirmed or ruled out in the case–control study primary analysis.
In all of the strategies involving a decision rule, women with a positive decision rule result received a
scan and those with a negative result did not. If a woman’s scan result was positive, they then received
anticoagulation treatment. Strategies 9 and 10 are included as there is little evidence supporting whether
or not the benefits of current care outweigh the risks of exposing pregnant/postpartum women to radiation.
Literature review
Study identification
The searches were conducted in MEDLINE, MEDLINE In process and NHS Economic Evaluation Database on
the 25 August 2016. The disease-specific search terms were the same as those used in the DiPEP literature
review.7 The Scottish Intercollegiate Guidelines Network economic search filters were added to these
search terms. Cost-effectiveness studies on CDRs were identified using the criteria given in Appendix 12.
Results
No studies were found that estimated the cost-effectiveness of the use of selective imaging for the
diagnosis of PE in pregnant or postpartum women. The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) flow diagram is given in Appendix 12. The key finding is that no economic
study has previously been conducted in a population of women who were pregnant or post partum.
Methods
Decision problem and perspective
The economic modelling assessed whether or not using CDRs would be cost-effective compared with
scanning all (current care) and scanning none for pregnant or postpartum women who had a suspected PE
in the UK. In line with NICE guidance, the analyses took a NHS and personal social services perspective and
a lifetime horizon, and future costs and QALYs were discounted at a rate of 3.5% per annum.60
Model description
A patient-level decision tree was developed in Microsoft Excel 2016 to estimate the cost-effectiveness of
the 10 strategies for pregnant or postpartum women with a suspected PE at admission. A decision tree is
believed to be an appropriate model for this decision problem, as events do not repeatedly occur over
time, representing the likely clinical reality for pregnant/postpartum women with suspected PE. The
structure also reflects the fact that the model is estimating the impact of a single decision at a single point
in time. A patient-level model was chosen over a cohort model, as this allowed the model to include the
DOI: 10.3310/hta22470 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 47
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
fact that women who were more likely to die if untreated were also more likely to have a positive CDR
and hence be referred for a scan.
Patient population
The population included in the economic model was pregnant or post partum (up to 6 weeks after birth)
women who presented with a suspected PE at a UK hospital. The fetuses were considered to be outside
the scope of the model, apart from any imaging-induced childhood cancers.
The primary statistical classification was used to determine whether or not women had PE. In this analysis
group, the population was limited to women with PE diagnosed by imaging or post-mortem examination
and women with PE ruled out after imaging. After statistical imputation in the suspected PE cohort,
13 women with PE and 248 without PE had complete data for all decision rules. In line with the statistical
analysis of rule sensitivity and specificity, these data were supplemented by 144 women with diagnosed PE
and from the UKOSS observation data set.
Estimation of outcomes across the populations
The model estimates the costs and QALYs for each strategy in the PE and no PE populations separately.
The costs and QALYs for each strategy in the population with a suspected PE were calculated using the
following formula:
Mean outcome pop =mean outcome PE × probability of having PE +mean outcome no PE
× (1−probability of having PE),
(1)
in which the mean outcomes are derived from the model and the probability of having PE is obtained from
the suspected PE data set only.
Determining the number of patients
The model uses a bootstrapping procedure to estimate the lifetime costs and QALYs for each strategy.
Within each bootstrap, 157 women with PE and 248 women without PE are sampled from their respective
populations with replacement. It was determined that 100 bootstraps were sufficient to produce robust
results. Details of how this was determined are provided in Appendix 13.
Model structure
The model was structured as an individual-level decision tree; the key aspects of the model are presented
in Figure 8. The key events included in the decision tree were PE-related death, major bleeding events,
deaths associated with major bleeding events, chronic thromboembolic pulmonary hypertension (CTEPH),
recurrent VTE and deaths from recurrent VTE.
In the base case, it was assumed that recurrent VTE and CTEPH were modifiable by anticoagulation in pregnant/
postpartum women with a suspected PE. Furthermore, it was assumed that the risk of major bleeding events
was assumed to be solely attributable to anticoagulation. If a woman experienced a major bleeding event
following an initial anticoagulation treatment, then it was assumed that they would not receive anticoagulation
for any subsequent VTEs or gain a therapeutic benefit from their current anticoagulation treatment. Minor
bleeding events were excluded from the economic model, as the definition of major bleeding events included
all clinically overt bleeds that could have resulted in a hospitalisation. Finally, it was assumed that each woman
was at risk of only one recurrent VTE, which was assumed on the grounds that the PE for these women was
related to their pregnancy rather than other underlying conditions, which would typically be present in the
population that presents with a VTE.
For all women who were scanned, a QALY decrement and treatment cost were applied for imaging-induced
lung and breast cancers in the mother, and a QALY decrement was applied for childhood cancers induced by
imaging in the fetuses who would survive anticoagulation to term. These were identified as the key harms
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FIGURE 8 The key aspects of the economic model: (a) true-positive scan; (b) false-positive scan; (c) false-negative scan;
and (d) true-negative scan. CTEPH, chronic thromboembolic pulmonary hypertension; ICH, intracranial haemorrhage.
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from scanning. We did not model any cost or QALY loss associated with teratogenesis, as evidence suggests
that this is not a significant risk.61
Model data
Clinical parameters
The clinical parameters in the model included the CDRs, the sensitivity and specificity of scanning, the risk
of death after PE, the risk of major bleeding, the risk of recurrent VTE and the risk of CTEPH. A summary
of all clinical parameters used in the base case are given in Appendices 15–17.
The clinical decision rules
Seven CDRs were modelled in line with the statistical analysis. Details are provided on these rules in
Chapter 2 and Appendix 2. In brief, all decision rules assigned a score to clinically identifiable factors for
women with a suspected PE at presentation. This score was compared to a cut-off value that was specific
to each decision rule. If the woman scored above the cut-off value, they were sent to be scanned and if
they scored lower than the cut-off value, they did not receive scanning.
Sensitivity and specificity of scanning
In the base case, it was assumed that all scanning techniques allowed a perfect diagnosis of PE. This
assumption was made based on the clinical advice that it would not be possible to know which scan
results were false positive or false negative from the DiPEP study, but these were unlikely to be random
events and were instead likely to be linked to the woman’s characteristics and the severity of the PE.
Therefore, it was deemed to be clinically implausible that the sensitivity and specificity of the scan results
would be independent of the woman’s decision rule score. A scenario analysis was conducted, in which
it was assumed that the sensitivity and specificity of the scans were independent of the CDRs. In this
scenario analysis, the sensitivity and specificity of a CTPA scan was taken from Ohno et al.62 [magnetic
resonance angiography with sensitivity encoding (SENSE) for suspected PE: comparison with multidetector
computed tomography and VQ scintigraphy] and the sensitivity and specificity of a VQ scan was taken
from Gutte et al.,63 [comparison of VQ single photon emission computed tomography (VQ SPECT) and
planar VQ lung scintigraphy in diagnosing acute PE], as these values were used in the cost-effectiveness
analysis supporting the NICE guidelines on the diagnosis of PE.33
The risk of 30-day mortality following a pulmonary embolism
Aujesky et al.64 conducted a cohort study of adults (aged ≥ 18 years old) diagnosed with PE between
January 2000 and November 2002 in the USA. No restriction was made to limit the study population
to women who were either pregnant or in the postpartum period. The study assessed the risk factors
associated with 30-day all-cause mortality for people diagnosed with PE. However, the study could not be
used to estimate the risk of 30-day all-cause mortality in the model for three reasons. First, the constant
parameter was not presented in the paper, meaning that the mortality risk could not be estimated.
Second, it was unclear whether or not a multivariate logistic regression had been fitted or rather a series
of univariate analyses. Finally, the variance–covariance matrix was not given, meaning that the parameters
could not be correlated if they were from a multivariate analysis.
To overcome these limitations in the literature, an expert elicitation exercise was conducted. Data were
extracted for each woman with PE in the primary analysis on their heart rate, respiratory rate, oxygen
saturation, temperature, blood pressure, whether they were post partum or pregnant and, if they were
pregnant, how many weeks into the pregnancy they were. Risk factors that were not modifiable by
treatment, such as age and cancer status, should be excluded from the elicitation exercise on the advice of
clinical experts. Data were also presented to the experts on the risk of death in the UKOSS cohort (2.82%,
95% CI 0.92% to 6.47%), to ensure that each expert did not believe that the average elicited risk of death
was implausible to them. These data were presented to the four experts and they were asked to estimate
the risk of death for each woman if they had received anticoagulation treatment. Based on these data,
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four experts in the project management group (SG, GF, FL, CNP) were asked to estimate the probability of
death within 30 days for each woman if they had received anticoagulation treatment.
To combine the expert’s answers, the average value across all four expert answers for each woman’s risk
of death was taken. If more than one expert believed that they could not estimate a probability of death
for a woman given her characteristics, then these data were treated as missing.
These data were analysed into the model by preforming a beta regression.65 The risk of death from PE within
30 days was the predicted variable. All variables presented to the experts were included as explanatory
variables. Scenario analyses were conducted in the secondary, tertiary and quaternary statistical analysis
populations. Further scenario analyses were conducted in which the answers for each expert individually
were used in the primary population data set. The results of the beta regression and the scenario analyses
are presented in Appendix 15.
The risk of major bleeding and the split of bleeding types
The probability of a major bleeding event occurring was obtained from Carrier et al.66 Carrier et al.66 was a
systematic review of case fatality rates of recurrent VTE and major bleeding events among patients treated
for an initial VTE. Studies published between 1950 and September 2008 were identified.66 For people who
received anticoagulation treatment for 3 months, the probability of a major bleeding event was 1.8%
(95% CI 1.1% to 2.6%) and the probability of a fatal major bleeding event was 0.2% (95% CI 0.1% to
0.4%). For people who received anticoagulation treatment for 6 months, the probability of a major bleeding
event was 2.1% (95% CI 1.5% to 2.7%) and the probability of a fatal major bleeding event was 0.6%
(95% CI 0.01% to 2.5%).
The proportion of the different types of major bleeding events was taken from Ensor et al.,67 which reported
this parameter for a population that had a recurrent VTE in a large European data set (n = 15,041).67 The split
of major bleeding events in this database was 499 gastrointestinal bleeds, 245 intracranial haemorrhages and
622 other bleeds. These data were used to estimate the split of bleeding events in the base case.
The risk of recurrent venous thromboembolism
The probability of experiencing a recurrent VTE while on anticoagulation treatment was obtained from
Carrier et al.66 For people with an initial PE, the risk of a recurrent VTE while on anticoagulation treatment
was 3.6% (95% CI 2.3 to 5.0) for 3 months of anticoagulation treatment and 4.9% (95% CI 1.5 to 10.15)
for 6 months of anticoagulation treatment.
The risk of death following a recurrent venous thromboembolism
The probability of a recurrent VTE being fatal while a person is on anticoagulation treatment was obtained
from Carrier et al.66 For people with an initial PE, the case fatality rate for a recurrent VTE was 30.1%
(95% CI 12.3 to 51.8) for 3 months of anticoagulation treatment and 20.6% (95% CI 8.9 to 35.5) for
6 months of anticoagulation treatment. A sensitivity analysis was conducted in which the case fatality rate
for a recurrent VTE was set to 0, as the case fatality rate will reflect some underlying comorbidities that are
present in an older population, but are unlikely to be present in pregnant women.
The risk of chronic thromboembolic pulmonary hypertension
The risk of CTEPH following PE has been estimated to vary widely across studies, with studies estimating the
cumulative risk of CTEPH following PE to be 0.4–9.1%.68 The risk of CTEPH was estimated in the base case
by assuming that the probability of CTEPH was the same as the risk of death from PE obtained from the
expert elicitation exercise. This approach was preferred, as it meant that the risk of CTEPH was proportional
to the likely size of the embolus. A scenario analysis was conducted in which the risk of CTEPH after PE was
estimated to be 0.5% (4 out of 866 patients in the cohort were diagnosed with CTEPH) based on the data
presented in Klok et al.69 This study was chosen for the scenario analysis as, out of the studies referenced in Lang
et al.,68 it had adequate numbers of patients with PE (n= 866) who were relatively young (mean age 56 years),
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a high proportion of women (52.7%), a relatively long follow-up period of 34 months, and patients that were
recruited between 2001 and 2007 (which is relatively recent compared with the other studies).
Adjustments if a women with a pulmonary embolism did not receive
anticoagulation treatment
Barrit and Jordan70 conducted a small randomised controlled trial in one hospital that showed that the
odds ratios for untreated people with PE compared with people treated with anticoagulation treatment
were 6.923 (95% CI 0.734 to 65.259) for all-cause mortality (6/19 vs. 1/16), 16.667 (95% CI 1.818 to
152.770) for recurrent VTE or death (1/16 vs. 10/19) and 12.517 (95% CI 0.636 to 246.384) for odds ratio
for fatal PE (0/16 vs. 5/19). For people who were untreated, their risk of death from PE was modified using
the odds ratio estimated for the risk of death from a fatal PE, their risk of a recurrent VTE was modified
using the odds ratio estimated for the risk of recurrent VTE or death and their risk of a CTEPH event was
modified using the odds ratio estimated for the risk of recurrent VTE or death. The assumption that the
risk of CTEPH was modifiable by anticoagulation was made on the basis of the expert clinical input of the
four clinicians who took part in the expert elicitation exercise. For women who had their anticoagulation
treatment discontinued as a result of bleeding events, it was assumed that they received no benefit from
their initial anticoagulation treatment, as this is the worst-case scenario.
The percentage of fetuses that survive to term
The percentage of fetuses that survived to term was estimated using the data on the number of fetuses
that were either terminated, miscarried, died or were a still birth at the 30-day follow-up point for
women who were pregnant and did not die from PE. The percentage of fetuses that survived to term
was estimated separately for women who had a confirmed PE and women who had a suspected PE, but
not an actual PE. For the surviving women with PE, 96.5% of fetuses (167/173) survived until the 30-day
follow-up point. For the surviving women with suspected PE, 100% of fetuses (258/258) survived until the
30-day follow-up point.
Life expectancies
All-cause life expectancy
Women who had no adverse events or survived their adverse events and did not end up having a disabling
bleed or a CTEPH were assumed to have a normal life expectancy for their age at diagnosis. This age-specific
life expectancy was calculated for each woman by age at diagnosis using a Markov model. The model took a
time horizon of up to 100 years old and had a yearly time cycle. In each cycle, the woman’s age-specific risk
of death was obtained from the Office for National Statistics (ONS) all-cause mortality statistics for the UK.71
A half-cycle correction was applied, assuming that all deaths would occur, on average, half-way through
a year.
Pulmonary embolism and recurrent venous thromboembolism
Other than the case fatality rates, no long-term increased risk of death for women who experienced
PE or recurrent VTE was modelled. However, a short-term risk of death was applied based on the expert
elicitation exercise and the case fatality rates from Carrier et al.66 (see The risk of 30-day mortality following a
pulmonary embolism and The risk of death following a recurrent venous thromboembolism). If the women
survived the decision tree with no intracranial bleeds or CTEPH, then they were assumed to receive the same
life expectancy as the general population.
Life expectancy after chronic thromboembolic pulmonary hypertension
Delcroix et al.72 conducted a retrospective analysis of long-term outcomes in people with newly diagnosed
CTEPH from 27 centres in Europe and Canada between 2007 and 2009. They presented Kaplan–Meier curves
for two groups: those who were surgically treated and those who were medically treated. Quasi-patient-level
data were obtained from the Kaplan–Meier curves using the Guyot et al.73 method. Exponential, Weibull,
Gompertz, log-normal and log-logistic parametric survival curves were fitted to these data.74 The goodness
of fit of the curves was assessed using visual assessment and the Bayesian information criterion [(BIC) see
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Appendix 16]. On this basis, a log-normal curve was selected to model post-CTEPH mortality in the surgically
treated group and an exponential curve was selected to model post-CTEPH mortality in the medically treated
group. When the curves were extrapolated for use in the model, it was assumed that age did not influence
the extrapolated curve and that the probability of death in each year would be constrained so that it could
not be less than the age-matched risk of death for a woman in the ONS life tables.71 In the study by Delcroix
et al.,72 404 patients were treated surgically and 275 patients were treated medically. In the base case, it was
assumed that 59.4% (404/679) were treated surgically. A scenario analysis was also conducted in which
100% of women were treated surgically, as it was noted that the surgically treated group were much
younger than the medically treated group (mean age 60 years vs. 67 years). The life expectancy was calculated
using parametric survival curves and a yearly time cycle and deaths were assumed to occur half-way through
the year.
Life expectancy after an intracranial haemorrhage
In the economic model, it was assumed that all patients who had an intracranial haemorrhage suffered a
stroke. The base case used data from the study by Fogehom et al.,75 which suggested that the annual risk
of dying after a stroke compared with the general Finish population was 4.5-fold in the first year, 2.2-fold
in years 2–6 and 0.9-fold in years 7–16.75 The population analysed had a mean age of 67.3 years, and
48.4% of the population were male. No SEs were presented. In the base case, it was assumed that women
who suffered an intracranial haemorrhage had a 4.5-fold increase in their general population mortality in
the first year and a 2.2-fold increase in their general population mortality in the years 2–6. On the grounds
of clinical plausibility, it was assumed that women returned to their baseline risk of mortality from year 7
onwards rather than experiencing a reduction in their mortality risk. Other than the inclusion of the
mortality ratio in the all-cause risk of death, life expectancies were calculated using the same method as
was used to calculate the life expectancy in the general population.
Quality of life
The quality-of-life parameters used in the economic model, along with the distributions used in the
probabilistic sensitivity analysis (PSA), are given in Appendix 17.
General population
The utility of the general population was calculated using the formula from Ara and Brazier.76 The formula
adjusts each individual’s utility score for their gender and age, as given in the formula below:
General population utility = 0:9508566 + 0:0212126(1 =male, 0 = female) − 0:0002587
× age − 0:0000332 × age2.
(2)
Quality of life following a pulmonary embolism
Locadia et al.77 conducted the time trade-off technique to value health states (on the scale of 1 being
equivalent to perfect health and 0 being equivalent to death) related to VTE in 159 patients who had
either experienced a VTE, a bleeding event related to receiving a vitamin K antagonist (VKA), or had a
post-thrombotic syndrome. They reported the median valuations and interquartile ranges of no VKA
treatment, own current health, VKA treatment, post-thrombotic syndrome, DVT, muscular bleeding,
gastrointestinal bleeding, PE and non-fatal haemorrhagic stroke. The mean valuations were not reported.
Locadia et al.77 found that PE had a median valuation of 0.63, with an interquartile range of 0.36–0.86.
On the basis of clinical input, this median value was applied multiplicatively to each patient’s baseline
utility for a period of 4 weeks.
Quality of life following a recurrent venous thromboembolism
The ratio of PEs and DVT for people experiencing a recurrent VTE was taken from Carrier et al.,66 who
found that out of the people with initial PE, 3.0% (95% CI 2.5% to 3.7%) had recurrent PE and 3.6%
(95% CI 2.3% to 5.0%) had a recurrent VTE after 3 months of anticoagulation.66 The associated utility
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value for a DVT event was obtained from Locadia et al.,77 who found that the median valuation for a DVT
was 0.84, with an interquartile range of 0.64–0.98. On the basis of clinical input, this median value was
applied multiplicatively to each patient’s baseline utility for a period of 4 weeks.
Quality of life following a bleeding event
Locadia et al.77 reported utility losses related to bleeding associated with the treatment of VTE. The utility for
people with a gastrointestinal bleed was 0.65 with an interquartile range of 0.49–0.86 and the utility for
people with a non-fatal haemorrhagic stroke was 0.33 with an interquartile range of 0.14 to 0.53. No utility
values were reported that included all other types of bleeding; therefore, it was assumed that women who
experienced another bleeding event had the same utility value as women who had a gastrointestinal bleeding
event. In the model, women who experienced an intracranial haemorrhage had a permanently reduced quality
of life and women who experienced another type of bleeding had a reduced quality of life for 4 weeks.
Quality-of-life losses resulting from cancers induced by imaging
There were two elements to the quality-of-life losses resulting from an imaging-induced cancer. First, there
was a quality-of-life loss associated with cancer, and second, there was the estimated risk of a cancer
being induced by a scan.
A decrement was applied to those individuals who were estimated to have cancer. Ara and Brazier78
estimated the utility of an individual with cancer as being 0.697 (95% CI 0.657 to 0.736) and the utility
for equivalent people without cancer as being 0.795 (95% CI 0.754 to 0.836).78 This gave a utility
multiplier of 0.8767. This utility multiplier was applied to each individual’s baseline utility for the remainder
of their lifetime after they developed a type of cancer.
The lifetime attributable risks of developing radiation-induced cancers were obtained from the literature.61
Based on the available data, imaging-induced breast and lung cancers in the mother and childhood
cancers in the fetus were included in the analysis. No information was available on the yearly risk of
developing a type of cancer as a result of a single scan. Owing to this lack of data, it was assumed that
the incidence of radiation-induced cancers would follow that of the general population.79 The life
expectancy of individuals with and without cancer were therefore normalised based on the age-specific
incidence of cancer in the whole population, which will include some radiation-induced cancers and
cancers that develop as a result of other causes. For the mothers, if they were older than the lowest age
observed in the incidence statistics, the incidence of their cancer prior to the woman’s age was ignored
and the distribution was renormalised based on the remaining data. Relative survival statistics in the UK
population with each type of cancer and ONS all-cause mortality statistics were used to calculate the life
expectancy of people with cancer.71,79–86 A summary of the discounted cancer decrements by age for the
mother is given in Appendix 18. The mean discounted QALY decrement for the induction of childhood
cancer per scan was –0.000037.
Chronic thromboembolic pulmonary hypertension
There was a lack of evidence on the quality of life for CTEPH patients. Owing to this lack of evidence, it
was assumed that CTEPH patients would have the same utility as people with heart failure. The utility data
were sourced from Ara and Brazier,76 with people who had a heart problem other than a myocardial
infarction having a utility of 0.672 (95% CI 0.649 to 0.694) and a matched person without heart problems
having a utility of 0.802 (95% CI 0.771 to 0.831).78 This utility multiplier of 0.838 was applied to the
general population utility for the first year for those who could be treated surgically, and was applied for a
lifetime for those who could not be treated surgically.
Costs
This section provides a detailed description of the cost parameters used in the economic model. A
summary of all cost parameters used in the base case, and the distributions around them, are provided in
Appendix 19. The price year used for the costs was 2015–16. All costs from previous price years were
inflated to 2015–16 values using the Hospital and Community Health Services pay and prices index.87
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Performing the clinical decision rule
In the base case, it was assumed that collecting all of the necessary information to perform the CDRs
would be performed by a registrar and that this would take them on average 5 minutes longer than
the measurements that they would collect in standard practice for a woman with a suspected PE. The
assumption about the length of time was tested in a scenario analysis, in which it was assumed that it
would take the registrar 10 additional minutes to collect the information. The cost of registrar time was
obtained from the Unit Costs of Health and Social Care 2016.87
Anticoagulation treatment
The split of the different types of anticoagulation drugs was taken from the UKOSS and suspected PE
data set. For the women with PE, the three most common LWMHs used were enoxaparin (Clexane®;
Sanofi, Paris, France; n = 88), dalteparin (Fragmin®; Pfizer Inc., New York, NY, USA; n = 54) and tinzaparin
(Innohep®; Leo Pharma, Ballerup, Denmark; n = 30). A weighted average of the cost of using each of the
three drugs was used to calculate the drug costs in the model. The dose of these LWMHs was calculated
in accordance with information in the British National Formulary.88 In the base case, it was assumed that
the current weight of pregnant women was used to calculate the dose, despite doses having been based
on early pregnancy weight. In a scenario analysis, 12.5 kg was removed from a pregnant woman’s weight
for the calculation of the dose if they were > 20 weeks pregnant. This scenario was conducted as this is
the upper range of the typical weight gain for a pregnant woman in the UK and this weight is typically
gained in the second half of the pregnancy.89 In line with recommendations made by the RCOG, in the
model, women received anticoagulation treatment for whichever was the greater of 3 months or the
remaining length of their pregnancy plus 6 weeks.2 In the base case, it was assumed that women received
the same duration and dose of anticoagulant drugs for the initial PE as for a recurrent VTE. This assumption
was tested in a scenario analysis in which it was assumed that there was no additional cost of a second
VTE, if the woman was treated for her initial PE.
Pulmonary embolism
The cost of PE event was taken from the NHS Reference Costs 2015 to 2016.90 PE was assumed to be any
pulmonary embolus with a complication score of 0–8 or 9+ (currency code DZ09K and DZ09J) that was a
non-elective stay. Excess bed-days were included in the calculation of this cost. The mean cost of treating
PE was £4778 with a SE of £224.7.
Recurrent venous thromboembolism
The ratio of DVT-related events (17%) and PE-related events (83%) for recurrent VTE was calculated as
described in the clinical parameters section. The cost of DVT was obtained from the NHS Reference Costs
2015 to 2016.90 The cost of a DVT was assumed to be the weighted average of the cost of a DVT score of
0–2, 3–5, 6–8, 9–11 and 12+ (currency codes YQ51A to YQ51E) using the number of finished consultant
episodes that were non-elective inpatient stays. The mean cost of treating a DVT was £2612 with a SE
of £68.6.
Bleeding
The cost of an intracranial haemorrhage was obtained from Luengo-Fernandez et al.,91 as there would be
an initial hospitalisation cost and an ongoing cost for rehabilitation.91 This study had up to 5 years of
follow-up of 729 stroke patients in Oxfordshire, UK. The cost in the first year was taken from the first year
of follow-up and an ongoing cost of treating stroke patients was calculated by taking a weighted average
based on the number of remaining patients and the mean costs in each year following the first. The
lifetime costs of intracranial bleeding were calculated by attaching the health state costs to the estimated
life expectancy of people with an intracranial haemorrhage and assuming that individuals who died did so
half-way through the year. No information on the SE of these costs was presented, so it was assumed that
the SE was 20% of the mean cost. The cost of intracranial bleeding in year 1 was £11,707 with a SE of
2341 and the cost of intracranial bleeding in subsequent years was £1524 with a SE of 305.
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Chronic thromboembolic pulmonary hypertension
The cost of a pulmonary endarterectomy was taken from NICE guidelines33 on the use of rivaroxaban for
the treatment of DVT.33 This was applied as a one-off cost for everyone who was eligible to receive surgery
for their CTEPH. This was found to be £6558.11 after inflation to 2015–16 prices. The ongoing cost of
CTEPH was also taken from the same guidelines and was found to be £15,968 per annum after inflation
to 2015–16 prices. The lifetime costs of CTEPH were calculated by attaching the health state costs to the
estimated life expectancy of people with CTEPH and by assuming that individuals who died did so half-way
through the year.
Cancer
The lifetime attributable cost of breast cancer was obtained from a 15-month follow-up study of women
diagnosed with breast cancer at one UK site by Hall et al.92 They found that the cost of breast cancer was
£13,241 in 2015–16 prices and that at least 75% of the costs were incurred within 6 months; as such, no
upwards adjustment to these costs was applied. The lifetime attributable cost of lung cancer was obtained
from a report by Incisive Health.93 This report provided costs of non-small-cell lung cancer by stage at
diagnosis. These stage-specific costs were weighted by the stage distribution of non-small-cell lung cancer by
Cancer Research UK.79 This gave a lifetime cost of a lung cancer to be £16,095 in 2015–16 prices. The cost
of childhood cancers to health-care systems was found to be poorly understood. A study by van Listenburg
et al.94 compared the cost-effectiveness of two treatment regimens for childhood acute lymphoblastic
leukaemia with chemotherapy in one Dutch centre between 2002 and 2006. The cost of the most recent
regimen [ALL-10, the Dutch Childhood Oncology Group protocol for the treatment of children with acute
lymphoblastic leukaemia (ALL)] was converted into pounds sterling using purchasing power parity rates and
then inflated to 2015–16 prices. This gave the cost of treating a childhood cancer to be £126,273.
Outcome measures
The main outcome measure for this analysis is the incremental cost-effectiveness ratio (ICER) for each
strategy. A full incremental analysis will be conducted, which will compare all of the strategies with each
other. The ICER will be compared with a maximum acceptable ICER (MAICER) of £20,000 per QALY
gained. This is in line with decision-making processes by NICE.60
A value-of-information analysis will also be conducted to determine if further research into the
cost-effectiveness of the strategies is an efficient use of resources from the health-care system perspective.
In the value-of-information analysis, it was expected that the number of women affected per year was
2231. This was based on there being 723,913 live births in England and Wales in 2011 and data from the
Scottish Morbidity Record suggesting a combined incidence of 2.0 per 10,000 maternities for antenatal
and postnatal PE.28 This value was then uplifted by assuming that for women with suspected PE, 18 out
of 277 women would have PE and 259 out of 277 women would not. On the basis of clinical input, it is
expected that any information generated by a future study would be useful for 10 years.
The value of research into particular questions will be assessed by calculating the partial value of information
for a particular set of parameters. Previously, this has not been feasible because of time constraints, but
recently developed techniques now allow for the calculation of the partial value of information from the
model outputs of the PSA,95 estimating multiparameter partial expected value of perfect information from a
PSA sample (a non-parametric regression approach). The value of particular study designs to address any
research question will not be explored, as performing this calculation would require a known study design to
address a particular research question, neither of which was developed in this project.96
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Summary of assumptions
l Long-term evidence from the population with PE is valid for pregnant/postpartum women who
have PE.
l The women were only at risk of VTE for 1 year because their suspected PE was caused by their
pregnancy. As such, the long-term risk factors that have been shown for other older populations with
VTE were not relevant.
l Fetuses are outside the decision problem, apart from the adverse effects of any imaging-induced cancers.
l When initiating anticoagulation treatment, it was assumed that, in the UK, the guidelines by the Royal
College of Obstetricians and Gynaecologists would be followed.
l For the base case, it was assumed that an accurate diagnosis of PE/no PE would be made when a
woman was referred to imaging.
l In the base case, it was assumed that CTEPH was a risk factor that depended on an individual’s
characteristics and was modifiable by anticoagulation treatment.
l The utility of a woman with CTEPH would likely be the same as someone with heart failure.
l The cost of anticoagulation treatment for a second VTE event would be the same as the cost of
anticoagulation treatment for the initial VTE.
l All doses are based on a woman’s current weight.
Analysis
Base case
A deterministic and probabilistic sensitivity analysis was performed for the base-case analysis. In the PSA,
1000 runs were conducted and the model produced stable estimates of the total costs and QALYs after
approximately 800 runs. Full details of the stability of the model results with respect to the number of PSA
runs are given in Appendix 20. A full incremental analysis of all 10 decision options was performed in
all analyses.
The robustness of the base-case results was assessed by conducting scenario analyses and
threshold analyses.
Threshold analyses
Two threshold analyses were conducted. Both threshold analyses were based on the base-case
deterministic analysis.
In the first threshold analysis, ‘scan all’ was compared with a series of hypothetical decision rules with
given sensitivity and specificity values. A necessary assumption in this threshold analysis was that these
hypothetical decision rules were unrelated to each woman’s characteristics. This analysis provides
information on how good a decision rule would have to be before it would be cost-effective compared
with the current standard of care for pregnant women with PE.
In the second threshold analysis, the QALY-maximising strategy out of ‘scan all’, SNTA and SNTN was
determined with respect to the probability that a woman had PE. To do this analysis, the base-case
deterministic analysis was adapted so that bootstrapped mean QALYs for women with PE and women
without PE were produced for each strategy. These QALYs were then combined using the threshold
probability that a woman has PE.
List of scenario analyses
(1) Assuming that the sensitivity and the specificity of the scanning tests are taken from the same sources
as the NICE guidelines.
(2) Assuming that the risk of CTEPH is estimated from data presented in Klok et al.69
(3) Assuming that the risk of CTEPH is not modifiable by anticoagulation.
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(4) Assuming that there is no risk of death from a recurrent VTE.
(5) Assuming that if the woman experiences a recurrent VTE and is treated for her initial PE then the cost
of anticoagulation treatment is £0.
(6) Assuming that the estimated risk of death from the expert elicitation exercise was conducted for:
(6.1) the combination of expert’s answers in the secondary statistical population
(6.2) the combination of expert’s answers in the tertiary statistical population
(6.3) the combination of expert’s answers in the quaternary statistical population
(6.4) expert 1’s answers in the primary statistical population
(6.5) expert 2’s answers in the primary statistical population
(6.6) expert 3’s answers in the primary statistical population
(6.7) expert 4’s answers in the primary statistical population.
(7) Using cohort data on the risk of death from PE in pregnant women from the UKOSS patient.
(8) Assuming that for the calculation of the drug costs, 12.5 kg is removed from the woman’s weight if
she is in the second half of her pregnancy.
(9) Assuming that the following costs for CTEPH are used:
(9.1) £24,000 for CTEPH surgery
(9.2) the costs of managing CTEPH are taken from Schweikert et al.97
(9.3) both 9.1 and 9.2.
(10) Women are not at risk of bleeding, recurrent VTE or CTEPH. In this scenario, the only risk is
immediate death associated with PE.
(10.1) When the risk of PE-related death is obtained from the expert elicitation exercise.
(10.2) When the risk of PE-related death is obtained from the UKOSS patient.
(11) All scanning-induced cancers present within 15 years of a scan rather than the woman’s lifetime.
All scenario analyses were based upon the model being run deterministically. In scenario 1, instead of
assuming perfect scanning, it was assumed that the scans would have a probability of producing both
false-positive and false-negative results, which were calculated from the sensitivity and specificity of the scan
that the patient received. The model structure diagram in Figure 8 provides the structure of these aspects of
the decision tree. It was assumed that those with a false-positive result were at risk of bleeding and it was
assumed that those with a false-negative result would be discharged without anticoagulation treatment
regardless of the result of the decision rule. All other scenario analyses assumed that false-positive and
false-negative scans were not possible, but used different assumptions or data in the base-case model.
Results
Base-case analysis
The results of the base-case health economic analysis are given in Table 16. In the deterministic analysis,
‘scan all’ was the dominant strategy, as it produced the most QALYs (20.3855) at the lowest cost (£1359).
In the PSA, the ‘scan all’ strategy also dominated all of the other 10 strategies, as again it produced the
most QALYs (20.3832) at a cost of £1360. As well as being dominant on average, in the 1000 PSA
replications, the ‘scan all’ strategy was the most cost-effective option in 98.9% of PSA replications when a
MAICER of £20,000 per QALY gained was used. This indicates that there is only a very small probability
(1.1%) that scanning all women would give an incorrect decision, given the parameter distributions used
in the base-case analysis. A cost-effectiveness acceptability curve showing the probability that each
intervention is the most cost-effective at different MAICERs is given in Appendix 21 (see Figure 62).
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TABLE 16 The results of the base-case health economic analysis
Strategy
Costs (£)
QALYs
Incremental
ICER
Probability of
being the most
cost-effective
strategy at
£20,000 per
QALY gained
Decision
rule Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
Deterministic analysis
No scan, treat none 0 0 15 56 1 0 2757 2830 19.8589 – – Dominated by
scan all
N/A
Wells’s score (strict) 4 27 73 155 4 1 1970 2233 20.0575 – – Dominated by
scan all
N/A
Delphi specificity score 4 49 71 157 4 2 1979 2265 20.0630 – – Dominated by
scan all
N/A
Geneva score 4 82 85 173 5 3 1825 2175 20.0952 – – Dominated by
scan all
N/A
Wells’s score
(permissive)
4 88 89 186 5 3 1727 2101 20.1213 – – Dominated by
scan all
N/A
Delphi primary score 4 96 104 222 6 3 1462 1896 20.1914 – – Dominated by
scan all
N/A
PERC score 4 109 109 236 6 4 1351 1818 20.2164 – – Dominated by
scan all
N/A
No scan, treat all 0 0 1260 322 122 0 647 2352 20.3013 – – Dominated by
scan all
N/A
Delphi sensitivity score 4 215 145 313 9 7 733 1424 20.3663 – – Dominated by
scan all
N/A
Scan all 0 223 151 322 9 7 647 1359 20.3855 –1470 0.5266 Dominant N/A
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TABLE 16 The results of the base-case health economic analysis (continued )
Strategy
Costs (£)
QALYs
Incremental
ICER
Probability of
being the most
cost-effective
strategy at
£20,000 per
QALY gained
Decision
rule Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
PSA
No scanning, treat none 0 0 16 59 1 0 2173 2249 19.8157 – – Dominated by
scan all
0.5%
Delphi specificity score 4 49 70 157 4 1 1629 1914 20.0291 – – Dominated by
scan all
0.0%
Wells’s score (strict) 4 27 73 157 4 1 1599 1865 20.0308 – – Dominated by
scan all
0.4%
Geneva score 4 83 84 175 5 2 1504 1855 20.0695 – – Dominated by
scan all
0.0%
Wells’s score
(permissive)
4 88 89 188 5 2 1430 1805 20.0984 – – Dominated by
scan all
0.0%
Delphi primary score 4 95 103 222 6 2 1250 1682 20.1710 – – Dominated by
scan all
0.0%
PERC score 4 109 108 237 7 3 1161 1628 20.2006 – – Dominated by
scan all
0.1%
No scanning, treat all 0 0 1260 321 123 0 650 2353 20.2937 – – Dominated by
scan all
0.0%
Delphi sensitivity score 4 217 143 312 9 5 714 1403 20.3618 – – Dominated by
scan all
0.1%
Scan all 0 225 150 321 9 5 650 1360 20.3832 –888 0.5675 Dominant 98.9%
N/A, not applicable; –, no data.
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Value-of-information analysis
Table 17 shows the results of value-of-information analysis. The value-of-information analysis found that
reducing all uncertainty in the economic model for this decision problem would have a maximum value of
£4.57 per person per year. Assuming that 2231 women per year are able to benefit from any research
over a period of 10 years, this gives a maximum value of conducting research into this decision problem
of £101,952. However, using one piece of research to reduce all of the parameters used in the economic
model is highly optimistic, so we conducted an analysis of the value of conducting further research into
a group of parameters for which a single study could be designed. The group with the highest value was
the effectiveness of anticoagulation treatment, as this had a value of £72.77 for 2231 women with a
suspected PE over a 10-year time horizon. As this is the maximum value of future research into this
parameter, conducting any research into these values that costs more than this is not indicated in this
decision analysis. Given the value-of-information analysis, further research to reduce uncertainty in
the parameter estimates used in the economic model does not appear to be indicated for this decision
problem. It should be noted that the accuracy of the decision rules could not be included in this analysis,
as they were applied to each woman’s modelled characteristics. Therefore, they were not random variables
in the PSA, which is necessary to be able to conduct a value-of-information analysis. Instead, the value of
conducting the analysis was assessed by conducting the threshold analysis that compared decision rules
with hypothetical sensitivity and specificity values to scanning all women. It should also be noted that
much of the data in the base case came from the general population with PE and, therefore, these data
may not be representative of pregnant/postpartum women with PE. This uncertainty was addressed in the
scenario analysis in which the probability of recurrent VTE, CTEPH and bleeding were set to 0%.
Scenario analyses
A summary of the scenario analysis results are provided in Table 18; detailed results for each scenario are
provided in Appendix 20. When using a MAICER of £20,000 per QALY gained, scanning all women was the
most cost-effective strategy in all scenario analyses. In fact, scanning all women dominated all of the other
strategies in every scenario, except when CTEPH was not modifiable by anticoagulation treatment, when the
TABLE 17 The results of the value-of-information analysis for the diagnosis of pregnant or postpartum women
with PE
Parameters
Value (£) per
person per yeara
Approximate
SE (£)
Value (£) for 2231 pregnant
and postpartum women
over 10 yearsa
All parameters
Overall 3.64 N/A 81,114
Parameter groups
The effectiveness of anticoagulation
treatment
0.00 1.31 0.00
The risk of recurrent VTE 0.00 1.33 0.00
Death resulting from recurrent VTEs 0.00 0.00 0.00
Incidence of major bleeding events 0.00 0.00 0.00
Life expectancy of women with CTEPH 0.22 7.68 4828
Risk of death from PE/risk of experiencing a
CTEPH
0.00 0.62 0.00
All utility parameters 0.00 0.00 0.00
All cost parameters 0.09 10.86 1920
N/A, not applicable.
a At a MAICER of £20,000 per QALY gained.
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TABLE 18 A summary of the scenario analysis results
Scenario analysis
Most cost-effective
strategy using a
MAICER of £20,000
per QALY gained
Location of the table
with the full results
(1) Scanning is assumed to result in an imperfect diagnosis Scan all Appendix 21, Table 83
(2) Risk of CTEPH from Klok et al.69 is used Scan all Appendix 21, Table 84
(3) CTEPH is not modifiable by anticoagulation treatment Scan all Appendix 21, Table 85
(4) 100% of patients with CTEPH were treated surgically Scan all Appendix 21, Table 86
(5) A Weibull curve is used to estimate the life expectancy of
women with a surgically treated CTEPH
Scan all Appendix 21, Table 87
(5) A Gompertz curve is used to estimate the life expectancy of
women with a surgically treated CTEPH
Scan all Appendix 21, Table 88
(5) A log-logistic curve is used to estimate the life expectancy
of women with a surgically treated CTEPH
Scan all Appendix 21, Table 89
(5) A gamma curve is used to estimate the life expectancy of
women with a surgically treated CTEPH
Scan all Appendix 21, Table 90
(5) A generalised gamma curve is used to estimate the life
expectancy of women with a surgically treated CTEPH
Scan all Appendix 21, Table 91
(6) A Weibull curve is used to estimate the life expectancy of
women with a medically treated CTEPH
Scan all Appendix 21, Table 92
(6) A Gompertz curve is used to estimate the life expectancy of
women with a medically treated CTEPH
Scan all Appendix 21, Table 93
(6) A log-logistic curve is used to estimate the life expectancy
of women with a medically treated CTEPH
Scan all Appendix 21, Table 94
(6) A gamma curve is used to estimate the life expectancy of
women with a medically treated CTEPH
Scan all Appendix 21, Table 95
(6) A generalised gamma curve is used to estimate the life
expectancy of women with a medically treated CTEPH
Scan all Appendix 21, Table 96
(7) There is no risk of death following a recurrent VTE Scan all Appendix 21, Table 97
(8) There is no anticoagulation treatment cost for recurrent
VTEs
Scan all Appendix 21, Table 98
(9.1) The expert elicitation exercise on the risk of mortality
from PE was conducted for women with PE as defined in the
secondary statistical population
Scan all Appendix 21, Table 99
(9.2) The expert elicitation exercise on the risk of mortality
from PE was conducted for women with PE as defined in the
tertiary statistical population
Scan all Appendix 21, Table 100
(9.3) The expert elicitation exercise on the risk of mortality
from PE was conducted for women with PE as defined in the
quaternary statistical population
Scan all Appendix 21, Table 101
(9.4) The expert elicitation exercise on the risk of mortality
from PE was conducted for expert 1’s answers with PE as
defined in the primary statistical population
Scan all Appendix 21, Table 102
(9.5) The expert elicitation exercise on the risk of mortality
from PE was conducted for expert 2’s answers with PE as
defined in the primary statistical population
Scan all Appendix 21, Table 103
(9.6) The expert elicitation exercise on the risk of mortality
from PE was conducted for expert 3’s answers with PE as
defined in the primary statistical population
Scan all Appendix 21, Table 104
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risk of CTEPH was estimated from data presented in the literature and when women were not at risk of bleeding,
recurrent VTE or CTEPH. The final scenario is of particular note, as this is the most unfavourable scenario to the
‘scan all’ strategy, as the only benefit of anticoagulation treatment is the prevention of death associated with a
woman’s initial PE and there are no harms associated with anticoagulation treatment. This indicates that the
results of the economic model are relatively robust to the model assumptions that have been tested.
Threshold analyses
The threshold analyses explored which strategy out of ‘scan all’, ‘scan none, treat all’ and ‘scan none, treat
none’ would be the most effective strategy, conditional on the probability that a woman with suspected
PE actually had PE. In the first threshold analysis, the model base case was used, and in the second
threshold analysis, the scenario in which CTEPH was not modifiable by anticoagulation treatment was
used. In the analysis that used the base case, scanning all women is optimal if the probability that they
have PE ranges from 0.1% to an upper limit of between 96.5% and 97.0%. At a probability of having
PE of 97.0% or above, a woman should be given treatment directly, as the small chance of inducing a
bleed in women without PE is outweighed by the QALY losses associated with radiation-induced cancers
for the mother and the fetus (if applicable). The results in the scenario in which anticoagulation treatment
does not have an impact on a woman’s risk of CTEPH are broadly similar to those of the base-case analysis.
However, the threshold at which all women are treated without scanning increases slightly to 98.0%,
compared with 97.0% in the base case.
The second threshold analysis calculated pairwise ICERs comparing scanning all women with a series of
hypothetical CDRs in which the rules being positive or not is independent of each woman’s characteristics.
The sensitivity and 1 – specificity provide the probabilities that the rules are positive for pregnant and
postpartum women with a suspected PE, who actually have PE and actually do not have PE, respectively. The
results of this threshold analysis are given in Tables 19 and 20. The tables show that even if a decision rule
could be developed that had 97.5% sensitivity and 90% specificity, the ICER would be £13,392, which is
TABLE 18 A summary of the scenario analysis results (continued )
Scenario analysis
Most cost-effective
strategy using a
MAICER of £20,000
per QALY gained
Location of the table
with the full results
(9.7) The expert elicitation exercise on the risk of mortality
from PE was conducted for expert 4’s answers with PE as
defined in the primary statistical population
Scan all Appendix 21, Table 105
(10) The risk of PE-related mortality is taken from UKOSS Scan all Appendix 21, Table 106
(11) 12.5 kg reduction in the weight of pregnant women who
were > 20 weeks pregnant for the purpose of calculating their
anticoagulant drug dose
Scan all Appendix 21, Table 107
(12.1) The cost of CTEPH surgery is £24,000 Scan all Appendix 21, Table 108
(12.2) The cost of CTEPH management is taken from
Schweikert et al.97
Scan all Appendix 21, Table 109
(12.3) 12.1 and 12.2 Scan all Appendix 21, Table 110
(13.1) Women are not at risk of bleeding, recurrent VTE or
CTEPH, and the risk of PE-related death is from the expert
elicitation base case
Scan all Appendix 21, Table 111
(13.2) Women are not at risk of bleeding, recurrent VTE
or CTEPH, and the risk of PE-related death is from UKOSS
patients
Scan all Appendix 21, Table 112
(14) All scanning-induced cancers are present within 15 years Scan all Appendix 21, Table 113
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well below the £20,000-per-QALY-gained threshold. This indicates that scanning all women would
probably be considered to be cost-effective, even if such a decision rule could be developed for pregnant
and postpartum women with a suspected PE. It should be noted that all of the hypothetical decision rules
lead to fewer expected QALYs than scanning all women.
Discussion
We found that scanning all women dominated all other strategies considered for pregnant and
postpartum women with a suspected PE. In all scenario analyses and in the PSA, scanning all women
either was the dominant strategy or had the highest ICER below £20,000 per QALY gained of the
10 strategies being considered. The value of conducting further research into parameters used in the
economic model was likely to be below the cost of conducting further research into any subset of feasible
parameters. The threshold analyses indicated that, if a CDR was to be developed for the diagnosis of PE in
pregnant or postpartum women with a suspected PE, the rule would require a sensitivity value in excess of
97.5% for the ICER of ‘scan all’ versus the decision rule to exceed £20,000 per QALY gained. It should
also be noted that the sensitivity of the decision rule would need to exceed 97.5% for the hypothetical
decision rule to result in expected QALY gains compared with scanning all women. Another point to note
is that our threshold analyses demonstrated that clinicians must believe that the probability of a pregnant
or postpartum woman having PE is < 0.1% for discharging the women to result in a higher number of
lifetime QALYs than sending the woman for a scan. To our knowledge, this study is the first to assess the
outcomes associated with selectively scanning pregnant or postpartum women with a suspected PE.
TABLE 20 The incremental QALY gains of a hypothetical decision rule to selectively scan women with a suspected
PE compared with scanning all women
Specificity
Sensitivity
97.5 95 90 85 80 75
90 –0.0110 –0.0242 –0.0507 –0.0772 –0.1036 –0.1301
80 –0.0113 –0.0245 –0.0510 –0.0774 –0.1039 –0.1303
70 –0.0115 –0.0247 –0.0512 –0.0777 –0.1041 –0.1306
60 –0.0118 –0.0250 –0.0514 –0.0779 –0.1044 –0.1308
TABLE 19 The ICERs of a hypothetical decision rule to selectively scan women with a suspected PE compared with
scanning all women
Specificity
Sensitivity
97.5 95 90 85 80 75
90 £13,392 £4345 £414 Dominated Dominated Dominated
80 £11,193 £3425 Dominated Dominated Dominated Dominated
70 £9089 £2523 Dominated Dominated Dominated Dominated
60 £7072 £1639 Dominated Dominated Dominated Dominated
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The key implication of this study is that any diagnostic strategy other than scanning all pregnant and
postpartum women with suspected PE is unlikely to be cost-effective. Furthermore, threshold analyses
suggest that a clinician must be highly certain that a pregnant/postpartum woman with suspected PE does
not have PE to make scanning the woman result in fewer expected lifetime QALYs than discharging her
immediately would.
A key strength of this study is that this is the first mathematical model to assess the long-term outcomes of
selectively scanning pregnant and postpartum women with a suspected PE. However, the study does have
some limitations. First, much of the long-term evidence on outcomes for pregnant and postpartum women
with PE comes from a much older population with PE, who typically have experienced some comorbidities.
Although the older population provides the best available evidence on the long-term outcomes for pregnant
and postpartum women with suspected PE, the event rates may differ in the population of pregnant
and postpartum women with PE, as they are much younger. This limitation was addressed with a scenario
analysis in which all risks that were sourced from the general population (bleeding, CTEPH or recurrent VTE)
were set to 0%. This scenario was unfavourable to the ‘scan all’ strategy, but even then it remained the
most cost-effective strategy at a MAICER of £20,000 per QALY gained. Second, it was structurally assumed
on the grounds of clinical plausibility that, in the population of pregnant and postpartum women, it was their
pregnancy that caused their increased risk of PE. Consequently, it was assumed that these women were at
risk of complications resulting from their initial PE only during the anticoagulation treatment period. This
assumption could potentially be verified or refuted if data on long-term outcomes (> 1 year) were to be
collected on a large number of pregnant and postpartum women diagnosed with PE. Currently, the best
available evidence on the outcomes of pregnant and postpartum women with PE is from the UKOSS patients
used in this study, and these have only a 30-day follow-up period. Finally, as each woman’s DiPEP data were
directly used in the model, with the decision rules being applied to their individual characteristics, the
sensitivity and specificity values closely matched those of the statistical analyses. There could be some
design-related bias in the estimates of the sensitivity and specificity resulting from the design of the clinical
study. Given the results of the threshold analysis, which indicated that a decision rule would need a proven
sensitivity in excess of 97.5% in order to be cost-effective in the UK, it is highly unlikely that this limitation
would alter the conclusions of the health economic analysis.
The value-of-information analysis and the threshold analyses did not identify any promising areas for
conducting future research on this decision problem. A well-designed study on the long-term follow-up of
pregnant and postpartum women would be able to inform the modelled risks of bleeding, recurrent VTE
and CTEPH. However, designing sufficiently well-designed long-term follow-up studies to address the
limitations in the evidence on the long-term risks associated with having PE in pregnant and postpartum
women would probably be infeasible. This would be because of difficulties in maintaining a long enough
follow-up and recruiting enough women, as we estimated that there would be only 145 cases per year
of PE in pregnant or postpartum women in the UK. Based on our current evidence, the most promising
avenue for future research is probably research into reducing the radiation exposure to the mother and the
fetus from diagnostic imaging and hence reducing the QALY losses associated with the imaging technique
used. This research would have benefits for everyone who receives a diagnostic imaging scan, not just
pregnant and postpartum women with a suspected PE.
In conclusion, scanning all pregnant/postpartum women with suspected PE is likely to be cost-effective.
A CDR would need to have a high sensitivity value (> 97.5%) and a high specificity value (> 90%) to be
cost-effective compared with scanning all women. Future research into reducing the radiation dose
associated with scanning or developing new diagnostic technologies would probably be a more promising
way of providing cost-effective care to pregnant/postpartum women with a suspected PE than developing
a decision rule.
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Chapter 6 Implications for policy, practice and
future research
The main findings of the DiPEP study were as follows:
l In pregnant and postpartum women presenting to hospital with suspected PE, many of the recognised
clinical features of PE and risk factors for PE do not have diagnostic value and in a few patients may be
associated with the absence of PE. This may reflect selective referral or self-presentation of women with
clinical features or risk factors for PE (i.e. women with symptoms suggesting PE and recognised risk
factors or clinical features may be more likely to present for investigation than those with symptoms
suggesting PE but no other features).
l Expert-derived CDRs, existing CDRs (Wells’s score, Geneva score and PERC score) and D-dimer
measurement have poor diagnostic accuracy for PE in pregnant and postpartum women presenting to
hospital with suspected PE.
l We were unable to derive a new CDR using multivariate analysis or recursive partitioning that achieved
acceptable sensitivity and specificity without being overfitted. This probably reflects the limited
diagnostic value of the clinical features in this cohort.
l Biomarkers for VTE showed poor diagnostic accuracy, with only TG lag time achieving high sensitivity
with potentially worthwhile specificity. This may reflect the widespread use of anticoagulation
treatment prior to blood sampling. When women who had received anticoagulation treatment were
removed from the sample, the number of women with PE was too small for meaningful analysis.
l A prospective cohort design to validate a new CDR or biomarker is potentially feasible, but would require
recruitment across a large number of sites (≈50) for a substantial period of time (2 years). Our data
suggest that current decision rules and biomarkers show insufficient promise to justify such a study.
l A non-selective strategy of CT scan for all women with suspected PE was cheaper and more effective
than strategies that selected women for scanning on the basis of a CDR.
l The value of conducting further research into parameters used in the economic model is likely to be
below the cost of conducting further research into any subset of feasible parameters.
Implications for policy and practice
Our findings do not support the use of CDRs and biomarkers in selecting women with suspected PE in
pregnancy or post partum to receive imaging. This does not necessarily mean that all women with
suspected PE in pregnancy or post partum must receive imaging, given the recognised limitations of
imaging. The suspected PE cohort included 42 women who had PE ruled out without imaging. We did
not include these women in the primary analysis because without imaging it is uncertain whether or not PE
may have been missed, but we found no evidence of missed pathology on follow-up. We do not know
exactly why these women, who had been identified as requiring imaging, did not ultimately receive
imaging. Responses to enquiries to sites and comments on the CRF suggested that, for most patients,
a more senior or specialist clinician had decided that imaging was not necessary after a more junior or
generalist clinician had initially decided that it was. The DiPEP study was not designed to explore the
reasons for or the appropriateness of decisions to perform imaging, so we are unable to determine
whether or not the decision to forgo imaging for these patients was reasonable.
Our findings regarding the limited diagnostic value of clinical features suggest that there is little objective
evidence to guide decision-making regarding imaging. Many of the women with PE had normal
physiology and no risk factors for PE, so normal physiology and the absence of risk factors should provide
little reassurance that PE can be ruled out without imaging. In general, risk factors, clinical features and
physiology showed little difference between women with PE and women without PE.
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We found that chest radiograph abnormality is associated with PE even when the reported abnormality is
not thought to be PE related. RCOG guidance2 recommends performing chest radiography prior to
investigation for PE. Our findings suggest that non-specific chest radiograph abnormalities should increase
rather than reduce the suspicion of PE.
It is important to recognise that our findings apply specifically to the diagnostic assessment of women with
suspected PE in secondary care. The DiPEP study was not designed to evaluate the risk of developing PE in
pregnancy. Epidemiological studies comparing women who develop VTE in pregnancy with those who do
not have established the important risk factors for VTE in pregnancy.27–29,55 The failure of the risk factors
to be diagnostically useful in the DiPEP study probably reflects the process of selection into a population
undergoing diagnostic evaluation in hospital. Risk factors for VTE should continue to be used to guide the
provision of thromboprophylaxis in pregnancy and other relevant decisions. The findings may also not
apply to primary care or other out-of-hospital settings. Clinicians working in the community or patients
themselves may be successfully using clinical features to select women for hospital assessment, thus
explaining why these clinical features have little value in a selected hospital population.
The decision-analysis modelling showed that a strategy of non-selective scanning for all women was likely
to be cost-effective compared with strategies that used decision rules to select women for scanning or
the alternatives of treating all or treating none without the use of scanning. This probably reflects the
substantial QALY gains associated with accurately identifying and treating PE in pregnancy, compared with
the small QALY decrement associated with scanning. The non-selective use of scanning was not only more
effective than selective scanning, it was also cheaper in the base-case analysis. This was probably because
identifying and treating PE reduced the substantial long-term costs of treating CTEPH. A scenario analysis
in which it was assumed that treatment did not influence the probability of developing CTEPH showed
that non-selective scanning would be more expensive than selective scanning, but still had the highest
ICER below the £20,000-per-QALY-gained MAICER used by NICE.
The conclusion that scanning was likely to be cost-effective compared with using a decision rule was
robust in all sensitivity analyses and scenario analysis. A threshold analysis comparing scanning for all with
selection based on hypothetical decision rules with high sensitivity and specificity found that sensitivity
would need to exceed 97.5% and specificity would need to exceed 90% before a decision rule would be
cost-effective. This is far more accurate than the decision rules we developed and tested. It suggests that
there is little possibility of developing a decision rule with sufficient accuracy to be cost-effective.
Finally, our threshold analysis showed that scanning is not cost-effective compared with discharge without
treatment only when the probability of PE is < 0.1%. This again reflects the substantial health gains
associated with identifying and treating PE in pregnancy compared with the small health risks and modest
costs. It suggests that clinicians should have a low threshold for providing imaging and discharge without
imaging only when the risk of PE is negligible. If women are to be involved in decision-making, as
recommended by the RCOG,2 then the comparative risks and benefits of scanning need to be
accurately presented.
Implications for future research
We undertook a case–control study instead of a cohort study because of concerns about the high cost, long
duration and unknown feasibility of the latter design. The suspected PE cohort showed that recruitment
across a variety of sites was achievable and that the prevalence of PE was higher than suggested in previous
studies. As a consequence, we conclude that a prospective cohort study of pregnant and postpartum
women with suspected PE is feasible, but will require a large number of sites (≈50) and around 2 years of
recruitment to provide a sample with a sufficient number of women with PE to estimate sensitivity with
acceptable precision. However, a study of this size would require substantial funding and could be justified
only if there was a promising diagnostic technology with good evidence to suggest that it could be validated
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in a large cohort. Decision-analysis modelling suggested that a hypothetical decision rule would need a
far higher level of accuracy than any of the decision rules we evaluated in order for it to be cost-effective
compared with scanning all women. The value-of-information analysis showed that the value of conducting
further research into parameters used in the economic model was likely to be below the cost of conducting
further research into any subset of feasible parameters.
The biomarker study was limited by the small number of patients with PE and the fact that most women
received anticoagulation treatment prior to blood sampling. The former limitation was inevitable given
the low prevalence of PE, whereas the latter was an unavoidable consequence of a challenging research
environment and a clinical imperative to provide treatment if there is any delay in diagnosis. Further study
of biomarkers may be worthwhile, but only if these issues can be addressed.
Future research probably needs to go ‘back to the drawing board’. The physiological changes associated with
pregnancy clearly undermine the potential of many clinical features and biomarkers that could otherwise be
useful for diagnosing PE. An additional problem in developing new biomarkers is the widespread use of
anticoagulation treatment (either as thromboprophylaxis or as treatment during diagnostic assessment) that
interferes with biomarker assays. New diagnostic technologies for PE need to be developed specifically for the
pregnant and postpartum population. This may include imaging techniques that are more convenient for
women and/or do not involve ionising radiation.
Guidance from the RCOG2 suggests that women should be informed of the benefits and risks of imaging
and involved in the decision to undertake imaging. Our decision analysis has identified data sources that
could be used to inform decision-making and has developed a model that could be used to weigh the risks
and benefits. These data suggest that the benefits of imaging substantially outweigh the risks. However,
understanding these risks, applying them to the individual patient and weighing them against each other
is an extremely complex process. Future research is therefore required to develop tools, such as decision
aids, that could be used to present information to women and to help women to participate in a decision.
Research is also needed to develop ways of equipping clinicians to provide information and involve women
in decision-making.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Reference standard classification
The project description stated that two independent assessors, blind to clinical predictors and bloodresults, will classify participants as having PE using diagnostic imaging results, details of adverse events
and details of treatments given. Disagreements will be resolved through adjudication by a third assessor.
We structured the process of classification to ensure that it was transparent and reproducible. We provided
each independent assessor with details of the diagnostic imaging report, anticoagulant treatment given
and 30-day follow-up events, and asked them to classify the information using the following codes.
Classify imaging as:
I1a – imaging is reported as showing PE (including any qualified statement suggesting probable PE,
but excluding isolated subsegmental PE) or DVT
I1b – imaging shows only isolated subsegmental PE
I2 – imaging is reported as being equivocal, uninterpretable or indeterminate
I3 – imaging is reported as being negative for PE
I4 – lung imaging is not done.
Classify treatment as:
T1 – therapeutic anticoagulation treatment for > 1 week
T2 – anything less than T1.
Classify follow-up as:
F1 – subsequent PE diagnosis during 30-day follow-up or PE is confirmed at surgery or post-mortem
examination
F2 – no subsequent PE diagnosis during 30-day follow-up.
We then applied the principles outlined in Chapter 3, Reference standard classification, to these codes to
determine whether PE was diagnosed or ruled out, or whether or not the woman was excluded, in the
primary and secondary analyses. Table 21 summarises the process.
The process resulted in the classifications shown in Table 22.
This resulted in the classifications for the primary analysis and the secondary analysis, as shown in
Table 23.
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TABLE 21 Use of imaging, treatment and follow-up to classify the reference standard for primary and secondary analysis
Imaging Treatment Follow-up
Analysis
Primary Secondary 1 Secondary 2 Secondary 3
I1a T1 or T2 F1 or F2 PE PE PE PE
I1b T1 or T2 F1 or F2 PE PE PE Exclude
I2 T1 F1 PE PE PE PE
I2 T1 F2 Exclude PE Exclude Exclude
I2 T2 F1 PE PE PE PE
I2 T2 F2 No PE No PE No PE No PE
I3 T1 F1 PE PE PE PE
I3 T1 F2 No PE No PE No PE No PE
I3 T2 F1 PE PE PE PE
I3 T2 F2 No PE No PE No PE No PE
I4 T1 F1 PE PE PE PE
I4 T1 F2 Exclude PE Exclude Exclude
I4 T2 F1 PE PE PE PE
I4 T2 F2 Exclude Exclude No PE Exclude
Secondary analyses: (1) include clinically diagnosed PE; (2) include clinically ruled-out PE; (3) exclude subsegmental PE.
TABLE 22 Classification of participants on the basis of imaging, treatment and follow-up
Imaging Treatment Follow-up
Cohort
Diagnosed PE
Suspected PE
recruited
Suspected PE
non-recruited
I1a T1 F1 0 0 0
I1a T1 F2 146 17 3a
I1a T2 F1 1 0 0
I1a T2 F2 7 0 0
I1b T1 F1 0 0 0
I1b T1 F2 7 1 3b
I1b T2 F1 0 0 0
I1b T2 F2 0 0 0
I2 T1 F1 0 0 0
I2 T1 F2 29 3 4
I2 T2 F1 0 0 0
I2 T2 F2 0 5 2
I3 T1 F1 0 0 0
I3 T1 F2 0 19 4
I3 T2 F1 0 0 0
I3 T2 F2 0 235 67
I4 T1 F1 1 0 0
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TABLE 23 Reference standard classifications in the primary and secondary analyses
Analysis
Cohort
Diagnosed PE Suspected PE recruited Suspected PE non-recruited
PE No PE PE No PE PE No PE
Primary 163 0 18 259 6a 73
Secondary 1 198 0 23 259 11a 73
Secondary 2 163 0 18 301 6a 84
Secondary 3 156 0 17 259 3b 73
a Includes three patients duplicated in the diagnosed PE cohort.
b Includes one patient duplicated in the diagnosed PE cohort.
TABLE 22 Classification of participants on the basis of imaging, treatment and follow-up (continued )
Imaging Treatment Follow-up
Cohort
Diagnosed PE
Suspected PE
recruited
Suspected PE
non-recruited
I4 T1 F2 6 2 1
I4 T2 F1 1 0 0
I4 T2 F2 0 42 11
a Includes two patients duplicated in the diagnosed PE cohort.
b Includes one patient duplicated in the diagnosed PE cohort.
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Appendix 2 Mapping of clinical decision rules to
Diagnosis of Pulmonary Embolism in Pregnancy
study data
In practice, CDRs are applied prospectively by clinicians obtaining relevant information directly frompatients. In the DiPEP study, the CDRs were tested by being applied to data collected on the CRF. The
CRF was designed to meet a number of purposes and to be consistent and usable for both research nurses
collecting data prospectively from consented patients and UKOSS clinicians collecting anonymised data
retrospectively from case notes. This meant that the CRF data did not map precisely onto all criteria in the
CDRs. This appendix describes how we mapped the CDRs to CRF data.
Furthermore, as described in the main report, we excluded exogenous oestrogen use from the PERC score
and used the thresholds developed for our analysis to dichotomise age, oxygen saturation and heart rate,
so that the rules would be more applicable to a pregnant population.
Table 24 shows the consensus-derived CDRs. Most of the items map directly onto CRF variables. The time
period for the rules was intended to be 90 days, but the CRF identified hospital admission, surgery or
significant injury within only 28 days. Obstetric complications and active medical comorbidities were
identified from a number of sources on the CRF. The CRF items ‘Other problems in this pregnancy’ and
‘Other previous or pre-existing medical problems’ provided lists of specific problems on a drop-down list,
including those on the decision rule definition, along with a free-text box that was searched by a clinical
expert for relevant terms. Hospital admissions were not specifically identified on the CRF, although those
related to obstetric complications or active medical comorbidities were included under these criteria.
Caesarean section was recorded both as surgery and an obstetric complication, so we limited the criterion
including surgery within 90 days to operations other than caesarean section to avoid double-counting.
Clinical signs of DVT were identified by a specific CRF question, but clinical symptoms could be identified
only if ‘Presenting feature – other’ was ticked and the free text recorded a symptom such as lower limb
pain or swelling.
Table 25 shows the PERC score. The criterion ‘exogenous oestrogen’ was removed from the rule, as it was
felt to be inappropriate to apply in pregnant women. All other criteria mapped directly onto CRF items.
Age, heart rate and oxygen saturation were dichotomised using the thresholds developed for our analysis
rather than those in the original rule.
Table 26 shows Wells’s criteria for PE. Heart rate was dichotomised using the threshold developed for our
analysis rather than that in the original rule. As with the consensus-derived decision rules, the clinical
symptoms of DVT were identified only if recorded as free text after ‘Presenting features – other’ had been
ticked. There was insufficient detail to determine whether or not pre-existing cancer had been treated
within 6 months, so we included any women with previous cancer under this criterion. The criterion ‘PE is
the most likely diagnosis or equally likely’ was determined by clinical expert review of the free-text response
to the CRF question ‘What was considered the most likely diagnosis after initial clinical assessment?’ In the
main analysis, this was identified as positive if there was any mention of PE as a likely diagnosis, unless it
was in the context of ruling out PE or stating that PE was unlikely. A secondary analysis was undertaken in
which the criterion was positive only if the free text clearly indicated that PE was the most likely or equally
likely diagnosis.
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Table 27 shows the simplified revised Geneva score. Age and heart rate were dichotomised using the
thresholds developed for our analysis rather than those in the original rule. We were unable to determine
whether or not significant injury in the previous 4 weeks involved a lower limb fracture, so this criterion
was considered to be positive for any woman with a significant injury. We were unable to determine
whether or not previous cancer was an active malignant condition, so this criterion was considered to be
positive for any woman with previous cancer. Unilateral lower limb pain was identified only if it was
recorded as free text after ‘Presenting features – other’ had been ticked. We were unable to determine
whether or not clinical signs of DVT specifically involved pain on lower limb palpation, so this criterion was
considered to be positive in any woman with clinical signs of DVT recorded.
TABLE 24 Consensus-derived CDRs
Criterion CRF item and dichotomisation used (when relevant)
Haemoptysis Presenting feature haemoptysis ticked
Pleuritic chest pain Presenting feature pleuritic chest pain ticked
Previous VTE Does the woman have a past history of thrombosis (either in previous
pregnancies or when not pregnant)?
Family history of VTE in a first-degree relative Is there a history of thrombosis in first-degree relatives?
Hospital admission, surgery or significant injury
within 90 days (excluding NVD or caesarean
section)
Either (1) did the woman have surgery in the 4 weeks prior to PE in
this pregnancy or (2) did the woman have a significant injury in the
4 weeks prior to PE in this pregnancy? Excluding women who had a
caesarean section
Obstetric complicationa Any of (1) was this a multiple pregnancy? (2) was delivery by caesarean
section? (3) were there any other problems in this pregnancy? Selected
if any of the following were recorded: pre-eclampsia, ART/IVF,
prolonged labour (> 24 hours), PPH (> 1 litre or transfusion), preterm
birth at < 37+0 weeks in current pregnancy, stillbirth in current
pregnancy, hyperemesis or OHSS
Active medical comorbiditiesb Did the woman have any other previous or pre-existing medical
problems? Selected if any of the following were recorded: cancer, heart
failure, systemic lupus erythematosus, inflammatory polyarthropathy,
inflammatory bowel disease, nephrotic syndrome, diabetes mellitus
with nephropathy, sickle cell disease
Post partum or third trimester Calculated from expected or actual date of delivery
Raised BMI of ≥ 30 kg/m2 Calculated from booking weight and height
Clinical signs or symptoms of DVT Either (1) presenting feature other – lower limb pain or (2) clinical signs
of DVT?
Oxygen saturation of < 94% on room air Oxygen saturation on room air, dichotomised using a threshold of
< 94%
Tachycardia of > 100 b.p.m. (in first or second
trimester, or post partum)/tachycardia of
> 110 b.p.m. (in third trimester)
Heart rate, dichotomised using > 100 b.p.m. in first or second trimester
or post partum and < 110 b.p.m. in the third trimester
Increased respiratory rate of > 24 breaths per
minute
Respiratory rate, dichotomised using a threshold of > 24 breaths
per minute
ART, assisted reproductive technology; b.p.m., beats per minute; IVF, in vitro fertilisation; NVD, normal vaginal delivery;
OHSS, ovarian hyperstimulation syndrome; PPH, postpartum haemorrhage.
a Obstetric complications: apply once if any of the following are present – pre-eclampsia in current pregnancy assisted
reproductive technology/in vitro fertilisation (antenatal only), multiple pregnancy, caesarean section in labour, elective
caesarean section, mid-cavity or rotational operative delivery, prolonged labour (> 24 hours), postpartum haemorrhage
(> 1 litre or transfusion), preterm birth at < 37+0 weeks in current pregnancy, stillbirth in current pregnancy, hyperemesis,
ovarian hyperstimulation syndrome (first trimester only).
b Active medical comorbidities: apply once if any of the following are present – cancer, heart failure; systemic lupus
erythematosus, inflammatory polyarthropathy or inflammatory bowel disease; nephrotic syndrome; type I or type 2
diabetes mellitus with nephropathy; sickle cell disease.
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TABLE 25 The pregnancy-adapted PERC score
Criterion CRF item and dichotomisation used (when relevant)
Aged ≥ 50 years Calculated from year of birth, using a threshold of > 35 years
Heart rate of ≥ 100 b.p.m. Heart rate, dichotomised using > 100 b.p.m. in the first or second trimester or post partum
and < 110 b.p.m. in the third trimester
Oxygen saturation on room
air of < 95%
Oxygen saturation on room air, dichotomised using a threshold of < 94%
Prior history of DVT/PE Does the woman have a past history of thrombosis (either in previous pregnancies or when
not pregnant)?
Recent trauma or surgery Either (1) did the woman have surgery in the 4 weeks prior to PE in this pregnancy or (2) did
the woman have a significant injury in the 4 weeks prior to PE in this pregnancy?
Haemoptysis Presenting feature haemoptysis ticked
Exogenous oestrogen Removed from rule
Unilateral leg swelling Presenting feature other – lower limb swelling
b.p.m., beats per minute.
TABLE 26 The pregnancy-adapted Wells’s criteria
Criterion CRF item and dichotomisation used (when relevant)
Clinical signs or symptoms
of DVT
Either (1) presenting feature other – lower limb pain or (2) clinical signs of DVT?
PE is the most likely
diagnosis OR equally likely
What was considered to be the most likely diagnosis after initial clinical assessment? See
details in text
Heart rate of > 100 b.p.m. Heart rate, dichotomised using > 100 b.p.m. in the first or second trimester or post partum
and < 110 b.p.m. in the third trimester
Immobilisation for at least
3 days OR surgery in the
previous 4 weeks
Either (1) did the woman have surgery in the 4 weeks prior to PE in this pregnancy or
(2) period of immobility/bed rest during this pregnancy (≥ 3 days)
Previous objectively
diagnosed PE or DVT
Does the woman have a past history of thrombosis (either in previous pregnancies or when
not pregnant)?
Haemoptysis Presenting feature haemoptysis ticked
Malignancy with treatment
within 6 months or
palliative
Did the woman have any other previous or pre-existing medical problem? Selected if cancer
was recorded
b.p.m., beats per minute.
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TABLE 27 The pregnancy-adapted simplified revised Geneva score
Criterion CRF item
Aged > 65 years Calculated from year of birth, using a threshold of > 35 years
Previous DVT or PE Does the woman have a past history of thrombosis (either in previous pregnancies or when
not pregnant)?
Surgery (under general
anaesthesia) or lower limb
fracture in the past month
Either (1) did the woman have surgery in the 4 weeks prior to PE in this pregnancy or
(2) did the woman have a significant injury in the 4 weeks prior to PE in this pregnancy?
Active malignant condition Did the woman have any other previous or pre-existing medical problem? Selected if cancer
was recorded
Unilateral lower limb pain Presenting feature other – lower limb pain
Haemoptysis Presenting feature haemoptysis ticked
Heart rate Heart rate, dichotomised using > 100 b.p.m. in first or second trimester or post partum and
< 110 b.p.m. in the third trimester
Pain on limb palpation Clinical signs of DVT?
b.p.m., beats per minute.
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Appendix 3 Recruitment of women with
suspected pulmonary embolism and diagnosed
deep-vein thrombosis
Women with suspected PE and diagnosed DVT were prospectively recruited from 11 sites, incorporating10 emergency departments and seven maternity units. Service delivery for women with suspected PE
varied between sites, with some sites managing the patients through the emergency department, other sites
managing them through the maternity unit and other sites managing them through either route. Table 28
shows recruitment by each unit and indicates whether recruitment was led by the emergency department or
the maternity team. All of the women diagnosed with DVT were recruited through maternity units, whereas
182 women with suspected PE were recruited through emergency departments and 142 women with
suspected PE were recruited through maternity units.
TABLE 28 Recruitment by participating site
Site and unit/department
Cohort
Time open to
recruitment
Diagnosed
DVT
Suspected
PE: recruited
Suspected
PE: not
recruited
Royal Bolton Hospital Emergency Department 0 40 12 16 months, 10 days
Bradford Royal Infirmary Maternity Department 1 35 12 17 months, 15 days
Hull Royal Infirmary Emergency Department 0 15 5 16 months, 10 days
Sheffield Teaching Hospital Emergency Department 0 25 28 18 months, 20 days
Sheffield Teaching Hospital Maternity Department 0 5 8
Leeds Teaching Hospitals NHS Trust Emergency
Department
0 6 0 15 months, 20 days
Leeds Teaching Hospitals NHS Trust Maternity
Department
3 42 4
Manchester Royal Infirmary Emergency Department 0 20 6 15 months, 3 days
Portsmouth Hospitals NHS Trust Emergency
Department
0 3 0 12 months, 25 days
Portsmouth Hospitals NHS Trust Maternity
Department
3 18 6
Nottingham University Hospitals NHS Trust
Maternity Department (City Hospital)
0 7 0 10 months, 30 days
Nottingham University Hospitals NHS Trust
Maternity Department (Queen’s Medical Centre)
0 16 0
Royal Berkshire Hospital Emergency Department 0 16 0 10 months, 26 days
Royal Berkshire Hospital Maternity Department 2 11 3
Royal London Hospital Emergency Department 0 33 7 13 months, 28 days
Whipps Cross University Hospital Emergency
Department
0 8 4
GSTT Maternity Department 9 24 0 12 months, 17 days
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The number of women with suspected PE who were not recruited varied markedly between trusts, with
some reporting no patients. This variation is very likely to be attributable to variation in the ability to
identify eligible but non-recruited women, so we have not calculated the proportion of eligible
women recruited.
Overall, the 11 sites recruited 324 women with suspected PE over 190.52 site months of recruitment. This
suggests that any future prospective cohort study of women with suspected PE should be designed on the
basis of an estimated recruitment rate of 1.7 per site per month of recruitment (with each site including
both emergency department and maternity department recruitment, if both provide diagnostic assessment
of suspected PE).
Figure 9 shows the recruitment chart for the study with the actual number of women recruited compared
with the predicted number of women recruited. As described in the main text, we deliberately over-recruited
to ensure sufficient numbers in the primary analysis that excludes women with clinically diagnosed or
ruled-out PE.
The recruitment of women diagnosed with DVT occurred at 5 out of 11 sites; however, 50% of cases of
DVT were identified at St Thomas’ Hospital. This is likely to represent the local referral pathway for women
with VTE in pregnancy for which St Thomas’ Hospital is regarded as a specialist centre.
Figure 10 shows the flow of patients with suspected PE and those with diagnosed PE through the study
and into the analysis populations.
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FIGURE 9 Actual and target recruitment for women with a suspected PE.
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Identified via
UKOSS
(n = 224)
Excluded, presented
as life-threatening
(n = 13)
Excluded, unable to
determine whether
or not life-threatening
(n = 8)
Duplicate, identified
in prospective cohort
(n = 5)
Included in the
DiPEP analysis
(n = 198)
Subsegmental PE
(n = 8)
Suspected PE, n = 1
UKOSS, n = 7
Primary analysis
(n = 440)
PE, n = 181
No PE, n = 259
Secondary analysis
(n = 480)
PE, n = 221
No PE, n = 259
Secondary analysis
(n = 482)
PE, n = 181
No PE, n = 301
Secondary analysis
(n = 432)
PE, n = 173
No PE, n = 259
PE confirmed via
imaging or post-mortem
examination
(n = 173)
Suspected PE, n = 17
UKOSS, n = 156
PE clinically diagnosed
(n = 40)
Suspected PE, n = 5
UKOSS, n = 35
No PE: imaging ruled out
(n = 259)
Suspected PE, n = 259
No PE: clinically ruled out
without lung imaging
(n = 42)
Suspected PE, n = 42
Eligible and
consented
(n = 324)
Not approached
to participate
(n = 95)
Declined
participation
(n = 35)
Eligible for the
DiPEP study
(n = 203)
Prospective: eligible
for suspected PE
(n = 454)
FIGURE 10 Recruitment flow and analysis populations.
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Appendix 4 Clinical variables missing data
As described in the methods, we excluded patients from the multivariable analysis and the analysis ofCDRs, if any of the following criteria were met:
l More than one of heart rate, respiratory rate and oxygen saturation were missing.
l More than half of the predictors relating to previous medical history were missing.
l More than half of the predictors relating to the current pregnancy were missing.
Table 29 shows the number of missing physiological variables, Table 30 shows the number of missing
variables for previous medical history, Table 31 shows the number of missing variables for the current
pregnancy and Table 32 shows the number of missing variables for previous pregnancies.
TABLE 29 Number of missing physiological variables by cohort
Cohort
Number (% of total) of missing physiological variables (out of 8)
0 1 2 3 4 5 6 7
Diagnosed PE 141 (71.21) 33 (16.67) 6 (3.03) 5 (2.53) 2 (1.01) 1 (0.51) 10 (5.05) 0 (0.00)
Non-recruited 49 (51.58) 38 (40.00) 5 (5.26) 1 (1.05) 0 (0.00) 0 (0.00) 0 (0.00) 2 (2.11)
Suspected PE 286 (88.27) 35 (10.80) 1 (0.31) 1 (0.31) 0 (0.00) 0 (0.00) 1 (0.31) 0 (0.00)
Variables: age, BMI, heart rate, respiratory rate, systolic blood pressure, diastolic blood pressure, temperature and
oxygen saturation.
TABLE 30 Number of missing medical history variables by cohort
Cohort
Number (% of total) of missing medical history variables (out of 7)
0 1 2 5 6
Diagnosed PE 190 (95.96) 5 (2.53) 2 (1.01) 0 (0.00) 1 (0.51)
Non-recruited 88 (92.63) 4 (4.21) 1 (1.05) 1 (1.05) 1 (1.05)
Suspected PE 323 (99.69) 1 (0.31) 0 (0.00) 0 (0.00) 0 (0.00)
Variables: history of thrombosis in relatives, history of varicose veins, history of intravenous drug use, known thrombophilia,
surgery within the previous 4 weeks, injury within the previous 4 weeks, history of thrombosis.
TABLE 31 Number of missing variables for the current pregnancy by cohort
Cohort
Number (% of total) of missing variables for the current pregnancy (out of 3)
0 1 2
Diagnosed PE 189 (95.45) 5 (2.53) 4 (2.02)
Non-recruited 90 (94.74) 2 (2.11) 3 (3.16)
Suspected PE 324 (100.00) 0 (0.00) 0 (0.00)
Variables: multiple pregnancy, ≥ 4 hours’ travel during pregnancy, ≥ 3 days of immobility.
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Table 33 shows missing data rates for all key variables. Presenting features were recorded using a tick box
to indicate when they were present (with the assumption being that they were absent if the box was not
ticked), so missing data could not be reported for these variables. Most women did not have D-dimer
measurement as part of their usual care, so the missing rate was high for this variable in all groups.
Missing data rates were generally very low in the recruited cohort with suspected PE, with only previous
pregnancy problems (22/324), temperature (18/324) and D-dimer (207/324) missing in more than 5% of
women. Missing data rates were higher in the cohort with diagnosed PE, with employment (13/198),
previous pregnancy problems (37/198), all physiological variables (14/198 to 30/198), ECG (10/198), likely
diagnosis (19/154) and D-dimer measurement (154/198) missing in > 5% of women.
TABLE 32 Number of missing variables for previous pregnancies by cohort
Cohort
Number (% of total) of missing variables for previous
pregnancies (out of 3)
0 1 2
Diagnosed PE 157 (79.29) 37 (18.69) 4 (2.02)
Non-recruited 83 (87.37) 10 (10.53) 2 (2.11)
Suspected PE 302 (93.21) 22 (6.79) 0 (0.00)
Variables: previous pregnancies lasting for ≥ 24 weeks’ gestation, previous pregnancies lasting for ≤ 24 weeks’ gestation,
previous pregnancy problems.
TABLE 33 Missing data for all key variables by group
Variable
Cohort, n
Diagnosed PE
(n= 198)
Non-recruited
(n= 95)
Suspected PE
(n= 324)
Year of birth 0 1 0
Ethnicity 3 2 0
Marital status 3 1 1
Employment 13 16 2
Height 5 34 11
Weight 5 25 7
Smoking status 1 4 1
Previous pregnancies lasting for > 24 weeks’
gestation
3 2 0
Previous pregnancies lasting for < 24 weeks’
gestation
8 6 0
Previous pregnancy problems 37 8 22
Thrombotic event during pregnancy 3 1 0
Receiving thromboprophylaxis 2 4 0
Family history of VTE 1 5 2
History of varicose veins 4 5 1
History of i.v. drug abuse 4 2 0
History of injury in the last 4 weeks 2 4 0
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TABLE 33 Missing data for all key variables by group (continued )
Variable
Cohort, n
Diagnosed PE
(n= 198)
Non-recruited
(n= 95)
Suspected PE
(n= 324)
History of thrombophilia 3 2 0
Previous VTE 1 3 0
Other medical problems 1 2 0
History of surgery in the last 4 weeks 1 1 0
Expected date of delivery 0 1 0
Multiple pregnancy 0 3 0
History of long-haul travel 7 4 0
History of immobilisation 6 4 0
Heart rate 14 2 2
Respiratory rate 30 5 9
Oxygen saturation 21 4 3
Systolic BP (mmHg) 15 3 1
Diastolic BP (mmHg) 15 4 1
Temperature 32 10 18
Clinical signs of DVT 2 1 0
ECG 10 1 1
Chest radiograph 9 1 0
Likely diagnosis after clinical assessment 19 1 11
D-dimer measurement 154 66 207
D-dimer normal range 163 56 141
BP, blood pressure; i.v., intravenous.
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Appendix 5 Distributions of physiological
measures for women with and without pulmonary
embolism
F igures 11–17 show the distributions of age and physiological parameters for women with and withoutPE and those excluded from the analysis.
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FIGURE 11 Distribution of age by classification in the primary analysis.
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FIGURE 12 Distribution of heart rate by classification in the primary analysis. b.p.m., beats per minute.
Exclude
30
20
10
R
es
p
ir
at
o
ry
 r
at
e 
(b
re
at
h
s 
p
er
 m
in
u
te
)
40
50
No PE PE
Primary classification
FIGURE 13 Distribution of respiratory rate by classification in the primary analysis.
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FIGURE 14 Distribution of oxygen saturation by classification in the primary analysis.
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FIGURE 15 Distribution of systolic blood pressure by classification in the primary analysis. BP, blood pressure.
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FIGURE 16 Distribution of diastolic blood pressure by classification in the primary analysis. BP, blood pressure.
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FIGURE 17 Distribution of temperature by classification in the primary analysis.
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Appendix 6 Diagnostic performance of the
clinical decision rules
F igures 18–24 show the diagnostic performance of each CDR across its range of possible scores.
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FIGURE 18 Number of women with and without PE and excluded (primary analysis) by the primary consensus
rule score.
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FIGURE 19 Number of women with and without PE and excluded (primary analysis) by the sensitive consensus
rule score.
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FIGURE 20 Number of women with and without PE and excluded (primary analysis) by the specific consensus rule score.
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FIGURE 21 Number of women with and without PE and excluded (primary analysis) by the PERC score.
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FIGURE 22 Number of women with and without PE and excluded (primary analysis) by the simplified Geneva score.
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FIGURE 23 Number of women with and without PE and excluded (primary analysis) by Wells’s score
(permissive application of PE likely). NA, not applicable.
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FIGURE 24 Number of women with and without PE and excluded (primary analysis) by Wells’s score
(strict application of PE likely). NA, not applicable.
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Appendix 7 Contributions of the individual
elements of clinical decision rules
Tables 34–37 show the odds ratio and p-value for each of the individual elements of each CDR.
TABLE 34 Contributions of the individual elements of the consensus-derived CDRs
Criterion Odds ratio 95% CI p-value
Haemoptysis 1.93 0.83 to 4.61 0.129
Pleuritic chest pain 0.96 0.66 to 1.41 0.842
Previous VTE 1.91 0.95 to 3.92 0.073
Family history of VTE in a first-degree relative 0.71 0.41 to 1.20 0.205
Surgery other than caesarean section 11.1 1.95 to 209 0.025
Significant injury 0.95 0.12 to 5.81 0.959
Obstetric complicationa 4.12 2.68 to 6.41 < 0.001
Active medical comorbiditiesb 1.02 0.26 to 2.62 0.978
Third trimester 0.69 0.33 to 1.46 0.324
Post partum 1.91 0.89 to 4.19 0.101
Raised BMI of ≥ 30 kg/m2 1.01 0.68 to 1.52 0.942
Clinical symptoms of DVT 2.19 0.61 to 8.65 0.231
Clinical signs of DVT 1.49 0.81 to 2.77 0.199
Oxygen saturation of < 94% on room air 4.37 2.12 to 9.71 < 0.001
Tachycardia of > 100 b.p.m. (in first or second trimester,
or post partum)/tachycardia > 110 b.p.m. (in third trimester)
1.13 0.75 to 1.72 0.556
Increased respiratory rate of > 24 breaths per minute 1.03 0.54 to 1.95 0.919
b.p.m., beats per minute.
a Obstetric complications: apply once if any of the following are present – pre-eclampsia in current pregnancy, assisted
reproductive technology/in vitro fertilisation (antenatal only), multiple pregnancy, caesarean section in labour, elective
caesarean section, mid-cavity or rotational operative delivery, prolonged labour (> 24 hours), postpartum haemorrhage
(> 1 litre or transfusion), preterm birth < 37+0 weeks in current pregnancy, stillbirth in current pregnancy, hyperemesis,
ovarian hyperstimulation syndrome (first trimester only).
b Active medical comorbidities: apply once if any of the following are present – cancer, heart failure; systemic lupus
erythematosus, inflammatory polyarthropathy or inflammatory bowel disease; nephrotic syndrome; type I or type 2
diabetes mellitus with nephropathy; sickle cell disease.
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TABLE 35 Contributions of the individual elements of the pregnancy-adapted PERC score
Criterion Odds ratio 95% CI p-value
Aged > 35 years 1.41 0.86 to 2.31 0.176
Heart rate of > 100 b.p.m. (first or second trimester or post partum)
or > 110 b.p.m. in the third trimester
1.13 0.75 to 1.72 0.556
Oxygen saturation of < 94% on room air 4.37 2.12 to 9.71 < 0.001
Prior history of DVT/PE 1.91 0.95 to 3.92 0.073
Recent trauma 0.95 0.12 to 5.81 0.959
Recent surgery 2.72 1.53 to 4.92 0.001
Haemoptysis 1.93 0.83 to 4.61 0.129
Unilateral leg swelling (clinical signs of DVT) 3.08 0.29 to 6.65 0.360
b.p.m., beats per minute.
TABLE 37 Contributions of the individual elements of the pregnancy-adapted simplified revised Geneva score
Criterion Odds ratio 95% CI p-value
Aged > 35 years 1.41 0.86 to 2.31 0.176
Previous DVT or PE 1.91 0.95 to 3.92 0.073
Surgery in the past month 2.72 1.53 to 4.92 0.001
Lower limb fracture in the past month (significant injury) 0.95 0.12 to 5.81 0.959
Active malignant condition 5.99 0.32 to 112.0 0.983
Unilateral lower limb pain 2.19 0.61 to 8.65 0.231
Haemoptysis 1.93 0.83 to 4.61 0.129
Heart rate of > 100 b.p.m. (first or second trimester or post partum)
or > 110 b.p.m. in the third trimester
1.13 0.75 to 1.72 0.556
Pain on limb palpation (clinical signs of DVT) 1.49 0.58 to 2.41 0.199
b.p.m., beats per minute.
TABLE 36 Contributions of the individual elements of the pregnancy-adapted Wells’s criteria
Criterion Odds ratio 95% CI p-value
Clinical symptoms of DVT 2.19 0.61 to 8.65 0.231
Clinical signs of DVT 1.49 0.81 to 2.77 0.199
PE is the most likely diagnosis OR equally likely (strict) 9.15 5.70 to 15.0 < 0.001
PE is the most likely diagnosis OR equally likely (permissive) 1.48 0.85 to 2.62 0.174
Heart rate of > 100 b.p.m. (first or second trimester or post partum)
or > 110 b.p.m. in the third trimester
1.13 0.75 to 1.72 0.556
Immobilisation for at least 3 days 0.95 0.46 to 1.91 0.887
Surgery in the previous 4 weeks 2.72 1.53 to 4.92 0.001
Previous objectively diagnosed PE or DVT 1.91 0.95 to 3.92 0.073
Haemoptysis 1.93 0.83 to 4.61 0.129
Malignancy with treatment within 6 months or palliative 5.99 0.32 to 112 0.983
b.p.m., beats per minute.
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Appendix 8 Details of the multivariable analysis
The LASSO is a method of automated selection of covariates/predictor variables that maximises theaccuracy of the model without inflating the estimated coefficients for each variable. The R package
glmnet was used to fit a model using the LASSO. Exactly what predictors are included/used in a model
varies, as LASSO regression seeks to select a subset of variables. Figure 25 shows the change in the
coefficients for each predictor variable over iterations of estimation via LASSO. L1 norm is a constraint
placed on the analysis for the sum of all coefficients and is one of the unique features of the LASSO.
Cross-validation
Leave-one-out cross-validation has been used internally at each step of the fitting of the LASSO to shrink
the point estimate and inform the next iteration. The model should not be overfitted though, and this can
be achieved by considering the parameter lambda and either taking the minimum value or the value
corresponding to 1 × SE of the point estimate of the mean squared error, which are the dashed lines on
Figure 26.
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FIGURE 25 Change in the coefficients for each predictor variable over iterations of estimation via LASSO.
DOI: 10.3310/hta22470 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 47
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
Receiver operating characteristic curve
Having selected an optimal value for lambda, the predicted probabilities are then obtained and ROC curves
are plotted along with the calculated AUC statistic, as shown in Figure 27. A cut-off point for probability
can be chosen, but in the absence of any choice, a default of p = 0.5 has been used in order to calculate
the various performance metrics shown in Table 38. Table 39 shows the coefficients for the lambda
thresholds.
Trade-off between complexity and predictive value
The question naturally arises as to whether or not a parsimonious model with fewer variables from an
earlier stage in the LASSO can be used without losing the predictive ability of the model. It is self-evident
that simpler models will have poorer predictive value because they use less information in order to make
the prediction but, in order to provide a visual overview and numerical quantification of the trade-off
between complexity and predictive value, all steps from the LASSO are plotted as ROC curves in Figure 28
and goodness-of-fit statistics have been calculated for each sequential step.
– 2
1.15
1.20
1.25
1.30
M
ea
n
 s
q
u
ar
ed
 e
rr
o
r
1.35
1.40
0 5 7 22 30 35 37
Number of iterations
37 37 37 38 38
– 4 – 6
Log(lambda)
– 8
FIGURE 26 Leave-one-out cross-validation.
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FIGURE 27 Receiver operating characteristic curves for the leave-one-out cross-validation.
TABLE 38 Predictive statistics for the lambda thresholds
Term
True
positive
True
negative
False
positive
False
negative AUC (95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
Lambda
1 × SE
124 18 215 0 0.668
(0.607 to 0.729)
1.000
(0.971 to 1.000)
0.077
(0.046 to 0.119)
Lambda
minimum
103 91 142 21 0.724
(0.669 to 0.779)
0.831
(0.753 to 0.892)
0.391
(0.328 to 0.456)
TABLE 39 Coefficients for lambda thresholds
Term 1 × SE Minimum
(Intercept) 1.915 –3.987
≥ 3 days of immobility/bed rest during pregnancy 0.000 0.000
Age (continuous) 0.000 0.000
BMI (continuous) 0.000 0.000
Cough 0.000 0.000
Diastolic (continuous) 0.000 0.000
dvt.cat 0.000 0.013
continued
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TABLE 39 Coefficients for lambda thresholds (continued )
Term 1 × SE Minimum
ECG.PE 0.000 0.000
Family history of thrombosis 0.000 0.000
Haemoptysis 0.000 0.000
Heart rate (continuous) 0.000 0.000
History of i.v. drug use 0.000 0.000
History of thrombosis 0.000 0.256
History of varicose veins 0.000 0.000
Injury 0.000 0.000
Known thrombophilia 0.000 0.000
Long-haul travel during pregnancy –0.428 –1.225
medical.probs 0.000 0.000
Multiple pregnancy 0.000 –0.402
Non-pleuritic 0.000 0.000
O2 saturation (continuous) –0.041 –0.065
Other 0.000 0.000
Other problem with this pregnancy (VTE related) 0.000 0.000
Palpitations 0.000 0.000
Pleuritic 0.000 0.000
Pregnancies < 24 weeks’ gestation (continuous) 0.000 0.000
Pregnancies > 24 weeks’ gestation (continuous) 0.000 0.000
Problems with this pregnancy (including other) 0.000 0.006
respiratory.rate 0.000 0.000
SOB (exertion) 0.000 0.000
SOB (rest) 0.000 0.000
Smoking (as recorded) 0.000 0.000
Surgery in previous 4 weeks 0.028 0.299
Syncope 0.000 0.000
Systolic (continuous) 0.000 0.000
Temperature (continuous) 0.037 0.273
thromb.event 0.000 0.000
Trimester 0.000 0.000
X-ray: normal.PE 0.413 0.660
i.v., intravenous; SOB, shortness of breath.
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FIGURE 28 Receiver operating characteristic for all steps of the cross-validated LASSO.
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Appendix 9 Recursive partitioning
Recursive partitioning is a method of automatically selecting variables and, when continuous, cut-offpoints within the range of a given variable, which maximise the classification of individuals. The R
package rpart was used to fit a model using recursive partitioning. Table 40 explains the definitions and
terms used in recursive partitioning. There are a number of control parameters that are used in running a
recursive partitioning model, and these are described in Table 41.
Table 42 shows the summary table for the full model. This model, because it was forced to fit a full model
that categorised everyone, is overfitted, meaning that its generalisability and application in individuals
not in the cohort will be poor. To improve the generalisability of the model, we pruned the tree by
selecting a more permissive value for the complexity parameter (cp). It is recommended that a decision tree
is pruned using the complexity parameter that corresponds to the minimum cross-validated error (xerror in
the table below48). The complexity parameter (cp), along with the associated cross-validated error (xerror),
is included in Table 42 and a plot of the two parameters is shown in Figure 29. The complexity parameter
(cp) at the step/number of splits (0.018) that corresponds to the minimum cross-validated error is 0.018.
TABLE 40 Definitions and terms in recursive partitioning
Term Definition
Leave-one-out
cross-validation
Observations are dropped, one at a time from the data set, the model fitted and the excluded persons
outcome predicted. This is repeated for each observation
Overfitting Trees produced that classify all people are too specific to the data set and will not be useful in
predicting outcomes in new patients
Pruning The process of trimming back an overfitted tree using the complexity parameter
Node A split in the partitioning tree
Complexity
parameter
A metric that quantifies the reduction in error afforded by a given split. As successive splits are made,
the reduction in error diminishes
Minimum bucket A control parameter for fitting trees, which forces each split to have a minimum number of
observations classified to each node
TABLE 41 Control parameters used in fitting models with rpart
Control
parameter Value Explanation
minsplit 4 The minimum number of observations that must exist in a node in order for a split to be attempted
minbucket 2 The mimimum number of observations in any terminal node
cp –1 The complexity parameter; a negative value ensures that a full model is fitted when everyone is
classified
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TABLE 42 Summary table for the overfitted full model
Complexity parameter Splits Relative error Cross-validated error Cross-validated SD
0.118 0 1.000 1.000 0.060
0.053 1 0.882 0.976 0.060
0.047 2 0.828 0.988 0.060
0.024 3 0.781 0.893 0.058
0.022 4 0.757 0.893 0.058
0.018 7 0.692 0.899 0.059
0.012 11 0.621 0.959 0.059
0.009 20 0.509 0.935 0.059
0.008 33 0.337 0.976 0.060
0.006 42 0.249 0.982 0.060
0.003 60 0.130 1.012 0.060
0.000 62 0.124 1.018 0.060
–1.000 78 0.124 1.018 0.060
SD, standard deviation.
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FIGURE 29 Complexity parameter along with the associated cross-validated error.
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We now needed to calculate the sensitivity and specificity. There was no single value for either of these
metrics, as individuals have a predicted probability of classification in the range of 0 < p < 1, rather than a
binary classification. The trade-off between sensitivity and specificity is shown in the ROC curve (Figure 30).
The question arises, however, as to whether or not it is possible to utilise a simpler, more parsimonious
tree with fewer splits, but still retain the ability to make useful and accurate predictions. To this end, the
ROC curve for each step/split in the recursive partitioning process is plotted in Figure 31, and Table 43
provides the performance statistics for each step. Dichotomising individuals’ predicted probability of
disease is required in order to calculate the sensitivity and specificity. For now, a cut-off point of p = 0.05
has been used, but this is unlikely to be optimal for any of the trees.
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FIGURE 30 Receiver operating characteristic curves for the pruned tree minimising the cross-validation error.
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FIGURE 31 Receiver operating characteristic curves for each pruned tree.
TABLE 43 Predictive statistics for the sequential splits of recursive partitioning, using a cut-off point of p= 0.5
Term AUC
AUC lower CI to
AUC upper CI Sensitivity
Sensitivity lower CI to
sensitivity upper CI Specificity
Specificity lower CI to
specificity upper CI
1 0.500 0.500 to 0.500 0.000 0.000 to 0.022 1.000 0.986 to 1.000
2 0.574 0.541 to 0.608 0.207 0.149 to 0.276 0.942 0.906 to 0.967
3 0.647 0.601 to 0.693 0.485 0.408 to 0.563 0.795 0.740 to 0.842
4 0.657 0.611 to 0.703 0.462 0.385 to 0.540 0.841 0.791 to 0.883
5 0.664 0.619 to 0.710 0.444 0.368 to 0.522 0.868 0.821 to 0.907
6 0.684 0.639 to 0.729 0.420 0.345 to 0.498 0.926 0.887 to 0.955
7 0.738 0.695 to 0.781 0.515 0.437 to 0.592 0.911 0.869 to 0.943
8 0.819 0.784 to 0.855 0.586 0.508 to 0.661 0.938 0.901 to 0.964
9 0.909 0.882 to 0.937 0.757 0.686 to 0.820 0.938 0.901 to 0.964
10 0.949 0.929 to 0.968 0.852 0.789 to 0.902 0.934 0.897 to 0.961
11 0.985 0.977 to 0.994 0.953 0.909 to 0.979 0.946 0.911 to 0.970
12 0.987 0.979 to 0.995 0.947 0.901 to 0.975 0.953 0.920 to 0.976
13 0.995 0.991 to 0.998 0.982 0.949 to 0.996 0.930 0.892 to 0.958
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Appendix 10 Results of the secondary analyses
T able 44 shows the p-values for the univariable analysis. There was little difference between theanalyses. Some variables were significant predictors (p < 0.05) on the secondary analysis that were not
significant predictors on the primary analysis, for example giving up smoking during the pregnancy, history
of varicose veins and previous VTE, but this simply reflected the p-value moving to the other side of the
0.05 threshold, presumably because of a slightly larger sample size.
TABLE 44 Primary and secondary univariable analysis (p-values)
Variable
Analysis
Primary
Secondary,
with clinically
diagnosed PE
Secondary,
with clinically
ruled-out PE
Secondary, with
subsegmental PE
excluded
Age, years (continuous) 0.179 0.307 0.166 0.187
Aged over 35 years 0.176 0.247 0.177 0.256
BMI, kg/m2 (continuous) 0.372 0.587 0.256 0.253
BMI of ≥ 30 kg/m2 0.942 0.631 0.775 0.781
Ex-smoker (prior) 0.837 0.901 0.842 0.792
Ex-smoker (during) 0.082 0.082 0.035 0.080
Current smoker 0.279 0.159 0.318 0.354
Pregnancies lasting for < 24 weeks’
gestation (continuous)
0.509 0.386 0.679 0.440
One or more pregnancy lasting for
< 24 weeks’ gestation
0.980 0.937 0.776 0.883
Pregnancies lasting for > 24 weeks’
gestation (continuous)
0.017 0.014 0.014 0.017
One or more pregnancy lasting for
> 24 weeks’ gestation
0.198 0.243 0.217 0.224
Previous pregnancy problems 0.442 0.888 0.252 0.493
Family history of VTE 0.205 0.125 0.324 0.160
History of varicose veins 0.045 0.084 0.033 0.056
History of i.v. drug use 0.800 0.910 0.719 0.775
Known thrombophilia 0.745 0.993 0.934 0.801
Surgery in the previous 4 weeks 0.001 0.003 0.000 0.000
Injury in the previous 4 weeks 0.959 0.845 0.910 0.998
Previous VTE 0.073 0.092 0.025 0.081
Other previous medical problem 0.829 0.989 0.760 0.955
Other previous medical problem
(VTE related)
0.941 0.941 0.941 0.941
Second trimester 0.234 0.573 0.064 0.185
Third trimester 0.324 0.635 0.196 0.283
Post partum 0.101 0.105 0.168 0.142
Multiple pregnancy 0.191 0.097 0.299 0.220
Long-haul travel during pregnancy 0.006 0.002 0.011 0.007
continued
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TABLE 44 Primary and secondary univariable analysis (p-values) (continued )
Variable
Analysis
Primary
Secondary,
with clinically
diagnosed PE
Secondary,
with clinically
ruled-out PE
Secondary, with
subsegmental PE
excluded
≥ 3 days of immobility/bed rest during
pregnancy
0.887 0.988 0.970 0.995
Received thromboprophylaxis 0.000 0.000 0.000 0.000
Previous thrombotic event this
pregnancy
0.226 0.085 0.157 0.203
Other problem with this pregnancy 0.006 0.095 0.003 0.006
Other problem with this pregnancy
(VTE related)
0.713 0.815 0.903 0.772
Presenting: pleuritic chest pain 0.842 0.774 0.982 0.767
Presenting: non-pleuritic chest pain 0.457 0.391 0.464 0.405
Presenting: SOB (exertion) 0.520 0.895 0.796 0.317
Presenting: SOB (rest) 0.142 0.135 0.104 0.239
Presenting: haemoptysis 0.129 0.109 0.320 0.103
Presenting: cough 0.988 0.913 0.772 0.940
Presenting: syncope 0.218 0.090 0.189 0.291
Presenting: palpitations 0.598 0.424 0.521 0.595
Presenting: other 0.914 0.771 0.888 0.989
Temperature of > 37.5 °C 0.020 0.017 0.022 0.015
Temperature, °C (continuous) 0.003 0.002 0.001 0.003
Diastolic BP of < 50mmHg 0.221 0.195 0.162 0.202
Diastolic BP (continuous) 0.256 0.503 0.210 0.265
Systolic BP of < 90mmHg 0.205 0.164 0.162 0.191
Systolic (continuous) 0.322 0.137 0.480 0.350
Oxygen saturation of < 94% 0.000 0.001 0.000 0.000
Oxygen saturation, % (continuous) 0.000 0.001 0.000 0.000
Respiratory rate of > 24 breaths
per minute
0.919 0.956 0.722 0.798
Respiratory rate (continuous) 0.948 0.841 0.592 0.869
Heart rate of > 100 b.p.m. (110 b.p.m. in
the third trimester)
0.556 0.618 0.615 0.524
Heart rate, b.p.m. (continuous) 0.126 0.063 0.126 0.084
Clinical signs of DVT 0.199 0.104 0.418 0.274
PE-related ECG abnormality 0.579 0.580 0.760 0.631
PE-related chest radiograph abnormality 0.010 0.018 0.007 0.019
Other chest radiograph abnormality 0.001 0.001 0.001 0.001
PE is the most likely diagnosis or equally
likely (permissive)
0.156 0.156 0.156 0.156
PE is the most likely diagnosis or equally
likely (strict)
0.000 0.000 0.000 0.000
BP, blood pressure; b.p.m., beats per minute; i.v., intravenous; SOB, shortness of breath.
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Table 45 shows the AUROC estimates for the CDRs. The results for the secondary analyses were similar to
those of the primary analysis.
Table 46 shows the results for D-dimer analysis using the hospital laboratory measurements. The inclusion
of women with clinically diagnosed PE and the exclusion of women with subsegmental PE resulted in small
changes to sensitivity, whereas the inclusion of women with clinically ruled-out PE resulted in a small
change in specificity. None of the estimates in the secondary analysis differed in a meaningful way from
the primary analysis.
TABLE 45 Primary and secondary analysis AUC estimates for the CDRs
Decision rule
Analysis
Primary
Secondary,
with clinically
diagnosed PE
Secondary,
with clinically
ruled-out PE
Secondary, with
subsegmental PE
excluded
Primary consensus 0.626 0.621 0.626 0.629
Sensitive consensus 0.620 0.599 0.629 0.622
Specific consensus 0.589 0.592 0.582 0.592
PERC score 0.621 0.610 0.619 0.623
Simplified revised Geneva score 0.579 0.575 0.572 0.579
Wells’s score (permissive) 0.577 0.580 0.577 0.578
Wells’s score (strict) 0.732 0.716 0.728 0.731
TABLE 46 Primary and secondary analysis of D-dimer (hospital) sensitivity and specificity
Threshold Parameter
Analysis
Primary analysis
Secondary,
with clinically
diagnosed PE
Secondary,
with clinically
ruled-out PE
Secondary, with
subsegmental PE
excluded
Standard Sensitivity
95% CI
n/N
0.884
0.741 to 0.956
38/43
0.878
0.7445 to 0.945
43/49
0.884
0.741 to 0.956
38/43
0.878
0.730 to 0.954
36/41
Specificity
95% CI
n/N
0.088
0.047 to 0.156
11/125
0.088
0.047 to 0.156
11/125
0.092
0.052 to 0.156
13/141
0.088
0.047 to 0.156
11/125
Gestation
specific
Sensitivity
95% CI
n/N
0.698
0.537 to 0.823
30/43
0.694
0.544 to 0.813
34/49
0.698
0.537 to 0.823
30/43
0.707
0.543 to 0.833
29/41
Specificity
95% CI
n/N
0.328
0.248 to 0.419
41/125
0.328
0.248 to 0.419
41/125
0.355
0.277 to 0.440
50/141
0.328
0.248 to 0.419
41/125
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Tables 47 and 48 show the coefficients for the multivariable models. The 1 × SE models for the secondary
analyses included the same five terms as the primary analysis (long-haul travel, oxygen saturation, surgery,
temperature and PE-related chest radiograph abnormality), but also included previous VTE when clinically
ruled-out PE was included or subsegmental PE was excluded. The models had similar accuracy in the
secondary analyses, with AUC estimates of around 0.7. The minimum value models for the secondary
analysis included similar terms to the primary analysis, but also included a number of additional terms,
especially when clinically diagnosed PE was included. The models had slightly higher accuracy, with AUCs
TABLE 47 Primary and secondary multivariable analysis 1 × SE model
Term or diagnostic parameter
Analysis
Primary
Secondary,
with clinically
diagnosed PE
Secondary,
with clinically
ruled-out PE
Secondary, with
subsegmental
PE excluded
(Intercept) 1.915 –1.202 0.523 –0.813
Immobility/bed rest during
pregnancy
0.000 0.000 0.000 0.000
Age, years (continuous) 0.000 0.000 0.000 0.000
BMI, kg/m2 (continuous) 0.000 0.000 0.000 0.000
Cough 0.000 0.000 0.000 0.000
Diastolic BP (continuous) 0.000 0.000 0.000 0.000
Clinical signs of DVT 0.000 0.000 0.000 0.000
PE-related ECG abnormality 0.000 0.000 0.000 0.000
Family history of VTE 0.000 0.000 0.000 0.000
Haemoptysis 0.000 0.000 0.000 0.000
Heart rate, b.p.m. (continuous) 0.000 0.000 0.000 0.000
History of i.v. drug use 0.000 0.000 0.000 0.000
Previous VTE 0.000 0.000 0.015 0.036
History of varicose veins 0.000 0.000 0.000 0.000
Injury 0.000 0.000 0.000 0.000
Known thrombophilia 0.000 0.000 0.000 0.000
Long-haul travel during
pregnancy
–0.428 –0.692 –0.432 –0.693
Previous medical problem 0.000 0.000 0.000 0.000
Multiple pregnancy 0.000 0.000 0.000 0.000
Non-pleuritic 0.000 0.000 0.000 0.000
Oxygen saturation, % (continuous) –0.041 –0.027 –0.055 –0.053
Other presenting complaint 0.000 0.000 0.000 0.000
Other problem with this
pregnancy (VTE related)
0.000 0.000 0.000 0.000
Palpitations 0.000 0.000 0.000 0.000
Pleuritic 0.000 0.000 0.000 0.000
Pregnancies lasting for < 24 weeks’
gestation (continuous)
0.000 0.000 0.000 0.000
Pregnancies lasting for > 24 weeks’
gestation (continuous)
0.000 0.000 0.000 0.000
Problems with this pregnancy 0.000 0.000 0.000 0.000
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TABLE 47 Primary and secondary multivariable analysis 1 × SE model (continued )
Term or diagnostic parameter
Analysis
Primary
Secondary,
with clinically
diagnosed PE
Secondary,
with clinically
ruled-out PE
Secondary, with
subsegmental
PE excluded
Respiratory rate (breaths per
minute)
0.000 0.000 0.000 0.000
SOB (exertion) 0.000 0.000 0.000 0.000
SOB (rest) 0.000 0.000 0.000 0.000
Smoking (as recorded) 0.000 0.000 0.000 0.000
Surgery in the previous 4 weeks 0.028 0.000 0.170 0.193
Syncope 0.000 0.000 0.000 0.000
Systolic BP (continuous) 0.000 0.000 0.000 0.000
Temperature, °C (continuous) 0.037 0.099 0.101 0.140
Thrombotic event in this
pregnancy
0.000 0.000 0.000 0.000
Trimester 0.000 0.000 0.000 0.000
PE-related chest radiograph
abnormality
0.413 0.394 0.525 0.556
AUC (95%CI) 0.668
(0.607 to 0.729)
0.677
(0.621 to 0.732)
0.692
(0.634 to 0.750)
0.708
(0.650 to 0.766)
Sensitivity (95% CI) 1.00
(0.971 to 1.000)
1.000
(0.975 to 1.000)
0.613
(0.521 to 0.699)
0.832
(0.752 to 0.894)
Specificity (95% CI) 0.077
(0.046 to 0.119)
0.077
(0.046 to 0.119)
0.644
(0.584 to 0.702)
0.373
(0.311 to 0.439)
BP, blood pressure; b.p.m., beats per minute; i.v., intravenous; SOB, shortness of breath.
TABLE 48 Primary and secondary multivariable analysis minimum value model
Term or diagnostic parameter
Analysis
Primary
Secondary,
with clinically
diagnosed PE
Secondary,
with clinically
ruled-out PE
Secondary, with
subsegmental
PE excluded
(Intercept) –3.987 –7.262 –5.164 –5.440
Immobility/bed rest during
pregnancy
0.000 0.000 0.000 0.000
Age, years (continuous) 0.000 0.000 0.000 0.000
BMI, kg/m2 (continuous) 0.000 0.000 0.000 0.000
Cough 0.000 0.000 0.000 0.000
Diastolic BP (continuous) 0.000 0.000 0.000 0.000
Clinical signs of DVT 0.013 0.209 0.000 0.000
PE-related ECG abnormality 0.000 –0.453 0.000 0.000
Family history of VTE 0.000 –0.157 0.000 0.000
Haemoptysis 0.000 0.117 0.000 0.061
Heart rate, b.p.m. (continuous) 0.000 0.002 0.000 0.000
History of i.v. drug use 0.000 0.000 0.000 0.000
continued
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TABLE 48 Primary and secondary multivariable analysis minimum value model (continued )
Term or diagnostic parameter
Analysis
Primary
Secondary,
with clinically
diagnosed PE
Secondary,
with clinically
ruled-out PE
Secondary, with
subsegmental
PE excluded
Previous VTE 0.256 0.353 0.421 0.352
History of varicose veins 0.000 –0.108 0.000 0.000
Injury 0.000 0.000 0.000 0.000
Known thrombophilia 0.000 0.000 0.000 0.000
Long-haul travel during
pregnancy
–1.225 –1.786 –1.090 –1.248
Previous medical problems 0.000 0.000 0.000 0.000
Multiple pregnancy –0.402 –0.887 –0.290 –0.429
Non-pleuritic 0.000 0.044 0.000 0.000
Oxygen saturation, %
(continuous)
–0.065 –0.056 –0.075 –0.069
Other presenting complaint 0.000 0.000 0.000 0.000
Other problem with this
pregnancy (VTE related)
0.000 0.000 0.000 0.000
Palpitations 0.000 0.000 0.000 0.000
Pleuritic 0.000 0.000 0.000 0.000
Pregnancies lasting for < 24 weeks’
gestation (continuous)
0.000 0.000 0.000 0.000
Pregnancies lasting for > 24 weeks’
gestation (continuous)
0.000 0.000 0.000 0.000
Problems with this pregnancy 0.006 0.000 0.000 0.000
Respiratory rate (breaths per
minute)
0.000 0.000 0.000 0.000
SOB (exertion) 0.000 0.000 0.000 0.089
SOB (rest) 0.000 0.000 –0.038 0.000
Smoking (as recorded) 0.000 0.000 0.000 0.000
Surgery in the previous 4 weeks 0.299 0.323 0.379 0.366
Syncope 0.000 0.085 0.000 0.000
Systolic BP (continuous) 0.000 –0.006 0.000 –0.002
Temperature, °C (continuous) 0.273 0.380 0.313 0.318
Thrombotic event in this
pregnancy
0.000 0.313 0.000 0.000
Trimester 0.000 0.000 0.000 0.000
PE-related chest radiograph
abnormality
0.660 0.664 0.731 0.729
AUC (95%CI) 0.724
(0.669 to 0.779)
0.735
(0.685 to 0.786)
0.731
(0.677 to 0.785)
0.746
(0.692 to 0.800)
Sensitivity (95% CI) 0.831
(0.753 to 0.892)
0.972
(0.931 to 0.992)
0.621
(0.529 to 0.707)
0.748
(0.660 to 0.823)
Specificity (95% CI) 0.391
(0.328 to 0.456)
0.262
(0.207 to 0.323)
0.674
(0.614 to 0.730)
0.545
(0.479 to 0.610)
BP, blood pressure; b.p.m., beats per minute; i.v., intravenous; SOB, shortness of breath.
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
of up to 0.757. The slightly higher accuracy in the secondary analysis may reflect the fact that the increase
in the size of the data set provided more statistical power to develop a more accurate model or this may
reflect bias, with the clinical diagnosis or the ruling out of PE being based on variables included in
the models.
Accuracy remained short of what would be required from an acceptable model, whereas problems of
overfitting and potential bias are likely to be greater than those in the primary analysis.
Table 49 shows the AUROC for each biomarker with a 95% CI. There were no meaningful differences
between the analyses.
TABLE 49 Primary and secondary analysis AUROC (95% CI) for each biomarker
Biomarker
Analysis
Primary
Secondary,
with clinically
diagnosed PE
Secondary,
with clinically
ruled-out PE
Secondary, with
subsegmental PE
excluded
APTT (minutes) 0.669
(0.570 to 0.768)
0.638
(0.54 to 0.735)
0.681
(0.584 to 0.778)
0.676
(0.576 to 0.777)
BNP level 0.549
(0.453 to 0.645)
0.543
(0.449 to 0.636)
0.549
(0.451 to 0.647)
0.546
(0.448 to 0.645)
CRP level (pg/ml) 0.542
(0.445 to 0.639)
0.557
(0.465 to 0.649)
0.542
(0.447 to 0.636)
0.531
(0.434 to 0.628)
Clauss fibrinogen 0.589
(0.476 to 0.701)
0.559
(0.452 to 0.666)
0.600
(0.489 to 0.712)
0.604
(90.492 to 0.715)
D-dimer (ELISA) 0.668
(0.561 to 0.776)
0.64
(0.537 to 0.743)
0.669
(0.561 to 0.776)
0.679
(0.571 to 0.787)
D-dimer (Innovance) 0.651
(0.545 to 0.758)
0.624
(0.522 to 0.725)
0.655
(0.549 to 0.761)
0.667
(0.562 to 0.772)
MRproANP 0.524
(0.418 to 0.630)
0.523
(0.423 to 0.622)
0.526
(0.422 to 0.631)
0.483
(0.376 to 0.591)
PF 1 + 2 0.562
(0.462 to 0.661)
0.546
(0.453 to 0.638)
0.569
(0.470 to 0.668)
0.556
(0.455 to 0.658)
Plasmin–antiplasmin level 0.639
(0.536 to 0.742)
0.615
(0.518 to 0.712)
0.637
(0.534 to 0.740)
0.633
(0.528 to 0.738)
PT (minutes) 0.613
(0.508 to 0.718)
0.588
(0.488 to 0.688)
0.623
(0.518 to 0.727)
0.623
(0.517 to 0.729)
TG (endogenous potential) 0.559
(0.437 to 0.681)
0.556
(0.448 to 0.665)
0.566
(0.442 to 0.690)
0.566
(0.440 to 0.692)
TG (lag time) 0.702
(0.598 to 0.806)
0.656
(0.551 to 0.761)
0.721
(0.622 to 0.819)
0.704
(0.598 to 0.811)
TG (peak) 0.596
(0.478 to 0.715)
0.569
(0.459 to 0.679)
0.610
(0.492 to 0.729)
0.597
(0.475 to 0.719)
TG (time to peak) 0.655
(0.541 to 0.769)
0.613
(0.503 to 0.723)
0.675
(0.564 to 0.786)
0.657
(0.540 to 0.774)
Tissue factor (pg/ml) 0.531
(0.424 to 0.638)
0.565
(0.464 to 0.666)
0.515
(0.409 to 0.620)
0.518
(0.411 to 0.625)
Troponin level (ng/ml) 0.597
(0.499 to 0.695)
0.559
(0.462 to 0.655)
0.609
(0.514 to 0.704)
0.608
(0.510 to 0.706)
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Appendix 11 Details of the biomarker analysis
(including women who had received anticoagulation
treatment)
F igures 32–47 show, for each biomarker, a box-and-whisker plot comparing biomarker levels for womenwith DVT, women with PE, women with no PE and women excluded from the primary analysis.
Activated partial thromboplastin time
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Primary classification
FIGURE 32 Box-and-whisker plot comparing the APTT levels for women with DVT, women with PE, women with no
PE and women excluded from the primary analysis.
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FIGURE 33 Box-and-whisker plot comparing Clauss fibrinogen levels for women with DVT, women with PE,
women with no PE and women excluded from the primary analysis.
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FIGURE 34 Box-and-whisker plot comparing PT levels for women with DVT, women with PE, women with no PE
and women excluded from the primary analysis.
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D-dimer (Innovance) levels
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FIGURE 35 Box-and-whisker plot comparing D-dimer (Innovance) levels for women with DVT, PE, no PE and those
excluded from the primary analysis.
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
D-dimer (ELISA) levels
DVT Excluded
0
D
-d
im
er
 –
 E
LI
SA
 (
n
g
/l)
5000
10,000
No PE PE
Primary classification
FIGURE 36 Box-and-whisker plot comparing D-dimer (ELISA) levels for women with DVT, women with PE,
women with no PE and women excluded from the primary analysis.
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FIGURE 37 Box-and-whisker plot comparing TG (lag time) levels for women with DVT, women with PE,
women with no PE and women excluded from the primary analysis.
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FIGURE 38 Box-and-whisker plot comparing TG (endogenous potential) levels for women with DVT, women with
PE, women with no PE and women excluded from the primary analysis.
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FIGURE 39 Box-and-whisker plot comparing TG (peak) levels for women with DVT, women with PE, women with
no PE and women excluded from the primary analysis.
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FIGURE 40 Box-and-whisker plot comparing TG (time to peak) levels for women with DVT, women with PE, women
with no PE and women excluded from the primary analysis.
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FIGURE 41 Box-and-whisker plot comparing the plasmin–antiplasmin levels for women with DVT, women with PE,
women with no PE and women excluded from the primary analysis.
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FIGURE 42 Box-and-whisker plot comparing MRProANP levels for women with DVT, women with PE, women with
no PE and women excluded from the primary analysis.
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FIGURE 43 Box-and-whisker plot comparing BNP levels for women with DVT, women with PE, women with no PE
and women excluded from the primary analysis.
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FIGURE 44 Box-and-whisker plot comparing tissue factor levels (pg/ml) for women with DVT, women with PE,
women with no PE and women excluded from the primary analysis.
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FIGURE 45 Box-and-whisker plot comparing PF 1+ 2 levels (pmol/l) for women with DVT, women with PE,
women with no PE and women excluded from the primary analysis.
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FIGURE 46 Box-and-whisker plot comparing troponin levels (ng/ml) for women with DVT, women with PE,
women with no PE and women excluded from the primary analysis.
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FIGURE 47 Box-and-whisker plot comparing CRP levels for women with DVT, women with PE, women with no PE
and women excluded from the primary analysis.
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Details of the biomarker analysis (excluding women who had received
anticoagulation treatment)
We repeated the primary biomarker analysis, having excluded 240 out of 328 women who had received
anticoagulation treatment prior to blood sampling. The analysis involved only 66 women, of whom four
women had VTE. Table 50 compares the mean biomarker levels between women with and without VTE
in the primary analysis. The differences observed in the main analysis disappeared or even reversed
when women receiving anticoagulation treatment were removed, but this probably reflects the small
numbers available for this analysis. There were no significant differences in biomarker levels between
the two groups.
Figures 48–50 show the ROC curves for the D-dimer biomarkers, the apothrombin, PF 1 + 2, prothrombin
and TG biomarkers and the other biomarkers.
TABLE 50 Mean (standard deviation) biomarker levels for the patient groups with those having received
anticoagulation treatment excluded
Biomarker
Mean biomarker level (SD) in women with
p-valueNo VTE (n= 62) VTE (n= 4)
APTT (minutes) 33.4 (16.67) 33.4 (6.57) 0.993
PT (minutes) 14.8 (2.108) 14.2 (0.772) 0.610
Clauss fibrinogen 5.41 (1.81) 6.61 (2.61) 0.219
D-dimer (ELISA) 1114 (848) 832 (667) 0.517
D-dimer (Innovance) 1.126 (0.826) 0.797 (0.420) 0.432
TG (lag time) 6.20 (1.646) 6.98 (0.919) 0.354
TG (endogenous potential) 1501 (389) 1575 (351) 0.711
TG (time to peak) 10.03 (2.57) 10.31 (1.40) 0.823
TG (peak) 235 (100.3) 248 (71.0) 0.798
Plasmin–antiplasmin level 678 (205) 821 (276) 0.204
BNP level 256 (586.31) 29 (5.47) 0.205
MRproANP 478 (904) 1371 (1358) 0.095
Tissue factor (pg/ml) 222 (157.8) 164 (37.4) 0.428
PF 1 + 2 (pmol/l) 711 (386) 373 (161) 0.095
Troponin level (ng/ml) 1.03 (1.24) 2.12 (1.65) 0.122
CRP level (pg/ml) 5410 (1596) 5884 (1734) 0.564
SD, standard deviation.
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FIGURE 48 Receiver operating characteristic curves for the D-dimer level biomarkers.
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FIGURE 49 Receiver operating characteristic curves for apothrombin, PF 1+ 2, prothrombin and TG biomarkers
(excluding women who had received anticoagulation treatment).
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FIGURE 50 Receiver operating characteristic curves for other biomarkers (excluding women who had received
anticoagulation treatment).
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Table 51 reports the AUROC for the continuous biomarkers and diagnostic parameters for the biomarkers
at the predefined threshold for positivity and the threshold that optimised sensitivity (> 95%) at the
expense of specificity. The analysis was limited by small numbers, especially of women with VTE. BNP,
PF 1 + 2, TG (lag time) and troponin may have some potential to rule out VTE with acceptable sensitivity,
but the CIs are wide and the estimates would need to be validated in a larger cohort of women with VTE.
TABLE 51 Area under the receiver operating characteristic value, sensitivity and specificity for each biomarker,
excluding women who had received anticoagulation treatment
Biomarker AUC (95% CI)
At predefined threshold (95% CI)
At threshold with optimal
sensitivity (95% CI)
Sensitivity Specificity Sensitivity Specificity
APTT (minutes) 0.581
(0.244 to 0.919)
0.00
(0.000 to 0.602)
0.967
(0.885 to 0.996)
1
(0.398 to 1)
0.217
(0.121 to 0.342)
BNP level 0.774
(0.670 to 0.878)
0.00
(0.000 to 0.602)
0.935
(0.843 to 0.982)
1
(0.398 to 1)
0.742
(0.615 to 0.845)
CRP level (pg/ml) 0.609
(0.250 to 0.968)
1.00
(0.398 to 1.000)
0.097
(0.036 to 0.199)
1
(0.398 to 1)
0.113
(0.047 to 0.219)
Clauss fibrinogen 0.648
(0.259 to 1.000)
0.75
(0.194 to 0.994)
0.250
(0.147 to 0.379)
1
(0.398 to 1)
0.117
(0.048 to 0.226)
D-dimer (ELISA) 0.615
(0.210 to 1.000)
0.50
(0.068 to 0.932)
0.148
(0.070 to 0.262)
1
(0.398 to 1)
0.213
(0.119 to 0.337)
D-dimer (Innovance) 0.613
(0.299 to 0.926)
0.25
(0.006 to 0.806)
0.672
(0.540 to 0.787)
1
(0.398 to 1)
0.262
(0.158 to 0.391)
MRproANP 0.698
(0.357 to 1.000)
0.50
(0.068 to 0.932)
0.823
(0.705 to 0.908)
1
(0.398 to 1)
0.210
(0.117 to 0.332)
PF 1 + 2 (pmol/l) 0.795
(0.644 to 0.947)
0.00
(0.000 to 0.602)
0.918
(0.819 to 0.973)
1
(0.398 to 1)
0.639
(0.506 to 0.758)
Plasmin–antiplasmin level 0.684
(0.335 to 1.000)
0.50
(0.068 to 0.932)
0.770
(0.645 to 0.868)
1
(0.398 to 1)
0.180
(0.094 to 0.300)
PT (minutes) 0.572
(0.306 to 0.838)
0.00
(0.000 to 0.602)
0.831
(0.710 to 0.916)
1
(0.398 to 1)
0.220
(0.123 to 0.347)
TG (lag time) 0.735
(0.531 to 0.940)
1.00
(0.398 to 1.000)
0.00
(0.000 to 0.060)
1
(0.398 to 1)
0.450
(0.321 to 0.584)
TG (endogenous potential) 0.454
(0.155 to 0.753)
0.50
(0.068 to 0.932)
0.525
(0.393 to 0.654)
1
(0.398 to 1)
0.233
(0.134 to 0.360)
TG (peak) 0.462
(0.229 to 0.696)
0.00
(0.000 to 0.602)
0.852
(0.738 to 0.930)
1
(0.398 to 1)
0.317
(0.203 to 0.450)
TG (time to peak) 0.577
(0.320 to 0.834)
1.00
(0.398 to 1.000)
0.213
(0.119 to 0.337)
1
(0.398 to 1)
0.350
(0.231 to 0.484)
Tissue factor (pg/ml) 0.422
(0.159 to 0.686)
0.00
(0.000 to 0.602)
0.885
(0.778 to 0.953)
1
(0.398 to 1)
0
(0.286 to 0.543)
Troponin level (ng/ml) 0.742
(0.453 to 1.000)
0.25
(0.006 to 0.806)
0.903
(0.801 to 0.964)
1
(0.398 to 1)
0.306
(0.196 to 0.437)
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Appendix 12 Results of the health economic
literature search
Databases
Date searched: 25 August 2016.
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations
Search terms
1. Pregnancy
2. Pulmonary Embolism/di [Diagnosis]
3. Pulmonary Embolism/ra [Radiography]
4. Pulmonary Embolism/ri [Radionuclide Imaging]
5. 2 or 3 or 4
6. 1 and 5
7. 6 and Scottish intercollegiate guidelines network (SIGN) economic search filters, available from
www.sign.ac.uk/search-filters.html
NHS Economic Evaluation Database
Search terms
1. Pulmonary embolism [exp]
Selection criteria
Table 52 shows the selection criteria for the literature search.
TABLE 52 The inclusion criteria used to assess the economic studies
Study characteristic Criteria
Design Cost–consequences analysis, cost-effectiveness analysis, cost–benefit analysis, cost–utility analysis,
cost studies
Population Patients aged ≥ 18 years
For pregnant or postpartum women
Mixed populations included, if the data can be extracted on pregnant or postpartum women
Intervention CDR to send the woman for scanning
Outcomes Cost-effectiveness, cost estimates, quality-of-life estimates
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Results of the literature review
Figure 51 shows the PRISMA flow diagram.
Records identified through database search after
removal of duplicates
(n = 184)
Records after duplicates removed
(n = 171)
Records screened
(n = 171)
Records excluded
(n = 122)
Full-text articles assessed for eligibility
(n = 49)
Not for a population of pregnant
and/or postpartum women, n = 34
Not an economic analysis, n = 11
Not in English, n = 2
Not a full paper, n = 1
Did not assess selective diagnostic
imaging, n = 1
FIGURE 51 The PRISMA flow diagram of the economic model results.
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Appendix 13 The optimal number of bootstraps
in the decision-analysis model
Bootstrapping procedure
Within each bootstrap, the model was run once in the PE cohort and once in the no PE cohort. A total of
157 patients in the PE cohort and 248 patients in the no PE cohort were sampled with replacement,
with both of these analyses drawing the patient data from the observed patient characteristics in the
DiPEP case-control study and/or the UKOSS cases.
Determining the number of model bootstraps to use
An estimator of unbiased costs and QALYs was obtained by running the model once for each patient with
PE and each patient with no PE. It should be noted that these estimators may not be completely unbiased
estimators of the population mean cost and QALY outcomes, as random numbers determine the scanning
methodology used (CTPA or VQ SPECT) and the risk of death from PE. As a result, there may be some
random noise in these estimators. From this analysis, it was determined that ‘scan all’ would be the
cost-effective strategy at £20,000 per QALY gained (Table 53).
TABLE 53 The results of the analysis used to determine the unbiased estimator of costs and QALYs for each
strategy in the population of women with suspected PE
Strategy Costs (£) QALYs
Incremental
ICER NMB (£)
iNMB vs. the
next most
cost-effective
optionCosts (£) QALYs
No scanning, treat none 1953 19.9164 – – Dominated by
scan all
396,374 –
Wells’s score (strict) 1673 20.0889 – – Dominated by
scan all
400,105 –
Delphi score (specific) 1729 20.0935 – – Dominated by
scan all
400,142 –
Geneva score 1673 20.1227 – – Dominated by
scan all
400,781 –
Wells’s score (permissive) 1644 20.1461 – – Dominated by
scan all
401,278 –
Delphi score (primary) 1579 20.2056 – – Dominated by
scan all
402,532 –
PERC score 1546 20.2265 – – Dominated by
scan all
402,983 –
No scanning, treat all 2404 20.2686 – – Dominated by
scan all
402,968 –
Delphi score (sensitive) 1409 20.3511 – – Dominated by
scan all
405,614 –
Scan all 1367 20.3705 –586 0.4541 Dominant 406,042 £428
NMB, net monetary benefit; iNMB, incremental net monetary benefit; –, no data.
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The model was then run deterministically with 200 bootstraps, with the results from each bootstrap
being recorded. The stability of the model results with respect to the number of bootstraps was assessed
using the iNMB of ‘scan all’ versus the most cost-effective treatment option out of the remaining nine
strategies at a MAICER of £20,000 per QALY gained. To determine the optimal number of bootstraps,
200 bootstraps were conducted, with the costs and QALYs of each strategy being recorded in each
bootstrap.
The average incremental net monetary benefit of ‘scan all’ versus the next most cost-effective strategy at
£20,000 per QALY with respect to the number of bootstraps conducted was calculated. The 95% CIs were
constructed around this measure using the normal approximation, percentile and bias-corrected methods.
The percentile t method to calculate the 95% CI was not used, as this method requires a further inner
loop in the bootstrapping procedure and, as such, was deemed to be too computationally expensive
to conduct.
Results
All methods showed that the 95% CI of the iNMB of ‘scan all’ versus the next most cost-effective option
at £20,000 per QALY gained does not cross zero when more than 100 bootstrap samples are taken
(Figure 52). Therefore, there is a < 2.5% probability that the true iNMB of ‘scan all’ versus the next most
cost-effective option is < 0 (i.e. another strategy is cost-effective at £20,000 per QALY gained). Therefore,
100 bootstraps per analysis was determined to be sufficient for running the model to determine the
cost-effectiveness of the different strategies.
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FIGURE 52 The average incremental net monetary benefit of ‘scan all’ compared with the next most cost-effective
option with respect to the number of bootstraps. iNMB, incremental net monetary benefit.
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Appendix 14 The clinical parameters used in the
decision-analysis model
T able 54 shows the clinical parameters used in the decision-analysis model.
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TABLE 54 The clinical parameters used in the decision-analysis model
Parameter Mean Distribution 95% CI Alpha/n Beta Source Notes
Initial PE
Probability that a woman had PE 6.5% Beta 3.9% to 9.7% 18 259 Suspected PE
data set
Probability of death from PE See Appendix 16 Expert elicitation See the beta regression results,
Appendix 16
Harms of withholding anticoagulation treatment
Odds ratio of fatal PE 12.517 Normal on log-odds 0.636 to 246.384 Barrit and
Jordan70
The distributions were
constrained on the grounds of
clinical plausibility, so that odds
ratios did not go below 1Odds ratio of a recurrent VTE or death 16.667 Normal on log-odds 1.818 to 152.770 Barrit and
Jordan70
Probability of recurrent VTEs
Recurrent PE with 3 months of
anticoagulation treatment
2.95% Beta 2.5% to 3.6% 103 3319 Carrier et al.66 See Table 4
Recurrent VTE with 3 months of
anticoagulation treatment
3.62% Beta 3.0% to 4.2% 123 3299 Carrier et al.66 See Table 4
Recurrent PE with 6 months of
anticoagulation treatment
4.83% Beta 3.6% to 5.3% 92 2001 Carrier et al.66 See Table 4
Recurrent VTE with 6 months of
anticoagulation treatment
2.17% Beta 4.0% to 5.9% 103 1990 Carrier et al.66 See Table 4
Case fatality rates for recurrent VTEs
3 months of anticoagulation treatment 29.97% Beta 22.3% to 38.4% 37 86 Carrier et al.66 See Table 4
6 months of anticoagulation treatment 31.19% Beta 13.2% to 28.6% 21 82 Carrier et al.66 See Table 4
Bleeding from anticoagulation
Major bleeding event with 3 months of
anticoagulation treatment
1.95% Beta 1.4% to 2.3% 62 3360 Carrier et al.66 See Table 6
Major bleeding event with 6 months of
anticoagulation treatment
2.36% Beta 1.5% to 2.8% 44 2049 Carrier et al.66 See Table 6
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Parameter Mean Distribution 95% CI Alpha/n Beta Source Notes
Fatal major bleeding event with 3 months of
anticoagulation treatment
0.25% Beta 0.1% to 0.4% 7 3415 Carrier et al.66 See Table 6. This was for the
whole population, not just
those who had a bleed
Fatal major bleeding event with 6 months of
anticoagulation treatment
0.62% Beta 0.3% to 1.0% 13 2080 Carrier et al.66
Split of non-fatal major bleeds
All gastrointestinal bleeds 35.9% Dirichlet 499 Ensor et al.67
All intracranial bleeds 18.1% Dirichlet 245 Ensor et al.67
All other bleeds 45.9% Dirichlet 622 Ensor et al.67
Probability that an intracranial bleed is fatal 39.03% Beta 26.5% to 38.2% 79 166 Ensor et al.67
Probability that a gastrointestinal bleed is
fatal
19.3% Beta 15.2% to 22.0% 92 407 Ensor et al.67
Probability that another major bleed is fatal 9.5% Beta 8.2% to 13.0% 65 557 Ensor et al.67
Standardised mortality ratios after an intracranial bleed
Year 1 4.50 Normal on the
log-scale
2.496 to 8.115 Fogelholm et al.75 The log-SE was assumed to be
20% of the log-mean
Years 2–6 2.20 Normal on the
log-scale
1.615 to 2.997 Fogelholm et al.75
Chronic thromboembolic pulmonary hypertension
Probability of CTEPH N/A Assumption Assumed to be the same as
the predicted risk of death
from PE
Probability that CTEPH is surgically treated 59.5% Beta 55.8% to 63.2% 404 275 Delcroix et al.72
Life expectancy after surgically treated
CTEPH – log-normal mean
5.081 Multivariate normal 3.956 to 6.206 See Appendix 17 See Appendix 17, for the
variance–covariance matrices
and SEs for these parameters
Life expectancy after surgically treated
CTEPH – log-normal SD
3.343 Multivariate normal 2.646 to 4.224 See Appendix 17
Life expectancy after medically treated
CTEPH – exponential rate
0.1168 Normal 0.0950 to 0.1436 See Appendix 17
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D
O
I:10.3310/hta22470
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.47
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
G
oodacre
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
163
TABLE 54 The clinical parameters used in the decision-analysis model (continued )
Parameter Mean Distribution 95% CI Alpha/n Beta Source Notes
Cancer risks to the woman
Lifetime attributable risk to the mother of
breast cancer as a result of scanning at the
age of 25 years
0.1% Fixed Hurwitz et al.98 No information on the
uncertainty in these parameters
was presented
Lifetime attributable risk to the mother of
breast cancer as a result of scanning at the
age of 55 years
0.02% Fixed Hurwitz et al.98
Lifetime attributable risk to the mother of
lung cancer as a result of scanning at the
age of 25 years
0.12% Fixed Hurwitz et al.98
Lifetime attributable risk to the mother of
lung cancer as a result of scanning at the
age of 55 years
0.09% Fixed Hurwitz et al.98
Reduction in the risk of breast cancer as a
result of using a VQ SPECT rather than a
CTPA scan
97% Fixed RCOG2
Cancer risks to the fetus
Risk of developing childhood cancer from a
CTPA scan
55/10,000,000 Fixed 10/10,000,000 to
100/10,000,000
Wall et al.61 Table on page 8 of Wall et al.61
The values are upper and
lower bounds rather than
95% CIs
N/A, not applicable; SD, standard deviation.
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Appendix 15 The results of the beta regressions
conducted on the data collected in the expert
elicitation exercise
Results of the base-case analysis
The results of the beta regression conducted in the primary statistical analysis population and fitted to the
average expert elicitation answers for all four experts are provided in Figure 53. The exponential of the
mean effect coefficients in beta regression is equivalent to the odds ratio. For the dispersion coefficients,
negative numbers indicate a higher mean variance and positive numbers indicate a lower mean variance.
Although the dispersion parameter is not clinically meaningful, it is incredibly useful for economic analyses
as it allows the variance term to change with the fitted value predicted by the mean effect parameters.
This allows the heterogeneity in each patient’s outcome to be incorporated into the economic model by
0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
Decreased risk No effect Increased risk
Heart rate (b.p.m.)
(a)
Blood pressure (mmHg)
Temperature (°C)
Respiratory rate (breaths per minute)
Peripheral oxygen saturation (%)
Post partum
Weeks pregnant (continuous)
– 1.800 – 1.400 – 1.000 – 0.600 – 0.200 0.200 0.600 1.000 1.400 1.800
Increased variance No effect Decreased variance
Heart rate (b.p.m.)
(b)
Blood pressure (mmHg)
Temperature (°C)
Respiratory rate (breaths per minute)
Peripheral oxygen saturation (%)
Post partum
Weeks pregnant (continuous)
FIGURE 53 The results of the beta regression fitted to the average probability, from all four experts, of 30-day
mortality for women with PE in the primary statistical analysis population with 95% CIs for (a) the effect of model
coefficients on the odds ratio; and (b) the effect of model coefficients on the dispersion parameter. b.p.m., beats
per minute.
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estimating the predicted mean effect and the predicted variance in the mean effect, and sampling the
modelled outcome from a beta distribution.
Part (a) of Figure 53 presents the results for the odds ratio for death within 30 days associated with the
fitted covariates. It was found that a unit increase in heart rate, systolic blood pressure, temperature or
respiratory rate led to a statistically significant increase in the 30-day mortality for a pregnant woman
with PE at the 5% level. Similarly, a higher peripheral oxygen saturation led to a statistically significant
decreased risk of 30-day mortality for a pregnant woman with PE at the 5% level. The duration of the
pregnancy in weeks (continuous) and whether or not the woman was post partum were not statistically
significant predictors.
Part (b) of Figure 53 presents the results for the impact on the included variables on the dispersion
parameter. It was found that an increased blood pressure and peripheral oxygen saturation predicted a
statistically significant decreased variance in the 30-day mortality for a pregnant woman with PE (holding
all other factors constant) at the 5% level. No other factors had a statistically significant effect.
Tables 55–63 provide the results of the beta regressions for all modelled scenario analyses. The
variance–covariance matrix for the base-case analysis is also provided in Table 56, as this was used to
parameterise the beta regression coefficients as multivariate normal within the model PSA.
TABLE 55 The beta regression coefficients for the base-case analysis (average of all experts’ answers, primary
statistical population)
Parameter Mean SE 95% CI
Logit (mean effect)
Intercept –3.815 1.68 –7.108 to –0.521
Heart rate (b.p.m.) 0.024 0.00 0.021 to 0.027
Blood pressure (mmHg) 0.000 0.00 –0.002 to 0.003
Temperature (°C) 0.100 0.04 0.018 to 0.183
Respiratory rate (breaths per minute) 0.053 0.01 0.042 to 0.063
Peripheral oxygen saturation (%) –0.077 0.01 –0.091 to –0.064
Post partum 0.107 0.08 –0.054 to 0.268
Weeks pregnant (continuous) –0.001 0.00 –0.002 to 0.001
Ln (dispersion)
Intercept –15.382 9.04 –33.100 to 2.335
Heart rate (b.p.m.) –0.004 0.01 –0.019 to 0.012
Blood pressure (mmHg) 0.034 0.01 0.019 to 0.050
Temperature (°C) 0.233 0.24 –0.228 to 0.694
Respiratory rate (breaths per minute) –0.007 0.03 –0.060 to 0.046
Peripheral oxygen saturation (%) 0.103 0.03 0.048 to 0.158
Post partum –0.756 0.42 –1.571 to 0.059
Weeks pregnant (continuous) –0.001 0.00 –0.011 to 0.008
b.p.m., beats per minute; Ln, natural logarithm.
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TABLE 56 The variance–covariance matrix associated with the base-case economic analysis
Parameter (Intercept) Heart.Rate SBP Temp Resp _ rate
Perip _
ox _ sat
Post _
partum
Weeks _
pregnant _
preg _
interact
(phi) _
(Intercept)
(phi) _
Heart.Rate (phi) _ SBP (phi) _ Temp
(phi) _
Resp _ rate
(phi) _
Perip _
ox _ sat
(phi) _ Post _
partum
(phi) _Weeks _
pregnant _
preg _ interact
(Intercept) 2.82x10+ 00 3.98x10 – 04 –1.49x10 – 04 –6.34x10 – 02 2.46x10 – 04 –5.23x10 – 03 1.08x10 – 02 1.20x10 – 05 –2.43x10+ 00 –3.57x10 – 04 8.23x10 – 05 5.55x10 – 02 3.59x10 – 04 4.13x10 – 03 –8.36x10 – 03 –1.57x10 – 05
Heart.Rate 3.98x10 – 04 2.23x10 – 06 1.19x10 – 07 –1.80x10 – 05 –2.26x10 – 06 6.40x10 – 07 1.48x10 – 05 4.37x10 – 08 –3.57x10 – 04 –2.10x10 – 06 –1.31x10 – 07 1.61x10 – 05 2.21x10 – 06 –4.34x10 – 07 –1.35x10 – 05 –4.05x10 – 08
SBP –1.49x10 – 04 1.19x10 – 07 1.72x10 – 06 –2.15x10 – 06 1.52x10 – 06 –4.08x10 – 07 –1.97x10 – 06 7.02x10 – 08 1.16x10 – 04 –1.33x10 – 07 –1.65x10 – 06 2.80x10 – 06 –1.61x10 – 06 4.47x10 – 07 1.54x10 – 06 –6.70x10 – 08
Temp –6.34x10 – 02 –1.80x10 – 05 –2.15x10 – 06 1.76x10 – 03 –3.39x10 – 05 1.39x10 – 05 –4.05x10 – 04 –6.74x10 – 07 5.54x10 – 02 1.61x10 – 05 3.97x10 – 06 –1.54x10 – 03 1.54x10 – 05 –1.12x10 – 05 3.19x10 – 04 9.41x10 – 07
Resp _ rate 2.46x10 – 04 –2.26x10 – 06 1.52x10 – 06 –3.39x10 – 05 3.00x10 – 05 5.01x10 – 06 –9.26x10 – 05 –5.83x10 – 07 3.10x10 – 04 2.22x10 – 06 –1.76x10 – 06 1.51x10 – 05 –2.57x10 – 05 –4.08x10 – 06 1.01x10 – 04 5.18x10 – 07
Perip _ ox _ sat –5.23x10 – 03 6.40x10 – 07 –4.08x10 – 07 1.39x10 – 05 5.01x10 – 06 4.77x10 – 05 1.67x10 – 05 –3.17x10 – 07 4.15x10 – 03 –4.50x10 – 07 3.73x10 – 07 –1.09x10 – 05 –4.86x10 – 06 –3.78x10 – 05 –1.22x10 – 05 2.43x10 – 07
Post _ partum 1.08x10 – 02 1.48x10 – 05 –1.97x10 – 06 –4.05x10 – 04 –9.26x10 – 05 1.67x10 – 05 6.75x10 – 03 4.27x10 – 05 –8.35x10 – 03 –1.36x10 – 05 1.29x10 – 06 3.40x10 – 04 9.86x10 – 05 –1.95x10 – 05 –6.48x10 – 03 –4.14x10 – 05
Weeks _
pregnant _
preg _ interact
1.20x10 – 05 4.37x10 – 08 7.02x10 – 08 –6.74x10 – 07 –5.83x10 – 07 –3.17x10 – 07 4.27x10 – 05 7.45x10 – 07 –1.92x10 – 05 –4.00x10 – 08 –6.25x10 – 08 1.14x10 – 06 4.88x10 – 07 2.04x10 – 07 –4.16x10 – 05 –7.16x10 – 07
(phi) _ (Intercept) –2.43x10+ 00 –3.57x10 – 04 1.16x10 – 04 5.54x10 – 02 3.10x10 – 04 4.15x10 – 03 –8.35x10 – 03 –1.92x10 – 05 8.17x10+ 01 5.64x10 – 03 –4.66x10 – 03 –2.00x10+ 00 –1.97x10 – 02 –8.07x10 – 02 3.52x10 – 01 –8.09x10 – 04
(phi) _ Heart.Rate –3.57x10 – 04 –2.10x10 – 06 –1.33x10 – 07 1.61x10 – 05 2.22x10 – 06 –4.50x10 – 07 –1.36x10 – 05 –4.00x10 – 08 5.64x10 – 03 6.24x10 – 05 –2.77x10 – 06 –3.28x10 – 04 –8.21x10 – 05 2.34x10 – 05 4.64x10 – 04 –1.50x10 – 06
(phi) _ SBP 8.23x10 – 05 –1.31x10 – 07 –1.65x10 – 06 3.97x10 – 06 –1.76x10 – 06 3.73x10 – 07 1.29x10 – 06 –6.25x10 – 08 –4.66x10 – 03 –2.77x10 – 06 6.29x10 – 05 –4.85x10 – 05 3.52x10 – 05 –1.42x10 – 05 –4.19x10 – 04 –5.82x10 – 07
(phi) _ Temp 5.55x10 – 02 1.61x10 – 05 2.80x10 – 06 –1.54x10 – 03 1.51x10 – 05 –1.09x10 – 05 3.40x10 – 04 1.14x10 – 06 –2.00x10+ 00 –3.28x10 – 04 –4.85x10 – 05 5.53x10 – 02 –1.00x10 – 04 5.22x10 – 05 –1.45x10 – 02 –8.72x10 – 06
(phi) _ Resp _ rate 3.59x10 – 04 2.21x10 – 06 –1.61x10 – 06 1.54x10 – 05 –2.57x10 – 05 –4.86x10 – 06 9.86x10 – 05 4.88x10 – 07 –1.97x10 – 02 –8.21x10 – 05 3.52x10 – 05 –1.00x10 – 04 7.38x10 – 04 1.43x10 – 04 –2.15x10 – 03 –6.76x10 – 06
(phi) _ Perip _
ox _ sat
4.13x10 – 03 –4.34x10 – 07 4.47x10 – 07 –1.12x10 – 05 –4.08x10 – 06 –3.78x10 – 05 –1.95x10 – 05 2.04x10 – 07 –8.07x10 – 02 2.34x10 – 05 –1.42x10 – 05 5.22x10 – 05 1.43x10 – 04 7.80x10 – 04 1.35x10 – 03 1.78x10 – 06
(phi) _ Post _
partum
–8.36x10 – 03 –1.35x10 – 05 1.54x10 – 06 3.19x10 – 04 1.01x10 – 04 –1.22x10 – 05 –6.48x10 – 03 –4.16x10 – 05 3.52x10 – 01 4.64x10 – 04 –4.19x10 – 04 –1.45x10 – 02 –2.15x10 – 03 1.35x10 – 03 1.73x10 – 01 1.32x10 – 03
(phi) _Weeks _
pregnant _
preg _ interact
–1.57x10 – 05 –4.05x10 – 08 –6.70x10 – 08 9.41x10 – 07 5.18x10 – 07 2.43x10 – 07 –4.14x10 – 05 –7.16x10 – 07 –8.09x10 – 04 –1.50x10 – 06 –5.82x10 – 07 –8.72x10 – 06 –6.76x10 – 06 1.78x10 – 06 1.32x10 – 03 2.28x10 – 05
SBP, systolic blood pressure.
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TABLE 57 The beta regression coefficients for the base-case analysis (average of all experts’ answers, secondary
statistical population)
Parameter Mean SE 95% CI
Logit (mean effect)
Intercept –4.35744 1.425821 –7.152 to –1.56288
Heart rate (b.p.m.) 0.024 0.00 0.020921 to 0.026877
Blood pressure (mmHg) –0.002 0.00 –0.00407 to 0.001067
Temperature (°C) 0.130 0.04 0.059289 to 0.200863
Respiratory rate (breaths per minute) 0.049 0.01 0.038068 to 0.059609
Peripheral oxygen saturation (%) –0.079 0.01 –0.09166 to –0.06675
Post partum 0.077 0.08 –0.07849 to 0.23275
Weeks pregnant (continuous) –0.002 0.00 –0.00327 to 4.78E – 05
Ln (dispersion)
Intercept –10.324 7.73 –25.4684 to 4.819999
Heart rate (b.p.m.) –0.001 0.01 –0.01518 to 0.013829
Blood pressure (mmHg) 0.024 0.01 0.009269 to 0.0384
Temperature (°C) 0.166 0.20 –0.22148 to 0.552588
Respiratory rate (breaths per minute) –0.022 0.03 –0.07306 to 0.02831
Peripheral oxygen saturation (%) 0.090 0.03 0.036247 to 0.144063
Post partum –0.808 0.39 –1.57152 to –0.04532
Weeks pregnant (continuous) –0.004 0.00 –0.01257 to 0.004924
b.p.m., beats per minute.
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TABLE 58 The beta regression coefficients for the base-case analysis (average of all experts’ answers, tertiary
statistical population)
Parameter Mean SE 95% CI
Logit (mean effect)
Intercept –3.81468 1.68042 –7.10825 to –0.52112
Heart rate (b.p.m.) 0.024 0.00 0.021198 to 0.027051
Blood pressure (mmHg) 0.000 0.00 –0.00217 to 0.002972
Temperature (°C) 0.100 0.04 0.018308 to 0.182639
Respiratory rate (breaths per minute) 0.053 0.01 0.041905 to 0.063361
Peripheral oxygen saturation (%) –0.077 0.01 –0.0908 to –0.06373
Post partum 0.107 0.08 –0.05427 to 0.267697
Weeks pregnant (continuous) –0.001 0.00 –0.00238 to 0.001002
Ln (dispersion)
Intercept –15.382 9.04 –33.0996 to 2.335226
Heart rate (b.p.m.) –0.004 0.01 –0.01909 to 0.011877
Blood pressure (mmHg) 0.034 0.01 0.018624 to 0.049721
Temperature (°C) 0.233 0.24 –0.22815 to 0.693645
Respiratory rate (breaths per minute) –0.007 0.03 –0.06021 to 0.046304
Peripheral oxygen saturation (%) 0.103 0.03 0.04805 to 0.157502
Post partum –0.756 0.42 –1.57078 to 0.058617
Weeks pregnant (continuous) –0.001 0.00 –0.01067 to 0.008039
b.p.m., beats per minute.
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TABLE 59 The beta regression coefficients for the base-case analysis (average of all experts’ answers, quaternary
statistical population)
Parameter Mean SE 95% CI
Logit (mean effect)
Intercept –3.59 1.677087 –6.87703 to –0.30297
Heart rate (b.p.m.) 0.024 0.00 0.021011 to 0.026792
Blood pressure (mmHg) 0.001 0.00 –0.00136 to 0.003529
Temperature (°C) 0.097 0.04 0.013497 to 0.180258
Respiratory rate (breaths per minute) 0.052 0.01 0.041777 to 0.063114
Peripheral oxygen saturation (%) –0.079 0.01 –0.09238 to –0.06563
Post partum 0.155 0.08 –0.00156 to 0.312137
Weeks pregnant (continuous) –0.001 0.00 –0.00219 to 0.001128
Ln (dispersion)
Intercept –14.672 9.08 –32.4684 to 3.123832
Heart rate (b.p.m.) –0.003 0.01 –0.01838 to 0.013273
Blood pressure (mmHg) 0.039 0.01 0.022945 to 0.054807
Temperature (°C) 0.192 0.24 –0.27241 to 0.6572
Respiratory rate (breaths per minute) –0.009 0.03 –0.06267 to 0.044416
Peripheral oxygen saturation (%) 0.104 0.03 0.049105 to 0.159394
Post partum –0.650 0.43 –1.48727 to 0.187474
Weeks pregnant (continuous) –0.001 0.00 –0.01052 to 0.008347
b.p.m., beats per minute.
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TABLE 60 The beta regression coefficients for the base-case analysis (expert one only, primary statistical population)
Parameter Mean SE 95% CI
Logit (mean effect)
Intercept –10.6046 3.027756 –16.5389 to –4.67033
Heart rate (b.p.m.) 0.034 0.00 0.02926 to 0.039054
Blood pressure (mmHg) 0.004 0.00 0.000921 to 0.007971
Temperature (°C) 0.273 0.07 0.126813 to 0.419116
Respiratory rate (breaths per minute) 0.081 0.01 0.070187 to 0.092472
Peripheral oxygen saturation (%) –0.093 0.01 –0.11333 to –0.07261
Post partum 0.186 0.14 –0.09588 to 0.467419
Weeks pregnant (continuous) –0.001 0.00 –0.00421 to 0.001827
Ln (dispersion)
Intercept 1.458 8.94 –16.0548 to 18.9707
Heart rate (b.p.m.) –0.056 0.01 –0.07094 to –0.04027
Blood pressure (mmHg) 0.036 0.01 0.020354 to 0.050788
Temperature (°C) –0.181 0.23 –0.63721 to 0.274615
Respiratory rate (breaths per minute) 0.065 0.03 0.012839 to 0.116601
Peripheral oxygen saturation (%) 0.112 0.03 0.059088 to 0.164267
Post partum –1.246 0.41 –2.0579 to –0.43364
Weeks pregnant (continuous) –0.001 0.00 –0.01 to 0.008805
b.p.m., beats per minute.
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TABLE 61 The beta regression coefficients for the base-case analysis (expert two only, primary statistical population)
Parameter Mean SE 95% CI
Logit (mean effect)
Intercept –5.32288 1.940926 –9.12702 to –1.51873
Heart rate (b.p.m.) 0.012 0.00 0.0093 to 0.014984
Blood pressure (mmHg) 0.001 0.00 –0.00048 to 0.003333
Temperature (°C) 0.176 0.05 0.079966 to 0.273029
Respiratory rate (breaths per minute) 0.047 0.01 0.036686 to 0.057529
Peripheral oxygen saturation (%) –0.080 0.01 –0.095 to –0.06561
Post partum 0.076 0.08 –0.08993 to 0.240977
Weeks pregnant (continuous) 0.000 0.00 –0.00191 to 0.001482
Ln (dispersion)
Intercept –4.394 8.98 –22.0034 to 13.21459
Heart rate (b.p.m.) –0.033 0.01 –0.04806 to –0.01708
Blood pressure (mmHg) 0.028 0.01 0.012448 to 0.043463
Temperature (°C) –0.006 0.23 –0.46311 to 0.451116
Respiratory rate (breaths per minute) –0.025 0.03 –0.07724 to 0.027719
Peripheral oxygen saturation (%) 0.119 0.03 0.064695 to 0.173743
Post partum –0.375 0.42 –1.19287 to 0.443607
Weeks pregnant (continuous) 0.007 0.00 –0.00207 to 0.016705
b.p.m., beats per minute.
APPENDIX 15
NIHR Journals Library www.journalslibrary.nihr.ac.uk
172
TABLE 62 The beta regression coefficients for the base-case analysis (expert three only, primary statistical population)
Parameter Mean SE 95% CI
Logit (mean effect)
Intercept 4.400131 0.963907 2.510908 to 6.289355
Heart rate (b.p.m.) 0.011 0.00 0.008667 to 0.013769
Blood pressure (mmHg) –0.001 0.00 –0.00436 to 0.001715
Temperature (°C) –0.049 0.03 –0.10065 to 0.003562
Respiratory rate (breaths per minute) 0.016 0.00 0.009221 to 0.023241
Peripheral oxygen saturation (%) –0.075 0.00 –0.07879 to –0.07122
Post partum –0.018 0.09 –0.1918 to 0.155907
Weeks pregnant (continuous) –0.001 0.00 –0.00238 to 0.001343
Ln (dispersion)
Intercept –7.329 9.00 –24.9632 to 10.30504
Heart rate (b.p.m.) 0.032 0.01 0.01627 to 0.04678
Blood pressure (mmHg) 0.010 0.01 –0.00567 to 0.025051
Temperature (°C) 0.311 0.23 –0.14807 to 0.769327
Respiratory rate (breaths per minute) 0.062 0.03 0.009499 to 0.11547
Peripheral oxygen saturation (%) –0.044 0.03 –0.09868 to 0.010815
Post partum –0.048 0.41 –0.85734 to 0.760827
Weeks pregnant (continuous) 0.004 0.00 –0.00518 to 0.013551
b.p.m., beats per minute.
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TABLE 63 The beta regression coefficients for the base-case analysis (expert four only, primary statistical population)
Parameter Mean SE 95% CI
Logit (mean effect)
Intercept 2.593387 2.010734 –1.34758 to 6.534354
Heart rate (b.p.m.) 0.023 0.00 0.018729 to 0.027486
Blood pressure (mmHg) –0.009 0.00 –0.01316 to –0.00442
Temperature (°C) 0.058 0.05 –0.03968 to 0.156479
Respiratory rate (breaths per minute) 0.015 0.01 0.000676 to 0.029638
Peripheral oxygen saturation (%) –0.097 0.01 –0.11525 to –0.07895
Post partum 0.337 0.10 0.137803 to 0.537004
Weeks pregnant (continuous) 0.000 0.00 –0.00226 to 0.002564
Ln (dispersion)
Intercept –10.013 8.96 –27.5773 to 7.552107
Heart rate (beats per minute) 0.016 0.01 0.000644 to 0.0314
Blood pressure (mmHg) –0.018 0.01 –0.03271 to –0.00234
Temperature (°C) 0.147 0.23 –0.31141 to 0.605584
Respiratory rate (breaths per minute) –0.068 0.03 –0.11987 to –0.01596
Peripheral oxygen saturation (%) 0.122 0.03 0.069916 to 0.174771
Post partum –0.235 0.42 –1.05028 to 0.581006
Weeks pregnant (continuous) –0.005 0.00 –0.01465 to 0.004101
b.p.m., beats per minute.
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Appendix 16 The survival curves fitted to the
Kaplan–Meier curves presented in Delcroix et al.72
F igure 54 indicates that the surgically treated group had a relatively smooth hazard function, whereas
there was a discontinuity in the hazard function for the medically treated group at around 3 years.
Figure 55 indicates that an exponential curve may be appropriate for the medically treated group, but not
for the surgically treated group. This is because the medically treated group approximated a straight line at
45 degrees, whereas the surgically treated group line did not.
Figure 56 indicates that the log-logistic curve may be appropriate for either of the groups, as the lines are
approximately straight.
Figure 57 indicates that the log-normal curve may be appropriate for either of the groups, as the lines are
approximately straight.
Figure 58 shows the estimated survivor functions for people whose CTEPH was surgically treated over a 20-year
horizon. Figure 59 shows the corresponding data for those people whose CTEPH was medically treated.
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FIGURE 54 The empirical hazard plot for the surgically and non-surgically treated CTEPH patients.
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FIGURE 56 The plot of the log-odds of survival vs. the log-time to assess the suitability of a log-logistic distribution.
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FIGURE 55 The plot of the log-cumulative hazard vs. the log-time to assess the suitability of the Weibull and
exponential parametric distributions.
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FIGURE 57 The plot of the inverse standard normal distribution vs. the log-time to assess the suitability of a
log-normal distribution.
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FIGURE 58 The fit of the parametric survival curves to the reconstructed Kaplan–Meier data for people with CTEPH
who were surgically treated.
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Table 64 shows the Akaike information criterion (AIC) and the BIC for each of the parametric survival
curves fitted to the reconstructed Kaplan–Meier data obtained from Delcroix et al.72 The curve with the
lowest BIC (and AIC) was considered to be the base-case survival curve used in the economic model. Each
of the other candidate curves was considered to be eligible for inclusion in the scenario analyses unless
there was very strong evidence against the curve compared with the best-fitting curve. This excluded the
generalised F and exponential curves for the surgically treated group and the generalised F and log-normal
for the medically treated group. The results of the fitted curves and the associated variance–covariance
0
0.0
0.2
0.4O
ve
ra
ll 
su
rv
iv
al 0.6
0.8
1.0
5 10 15 20
Time (years)
Generalised F
Generalised gamma
Gamma
Log-normal
Weibull
Exponential
Gompertz
Log-logistic
FIGURE 59 The fit of the parametric survival curves to the reconstructed Kaplan–Meier data for people with CTEPH
who were medically treated.
TABLE 64 The AIC and the BIC for each of the modelled survival curves
Parametric surviver curve
Surgically treated Medically treated
AIC BIC Evidence againsta AIC BIC Evidence againsta
Generalised F 433.0 449.0 Very strong 572.6 587.1 Very strong
Generalised gamma 431.0 443.0 Positive 570.6 581.4 Strong
Gamma 432.5 440.5 Positive 569.3 576.6 Positive
Log-normal 429.9 437.9 Base case 576.9 584.2 Very strong
Log-logistic 431.9 439.9 Positive 571.0 578.2 Strong
Gompertz 435.2 443.2 Positive 570.4 577.7 Positive
Weibull 432.3 440.3 Positive 569.5 576.7 Positive
Exponential 446.4 450.4 Very strong 568.5 572.2 Base case
a Evidence against is based on the recommendations of Kass et al.,99 which state that differences in BICs of 0–6 indicate
that there is positive evidence that the lowest BIC is the best fit, BICs of 6–10 indicate that there is strong evidence that
the lowest BIC is the best fit and BICs of > 10 indicate that there is decisive evidence that the lowest BIC is the best fit.
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matrices for the log-normal curve for the surgically treated CTEPH patients and the exponential curve for
the medically treated CTEPH patients are given in Tables 65–67.
The results of the other parametric curves are provided in Tables 68–78.
TABLE 68 The result of the fitted generalised gamma curve in the surgically treated population
Parameter Mean SE 95% CI
Mu 4.57 1.41 1.80 to 7.33
Sigma 5.01 1.44 2.85 to 8.82
Q –1.21 1.44 –4.03 to 1.60
TABLE 65 The result of the fitted log-normal curve in the surgically treated population
Parameter Mean SE 95% CI
Mean log 5.081 0.574 3.956 to 6.206
SD log 3.343 0.399 2.646 to 4.224
SD, standard deviation.
TABLE 66 The variance covariance matrix for the fitted log-normal curve in the surgically treated population
Parameter Mean log SD log
Mean log 0.01770766 –0.05571957
SD log –0.05571957 0.23093510
SD, standard deviation.
TABLE 67 The results of the fitted exponential curve in the medically treated population
Parameter Mean SE 95% CI
Lambda 0.1168 0.0123 0.0950 to 0.1436
TABLE 69 The result of the fitted gamma curve in the surgically treated population
Parameter Mean SE 95% CI
Shape 0.59128 0.08370 0.4480 to 0.78034
Rate 0.00709 0.00417 0.00224 to 0.02245
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TABLE 70 The result of the fitted log-logistic curve in the surgically treated population
Parameter Mean SE 95% CI
Shape 0.6281 0.0836 0.4839 to 0.8152
Scale 76.5809 36.8015 29.8586 to 196.4134
TABLE 71 The result of the fitted Gompertz curve in the surgically treated population
Parameter Mean SE 95% CI
Shape –0.4812 0.1385 –0.7527 to –0.2097
Rate 0.0805 0.0183 0.0515 to 0.1257
TABLE 72 The result of the fitted Weibull curve in the surgically treated population
Parameter Mean SE 95% CI
Shape 0.6073 0.0823 0.4655 to 0.7921
Scale 96.1513 48.4245 35.83 to 258.0
TABLE 73 The result of the fitted generalised gamma curve in the medically treated population
Parameter Mean SE 95% CI
Mu 2.34 0.677 1.02 to 3.67
Sigma 0.435 1.37 9.23e – 04 to 2.05e+ 02a
Q 2.80 8.80 –14.4 to 20.0
a Scientific notation is used to denote the number(s), as these are either very large or very close to zero.
TABLE 74 The result of the fitted gamma curve in the medically treated population
Parameter Mean SE 95% CI
Shape 0.8829 0.1023 (0.7036 to 1.1079)
Rate 0.0926 0.0232 (0.0567 to 0.1514)
TABLE 75 The result of the fitted log-logistic curve in the medically treated population
Parameter Mean SE 95% CI
Shape 0.9905 0.0948 0.8212 to 1.1948
Scale 7.1227 1.1133 5.2433 to 9.6758
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TABLE 78 The results of the fitted exponential curve in the medically treated population
Parameter Mean SE 95% CI
Lambda 0.1168 0.0123 0.0950 to 0.1436
TABLE 77 The result of the fitted Weibull curve in the medically treated population
Parameter Mean SE 95% CI
Shape 0.9053 0.0892 0.7463 to 1.0982
Scale 9.4806 1.4976 6.9563 to 12.9210
TABLE 76 The result of the fitted Gompertz curve in the medically treated population
Parameter Mean SE 95% CI
Shape –0.0289 0.0970 –0.2190 to 0.1613
Rate 0.1227 0.0238 0.0838 to 0.1794
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Appendix 17 The utility parameters used in the
decision-analysis model
Table 79 shows the utility parameters used in the decision-analysis model.
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TABLE 79 The utility parameters used in the decision-analysis model
Parameter Mean SE
Distribution
used 95% CI/IQR Alpha Beta Source Notes
Baseline utility
Constant 0.95086 Multivariate t,
df = 26678 (n – 1)
Ara and Brazier76 Variance-covariance matrix is available from
http://eprints.whiterose.ac.uk/10880/1/HEDS
DP 09-12.pdf (accessed 24 July 2018)Male 0.02121
Age –0.00026
Age2 –0.00003
Utility multiplier for a person with PE
No PE or DVT or bleeding 0.96 0.011 Beta 0.82 1 10.658 0.953 Locadia et al.77 SE was calculated from an IQRa
PE 0.63 0.033 Beta 0.36 0.86 77.478 0.660
Duration of the multiplier for PE 4 weeks Fixed Clinical input
Utility multiplier for a person with DVT
Utility of a person with DVT 0.84 0.033 Beta 0.64 0.98 219.537 41.817 Locadia et al.77 SE was calculated from an IQRa
Duration of the multiplier for
DVT
4 weeks Fixed Clinical input
Utility multiplier for a person with a gastrointestinal bleeding event
Utility for a person with a
gastrointestinal bleed
0.65 0.025 Beta 0.49 0.86 130.898 0.674 Locadia et al.77 SE was calculated from an IQRa
Duration of the multiplier for a
gastrointestinal bleed
4 weeks Fixed Clinical input
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Parameter Mean SE
Distribution
used 95% CI/IQR Alpha Beta Source Notes
Utility multiplier for a person with CTEPH
Utility of a person without
CTEPH
0.795 0.021 Beta 0.771 0.831 183.2 155.4 Ara and Brazier78 On the basis of clinical input, it was
assumed that other heart problems would
be a similar condition to CTEPH in terms
of quality of lifeUtility of a person with CTEPH 0.672 0.012 Beta 0.649 0.694 524.7 0.69
Duration of the multiplier for
CTEPH
Permanent Clinical input
Utility multiplier for a person with an intracranial haemorrhage
Utility of a person without an
intracranial haemorrhage
0.828 0.012 Beta 0.804 0.851 785.607 163.194 Ara and Brazier78 The effects of an intracranial haemorrhage
were assumed to be equivalent to those
of a stroke
Utility of a person with an
intracranial haemorrhage
0.541 0.027 Beta 0.488 0.593 183.177 155.413
Duration of the multiplier for an
intracranial haemorrhage
Permanent Clinical input
Utility multiplier for a person with cancer
Utility of a person without cancer 0.697 0.020 Beta 0.657 0.736 352.718 153.333 Ara and Brazier78
Utility of a person with cancer 0.795 0.021 Beta 0.754 0.836 295.290 76.144
Duration of the multiplier for
cancer
Permanent Clinical input
df, degrees of freedom; IQR, interquartile range.
a The SE was calculated from the interquartile ranges using the following two formulae:
l standard deviation = (interquartile range high − interquartile rangelow)/(2 × 0.6475).
l SE = standard deviation/(n− 1)0.5.
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Appendix 18 The discounted costs and
quality-adjusted life-year losses associated with
radiation-induced cancers in the mother by the age
at which they were scanned
T able 80 shows the discounted costs and QALY losses associated with radiation-induced cancers, when
they present over a lifetime, in the mother by the age of the mother when she was scanned. Table 81
shows the discounted costs and QALY losses associated with radiation-induced cancers, when they present
within 15 years, in the mother by the age at which they were scanned. All childhood cancers were assumed
to present within 12 years of the initial scan. The associated QALY loss per surviving fetus was –0.00004
QALYs per scan and the associated cost was £0.57 per scan.
TABLE 80 The discounted costs and QALY losses associated with radiation-induced cancers, when they present over
a lifetime, in the mother by the age at which they were scanned
Age (years)
at which the
mother was
scanned
Cancer
Breast Lung
QALYs Cost (£) QALYs Cost (£)
CT scan VQ SPECT CT scan VQ SPECT CT scan VQ SPECT CT scan VQ SPECT
16 –0.00140 –0.00004 4.56 0.14 –0.00141 –0.00141 3.08 3.08
17 –0.00142 –0.00004 4.62 0.14 –0.00144 –0.00144 3.16 3.16
18 –0.00143 –0.00004 4.67 0.14 –0.00148 –0.00148 3.24 3.24
19 –0.00145 –0.00004 4.72 0.14 –0.00152 –0.00152 3.33 3.33
20 –0.00146 –0.00004 4.76 0.14 –0.00156 –0.00156 3.41 3.41
21 –0.00147 –0.00004 4.81 0.14 –0.00160 –0.00160 3.50 3.50
22 –0.00148 –0.00004 4.85 0.15 –0.00164 –0.00164 3.59 3.59
23 –0.00150 –0.00004 4.88 0.15 –0.00168 –0.00168 3.68 3.68
24 –0.00151 –0.00005 4.92 0.15 –0.00172 –0.00172 3.78 3.78
25 –0.00151 –0.00005 4.95 0.15 –0.00177 –0.00177 3.87 3.87
26 –0.00152 –0.00005 4.97 0.15 –0.00181 –0.00181 3.97 3.97
27 –0.00152 –0.00005 4.98 0.15 –0.00186 –0.00186 4.07 4.07
28 –0.00152 –0.00005 4.99 0.15 –0.00190 –0.00190 4.17 4.17
29 –0.00152 –0.00005 5.00 0.15 –0.00195 –0.00195 4.28 4.28
30 –0.00152 –0.00005 5.00 0.15 –0.00200 –0.00200 4.39 4.39
31 –0.00150 –0.00005 4.98 0.15 –0.00204 –0.00204 4.49 4.49
32 –0.00149 –0.00004 4.96 0.15 –0.00209 –0.00209 4.61 4.61
33 –0.00148 –0.00004 4.94 0.15 –0.00214 –0.00214 4.72 4.72
34 –0.00146 –0.00004 4.90 0.15 –0.00219 –0.00219 4.83 4.83
35 –0.00144 –0.00004 4.87 0.15 –0.00225 –0.00225 4.95 4.95
continued
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TABLE 80 The discounted costs and QALY losses associated with radiation-induced cancers, when they present over
a lifetime, in the mother by the age at which they were scanned (continued )
Age (years)
at which the
mother was
scanned
Cancer
Breast Lung
QALYs Cost (£) QALYs Cost (£)
CT scan VQ SPECT CT scan VQ SPECT CT scan VQ SPECT CT scan VQ SPECT
36 –0.00141 –0.00004 4.80 0.14 –0.00230 –0.00230 5.07 5.07
37 –0.00138 –0.00004 4.73 0.14 –0.00235 –0.00235 5.19 5.19
38 –0.00135 –0.00004 4.66 0.14 –0.00240 –0.00240 5.31 5.31
39 –0.00132 –0.00004 4.58 0.14 –0.00245 –0.00245 5.44 5.44
40 –0.00129 –0.00004 4.49 0.13 –0.00251 –0.00251 5.57 5.57
41 –0.00123 –0.00004 4.36 0.13 –0.00256 –0.00256 5.69 5.69
42 –0.00118 –0.00004 4.23 0.13 –0.00260 –0.00260 5.81 5.81
43 –0.00112 –0.00003 4.09 0.12 –0.00265 –0.00265 5.94 5.94
44 –0.00107 –0.00003 3.94 0.12 –0.00270 –0.00270 6.07 6.07
45 –0.00101 –0.00003 3.79 0.11 –0.00276 –0.00276 6.20 6.20
46 –0.00094 –0.00003 3.59 0.11 –0.00279 –0.00279 6.32 6.32
47 –0.00087 –0.00003 3.39 0.10 –0.00283 –0.00283 6.45 6.45
48 –0.00079 –0.00002 3.18 0.10 –0.00287 –0.00287 6.57 6.57
49 –0.00072 –0.00002 2.96 0.09 –0.00291 –0.00291 6.70 6.70
50 –0.00065 –0.00002 2.74 0.08 –0.00296 –0.00296 6.83 6.83
TABLE 81 The discounted costs and QALY losses associated with radiation-induced cancers, when they present
within 15 years, in the mother by the age at which they were scanned
Age (years)
at which the
mother was
scanned
Cancer
Breast Lung
QALYs Cost (£) QALYs Cost (£)
CT scan VQ SPECT CT scan VQ SPECT CT scan VQ SPECT CT scan VQ SPECT
16 –0.00771 –0.00023 14.99 0.45 –0.01498 –0.01498 14.79 14.79
17 –0.00749 –0.00022 14.70 0.44 –0.01485 –0.01485 14.67 14.67
18 –0.00732 –0.00022 14.50 0.43 –0.01473 –0.01473 14.55 14.55
19 –0.00718 –0.00022 14.32 0.43 –0.01460 –0.01460 14.42 14.42
20 –0.00705 –0.00021 14.17 0.43 –0.01447 –0.01447 14.30 14.30
21 –0.00674 –0.00020 13.74 0.41 –0.01435 –0.01435 14.18 14.18
22 –0.00651 –0.00020 13.43 0.40 –0.01422 –0.01422 14.05 14.05
23 –0.00632 –0.00019 13.19 0.40 –0.01410 –0.01410 13.93 13.93
24 –0.00616 –0.00018 12.97 0.39 –0.01397 –0.01397 13.80 13.80
25 –0.00601 –0.00018 12.77 0.38 –0.01385 –0.01385 13.68 13.68
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TABLE 81 The discounted costs and QALY losses associated with radiation-induced cancers, when they present
within 15 years, in the mother by the age at which they were scanned (continued )
Age (years)
at which the
mother was
scanned
Cancer
Breast Lung
QALYs Cost (£) QALYs Cost (£)
CT scan VQ SPECT CT scan VQ SPECT CT scan VQ SPECT CT scan VQ SPECT
26 –0.00567 –0.00017 12.27 0.37 –0.01372 –0.01372 13.56 13.56
27 –0.00541 –0.00016 11.89 0.36 –0.01360 –0.01360 13.43 13.43
28 –0.00519 –0.00016 11.58 0.35 –0.01347 –0.01347 13.31 13.31
29 –0.00500 –0.00015 11.30 0.34 –0.01335 –0.01335 13.19 13.19
30 –0.00483 –0.00015 11.05 0.33 –0.01322 –0.01322 13.06 13.06
31 –0.00454 –0.00014 10.59 0.32 –0.01310 –0.01310 12.94 12.94
32 –0.00430 –0.00013 10.22 0.31 –0.01297 –0.01297 12.81 12.81
33 –0.00410 –0.00012 9.89 0.30 –0.01285 –0.01285 12.69 12.69
34 –0.00391 –0.00012 9.59 0.29 –0.01272 –0.01272 12.57 12.57
35 –0.00374 –0.00011 9.31 0.28 –0.01260 –0.01260 12.44 12.44
36 –0.00354 –0.00011 8.97 0.27 –0.01247 –0.01247 12.32 12.32
37 –0.00336 –0.00010 8.65 0.26 –0.01235 –0.01235 12.20 12.20
38 –0.00318 –0.00010 8.34 0.25 –0.01222 –0.01222 12.07 12.07
39 –0.00302 –0.00009 8.03 0.24 –0.01210 –0.01210 11.95 11.95
40 –0.00286 –0.00009 7.74 0.23 –0.01197 –0.01197 11.83 11.83
41 –0.00269 –0.00008 7.40 0.22 –0.01185 –0.01185 11.70 11.70
42 –0.00252 –0.00008 7.07 0.21 –0.01172 –0.01172 11.58 11.58
43 –0.00236 –0.00007 6.74 0.20 –0.01160 –0.01160 11.45 11.45
44 –0.00220 –0.00007 6.41 0.19 –0.01147 –0.01147 11.33 11.33
45 –0.00205 –0.00006 6.07 0.18 –0.01135 –0.01135 11.21 11.21
46 –0.00186 –0.00006 5.66 0.17 –0.01122 –0.01122 11.08 11.08
47 –0.00168 –0.00005 5.26 0.16 –0.01109 –0.01109 10.96 10.96
48 –0.00151 –0.00005 4.86 0.15 –0.01097 –0.01097 10.84 10.84
49 –0.00135 –0.00004 4.46 0.13 –0.01084 –0.01084 10.71 10.71
50 –0.00119 –0.00004 4.06 0.12 –0.01072 –0.01072 10.59 10.59
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Appendix 19 The cost parameters used in the
decision-analysis model
Table 82 shows the cost parameters used in the decision-analysis model.
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TABLE 82 The cost parameters used in the decision-analysis model
Parameter Mean SE
Distribution
used 95% CI Alpha/n Beta Source Notes
Decision rule costs
Cost per hour of registrar time £42 – Fixed – – – PSSRU (2015–16)87 –
Time taken to apply the DR 5 minutes – Fixed – – – Clinical input –
Cost of a decision rule £3.50 – Fixed – – – – –
Scanning costs
CTPA scan £130 4.9 Normal £121 to £140 – – NHS Reference Costs
2015 to 201690
Direct access imaging CT scan of
one area, post-contrast only
VQ scan (2009–10 prices) £253 – Gamma £142 to £395 15.15 16.69 NICE guideline
CG14433
p. 543
Cost of modelled events
Cost of treating PE £4778 224.7 Normal £4337 to £5218 – – NHS Reference Costs
2015 to 1690
Currency codes DZ09J–DZ09Ka
Cost of treating a DVT £2612 68.6 Normal £2478 to £2747 – – NHS Reference Costs
2015 to 1690
Currency codes YQ51A–YQ51Ea
Cost of treating a gastrointestinal bleed £2201 65.0 Normal £2074 to £2328 – – NHS Reference Costs
2015 to 1690
Currency codes FZ38G–FZ38Pa
Cost of treating an intracranial
haemorrhage – year 1
£11,707 2341 Gamma £7576 to £16,722 25.00 468.27 Luengo-Fernandez
et al.91
Assumed SE= 20% of the mean
Cost of treating an intracranial
haemorrhage – ongoing
£1686 337 Gamma £1091 to £2409 25.00 67.45 Luengo-Fernandez
et al.91
Assumed SE= 20% of the mean
Cost of CTEPH surgery £6558 – Normal £3987 to £9129 – – NICE100 –
Ongoing quarterly cost of CTEPH £15,968 – Normal £9709 to £22,227 – – NICE100 –
Lifetime cost of breast cancer £13,241 591 Normal £12,108 to £14,426 – – Hall et al.92 –
Lifetime cost of childhood cancer £126,273 5103 Normal £116,271 to £136,277 – – Van Listenburg et al.94 –
Lifetime cost of stage 1 NSCLC £16,408 3282 Normal £9976 to £22,840 – – Incisive Health93 Assumed SE= 20% of the mean
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Parameter Mean SE
Distribution
used 95% CI Alpha/n Beta Source Notes
Lifetime cost of stage 2 NSCLC £19,113 3823 Normal £11,621 to £26,606 – – Incisive Health93 Assumed SE= 20% of the mean
Lifetime cost of stage 3 NSCLC £21,454 4291 Normal £13,044 to £29,863 – – Incisive Health93 Assumed SE= 20% of the mean
Lifetime cost of stage 4 NSCLC £13,371 2674 Normal £8192 to £18,612 Incisive Health93 Assumed SE= 20% of the mean
Proportion of women diagnosed with
stage 1 NSCLC
16.9% – Dirichlet – 2557 – Cancer Research
UK101
The stage distribution was
multiplied by the number of
women diagnosed with NSCLC
in England in 2013Proportion of women diagnosed with
stage 2 NSCLC
8.2% – – – 1245 – Cancer Research
UK101
Proportion of women diagnosed with
stage 3 NSCLC
21.5% – – – 3264 – Cancer Research
UK101
–
Proportion of women diagnosed with
stage 4 NSCLC
53.4% – – – 8092 – Cancer Research
UK101
–
Cost of anticoagulation
Proportion on enoxaparin
(Clexane®, Sanofi)
51.2% – Fixed – – – DiPEP cohort –
Proportion on dalteparin
(Fragmin®, Pfizer)
31.4% – Fixed – – – DiPEP cohort –
Proportion on tinzaparin
(Innohep®, Leo Pharma)
17.4% – Fixed – – – DiPEP cohort –
Dose-dependent drug cost Varies – Fixed – – – BNF102 It was assumed that the woman
would receive the dose of the
drug closest to her calculated
therapeutic dose
NSCLC, non-small cell lung cancer; –, no data.
a Non-elective inpatient stays and associated excess bed-days.
D
O
I:10.3310/hta22470
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.47
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
G
oodacre
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
193

Appendix 20 The stability of the model results
with respect to the number of probabilistic sensitivity
analysis runs
F igures 60 and 61 show the stability of the average QALYs and that of the average costs, respectively,
with regard to the number of PSA runs.
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FIGURE 60 The stability of the average QALYs for each strategy with regard to the number of PSA runs. NSTA, no scanning, treat all; NSTN, no scanning, treat none.
1000
0 100 200 300 400 500 600 700 800 900 1000
1100
1200
1300
1400
1500
1600
1700
1800
1900
Number of PSA runs
C
o
s
t
 
(
£
)
 
o
f
 
e
a
c
h
 
s
t
r
a
t
e
g
y Scan all
Delphi primary score
Delphi sensitivity
Delphi specificity
Wells’s score (permissive)
Wells’s score (strict)
PERC score
Geneva score
NSTA
NSTN
Strategy
FIGURE 61 The stability of the average costs for each strategy with regard to the number of PSA runs.
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Appendix 21 Detailed results of the decision-
analysis modelling
F igure 62 shows the full cost-effectiveness acceptability curve associated with the base-case PSA.
Tables 83–113 show the detailed results of the scenario analysis conducted in the decision-analysis
modelling.
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FIGURE 62 The cost-effectiveness acceptability curve for the base-case decision-analysis modelling. NSTA, no scanning, treat all; NSTN, no scanning, treat none.
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TABLE 83 The results of imaging tests lead to an imperfect diagnosis of PE
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 57 1 0 2751 2824 19.8537 – – Dominated
Delphi specificity score 4 48 92 154 7 1 2047 2352 20.0370 – – Dominated
Wells’s score (strict) 4 27 84 155 5 1 2013 2288 20.0396 – – Dominated
Geneva score 4 81 124 172 9 2 1881 2273 20.0721 – – Dominated
Wells’s score (permissive) 4 86 129 184 10 3 1791 2207 20.0953 – – Dominated
Delphi primary score 4 94 145 216 11 3 1547 2020 20.1606 – – Dominated
PERC score 4 107 157 230 12 3 1435 1949 20.1851 – – Dominated
No scan, treat all 0 0 1258 322 141 0 641 2363 20.2948 – – Dominated
Delphi sensitivity score 4 215 246 303 21 7 852 1647 20.3225 – – Dominated
Scan all 0 222 258 312 22 7 772 1593 20.3400 –1231 0.4863 Dominant
DR, decision rule; –, no data.
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TABLE 84 The risk of CTEPH is obtained from Klok et al.69
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 20 75 2 0 551 648 19.9253 – – –
Wells’s score (strict) 4 27 75 167 4 1 371 650 20.1077 1 0.1824 £7
Delphi specificity score 4 49 72 167 4 1 380 677 20.1088 – – Extendedly dominated
Geneva score 4 83 86 184 5 3 342 705 20.1415 – – Dominated
Wells’s score (permissive) 4 86 90 196 5 3 319 703 20.1654 – – Extendedly dominated
Delphi primary score 4 95 105 229 6 3 263 704 20.2289 – – Extendedly dominated
PERC score 4 108 109 243 7 3 235 709 20.2541 60 0.1464 £408
No, scan treat all 0 0 1254 323 122 0 75 1775 20.3221 – – Dominated
Delphi sensitivity score 4 215 143 314 9 7 96 787 20.3880 – – Extendedly dominated
Scan all 0 223 150 323 9 7 75 788 20.4061 78 0.1520 £516
DR, decision rule; –, no incremental comparison of costs or QALY, was conducted by this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 85 Chronic thromboembolic pulmonary hypertension is not modifiable by anticoagulation
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 21 76 2 0 425 524 19.9315 – – –
Wells’s score (strict) 4 27 74 166 4 1 484 760 20.1008 236 0.1693 £1392
Delphi specificity score 4 48 72 167 4 1 500 797 20.1058 – – Extendedly dominated
Geneva score 4 83 85 182 5 3 498 859 20.1339 – – Extendedly dominated
Wells’s score (permissive) 4 88 90 195 5 3 508 892 20.1578 – – Extendedly dominated
Delphi primary score 4 94 104 228 6 3 538 976 20.2179 – – Extendedly dominated
PERC score 4 109 109 243 7 3 546 1020 20.2436 260 0.1428 £1822
No scan, treat all 0 0 1261 323 122 0 583 2289 20.3053 – – Dominated
Delphi sensitivity score 4 215 143 313 9 7 580 1270 20.3711 – – Extendedly dominated
Scan all 0 223 150 323 9 7 583 1295 20.3895 275 0.1459 £1888
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
D
O
I:10.3310/hta22470
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.47
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
G
oodacre
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
201
TABLE 86 One hundred per cent of patients with CTEPH were surgically treated
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2756 2829 19.8978 – – Dominated
Delphi specificity score 4 49 70 155 4 1 2002 2284 20.0810 – – Dominated
Wells’s score (strict) 4 27 73 156 4 1 1969 2234 20.0816 – – Dominated
Geneva score 4 82 84 173 5 3 1831 2181 20.1149 – – Dominated
Wells’s score (permissive) 4 87 88 186 5 3 1740 2112 20.1377 – – Dominated
Delphi primary score 4 95 103 221 6 3 1475 1908 20.2027 – – Dominated
PERC score 4 109 108 236 6 3 1358 1825 20.2272 – – Dominated
No scan, treat all 0 0 1264 322 122 0 667 2375 20.2961 – – Dominated
Delphi sensitivity score 4 214 143 312 9 7 757 1445 20.3620 – – Dominated
Scan all 0 222 150 322 9 7 667 1378 20.3806 –1451 0.4828 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 87 A Weibull curve is used to estimate the life expectancy of women with a surgically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 57 1 0 2752 2825 19.8553 – – Dominated
Delphi specificity score 4 49 70 155 4 2 1988 2270 20.0556 – – Dominated
Wells’s score (strict) 4 27 72 156 4 1 1955 2219 20.0577 – – Dominated
Geneva score 4 82 83 173 5 3 1822 2170 20.0926 – – Dominated
Wells’s score (permissive) 4 87 89 188 5 3 1708 2083 20.1225 – – Dominated
Delphi primary score 4 95 103 222 6 3 1450 1883 20.1912 – – Dominated
PERC score 4 108 108 236 6 3 1342 1807 20.2156 – – Dominated
No scan, treat all 0 0 1262 322 122 0 638 2345 20.3008 – – Dominated
Delphi sensitivity score 4 214 144 312 9 7 725 1414 20.3654 – – Dominated
Scan all 0 222 150 322 9 7 638 1349 20.3852 –1476 0.5299 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 88 A Gompertz curve is used to estimate the life expectancy of women with a surgically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 57 1 0 2749 2822 19.8706 – – Dominated by scan all
Delphi specificity 4 49 71 157 4 2 1970 2258 20.0717 – – Dominated by scan all
Wells’s score (strict) 4 27 74 158 4 1 1941 2209 20.0718 – – Dominated by scan all
Geneva score 4 82 84 174 5 3 1812 2163 20.1051 – – Dominated by scan all
Wells’s score (permissive) 4 87 89 188 5 3 1709 2085 20.1320 – – Dominated by scan all
Delphi primary score 4 94 104 222 6 3 1454 1887 20.1985 – – Dominated by scan all
PERC score 4 107 108 237 6 3 1338 1805 20.2246 – – Dominated by scan all
No scan, treat all 0 0 1262 322 122 0 647 2353 20.3031 – – Dominated by scan all
Delphi sensitivity score 4 215 143 312 9 7 737 1426 20.3678 – – Dominated by scan all
Scan all 0 223 150 322 9 7 647 1359 20.3878 –1463 0.5172 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 89 A log-logistic curve is used to estimate the life expectancy of women with surgically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2755 2828 19.7306 – – Dominated by scan all
Delphi specificity score 4 49 70 155 4 2 1968 2251 19.9622 – – Dominated by scan all
Wells’s score (strict) 4 27 74 157 4 1 1929 2196 19.9671 – – Dominated by scan all
Geneva score 4 81 84 174 5 3 1794 2143 20.0074 – – Dominated by scan all
Wells’s score (permissive) 4 87 89 187 5 3 1691 2065 20.0376 – – Dominated by scan all
Delphi primary score 4 94 104 222 6 3 1418 1851 20.1186 – – Dominated by scan all
PERC score 4 108 109 238 7 3 1295 1763 20.1503 – – Dominated by scan all
No scan, treat all 0 0 1257 322 122 0 592 2293 20.2606 – – Dominated by scan all
Delphi sensitivity score 4 214 144 313 9 7 679 1369 20.3218 – – Dominated by scan all
Scan all 0 222 151 322 9 7 592 1303 20.3446 –1525 0.6140 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 90 A gamma curve is used to estimate the life expectancy of women with surgically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2753 2826 19.8469 – – Dominated by scan all
Delphi specificity score 4 48 70 155 4 2 1992 2274 20.0489 – – Dominated by scan all
Wells’s score (strict) 4 27 73 156 4 1 1958 2223 20.0502 – – Dominated by scan all
Geneva score 4 81 84 174 5 3 1814 2165 20.0877 – – Dominated by scan all
Wells’s score (permissive) 4 86 89 188 5 4 1712 2088 20.1150 – – Dominated by scan all
Delphi primary score 4 93 104 221 6 4 1460 1892 20.1826 – – Dominated by scan all
PERC score 4 109 109 238 7 5 1333 1803 20.2119 – – Dominated by scan all
No scan, treat all 0 0 1259 322 122 0 643 2347 20.2952 – – Dominated by scan all
Delphi sensitivity score 4 214 144 312 9 9 731 1423 20.3585 – – Dominated by scan all
Scan all 0 222 151 322 9 10 643 1358 20.3783 –£1468 0.5314 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 91 A generalised gamma curve is used to estimate the life expectancy of women with surgically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 57 1 0 2750 2823 19.8659 – – Dominated by scan all
Wells’s score (strict) 4 27 73 156 4 1 1959 2224 20.0644 – – Dominated by scan all
Delphi specificity score 4 49 71 157 4 2 1972 2258 20.0680 – – Dominated by scan all
Geneva score 4 82 84 173 5 3 1820 2170 20.1001 – – Dominated by scan all
Wells’s score (permissive) 4 87 89 186 5 3 1722 2095 20.1262 – – Dominated by scan all
Delphi primary score 4 95 104 222 6 3 1453 1887 20.1967 – – Dominated by scan all
PERC score 4 109 108 237 6 3 1337 1805 20.2226 – – Dominated by scan all
No scan, treat all 0 0 1258 322 122 0 643 2346 20.3034 – – Dominated by scan all
Delphi sensitivity score 4 214 144 312 9 7 731 1420 20.3682 – – Dominated by scan all
Scan all 0 223 151 322 9 7 643 1355 20.3879 –1468 0.5220 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 92 A Weibull curve is used to estimate the life expectancy of women with medically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2750 2823 19.8551 – – Dominated
Wells’s score (strict) 4 28 72 156 4 1 1963 2227 20.0530 – – Dominated
Delphi specificity score 4 50 69 156 4 2 1981 2266 20.0557 – – Dominated
Geneva score 4 84 82 173 5 3 1823 2173 20.0891 – – Dominated
Wells’s score (permissive) 4 88 87 186 5 3 1729 2101 20.1143 – – Dominated
Delphi primary score 4 95 102 221 6 3 1464 1895 20.1841 – – Dominated
PERC score 4 109 108 238 7 3 1331 1800 20.2140 – – Dominated
No scan, treat all 0 0 1262 322 122 0 644 2351 20.2940 – – Dominated
Delphi sensitivity score 4 215 142 312 9 7 736 1424 20.3579 – – Dominated
Scan all 0 223 149 322 9 7 644 1355 20.3784 –1468 0.5233 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 93 A Gompertz curve is used to estimate the life expectancy of women with medically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 57 1 0 2748 2822 19.8576 – – Dominated
Delphi specificity score 4 48 68 153 4 1 2005 2283 20.0518 – – Dominated
Wells’s score (strict) 4 27 71 154 4 1 1971 2232 20.0533 – – Dominated
Geneva score 4 80 82 172 5 3 1832 2177 20.0892 – – Dominated
Wells’s score (permissive) 4 86 87 185 5 3 1734 2102 20.1150 – – Dominated
Delphi primary score 4 93 101 219 6 3 1482 1907 20.1816 – – Dominated
PERC score 4 106 106 235 6 3 1355 1816 20.2101 – – Dominated
No scan, treat all 0 0 1255 322 122 0 643 2343 20.2961 – – Dominated
Delphi sensitivity score 4 214 143 312 9 7 733 1421 20.3599 – – Dominated
Scan all 0 222 150 322 9 7 643 1353 20.3802 –1468 0.5226 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 94 A log-logistic curve is used to estimate the life expectancy of women with medically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2752 2825 19.8582 – – Dominated
Delphi specificity score 4 48 70 155 4 1 1990 2272 20.0552 – – Dominated
Wells’s score (strict) 4 27 74 158 4 1 1947 2214 20.0588 – – Dominated
Geneva score 4 81 84 174 5 3 1815 2165 20.0926 – – Dominated
Wells’s score (permissive) 4 87 89 189 5 3 1704 2080 20.1215 – – Dominated
Delphi primary score 4 93 104 223 6 3 1453 1885 20.1876 – – Dominated
PERC score 4 107 108 237 6 3 1342 1808 20.2119 – – Dominated
No scan, treat all 0 0 1253 322 122 0 648 2346 20.2927 – – Dominated
Delphi sensitivity score 4 214 143 313 9 7 733 1422 20.3576 – – Dominated
Scan all 0 222 150 322 9 7 648 1358 20.3766 –1467 0.5184 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 95 A gamma curve is used to estimate the life expectancy of women with medically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2755 2828 19.9090 – – Dominated
Wells’s score (strict) 4 28 72 155 4 1 1976 2239 20.0968 – – Dominated
Delphi specificity score 4 49 70 155 4 1 1995 2279 20.0992 – – Dominated
Geneva score 4 82 83 173 5 3 1836 2185 20.1318 – – Dominated
Wells’s score (permissive) 4 87 89 188 5 3 1726 2101 20.1597 – – Dominated
Delphi primary score 4 95 105 224 6 3 1451 1888 20.2284 – – Dominated
PERC score 4 109 109 237 6 3 1352 1819 20.2496 – – Dominated
No scan, treat all 0 0 1264 322 122 0 665 2374 20.3211 – – Dominated
Delphi sensitivity score 4 215 144 312 9 7 751 1442 20.3874 – – Dominated
Scan all 0 223 151 322 9 7 665 1378 20.4058 –1451 0.4968 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 96 A generalised gamma curve is used to estimate the life expectancy of women with medically treated CTEPH
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2755 2828 19.9090 – – Dominated by scan all
Wells’s score (strict) 4 28 72 155 4 1 1976 2239 20.0968 – – Dominated by scan all
Delphi specificity 4 49 70 155 4 1 1995 2279 20.0992 – – Dominated by scan all
Geneva score 4 82 83 173 5 3 1836 2185 20.1318 – – Dominated by scan all
Wells’s score (permissive) 4 87 89 188 5 3 1726 2101 20.1597 – – Dominated by scan all
Delphi primary score 4 95 105 224 6 3 1451 1888 20.2284 – – Dominated by scan all
PERC score 4 109 109 237 6 3 1352 1819 20.2496 – – Dominated by scan all
No scan, treat all 0 0 1264 322 122 0 665 2374 20.3211 – – Dominated by scan all
Delphi sensitivity 4 215 144 312 9 7 751 1442 20.3874 – – Dominated by scan all
Scan all 0 223 151 322 9 7 665 1378 20.4058 –1451 0.4968 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 97 There is no risk of death following a recurrent VTE
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 57 1 0 2756 2829 19.8549 – – Dominated
Wells’s score (strict) 4 26 73 155 4 1 1970 2233 20.0531 – – Dominated
Delphi specificity score 4 48 71 155 4 1 1990 2274 20.0553 – – Dominated
Geneva score 4 82 85 175 5 3 1812 2164 20.0946 – – Dominated
Wells’s score (permissive) 4 87 90 187 5 3 1719 2094 20.1193 – – Dominated
Delphi primary score 4 94 104 222 6 3 1461 1894 20.1872 – – Dominated
PERC score 4 107 110 237 7 3 1338 1805 20.2153 – – Dominated
No scan, treat all 0 0 1260 322 122 0 645 2350 20.2967 – – Dominated
Delphi sensitivity score 4 215 145 313 9 7 728 1420 20.3622 – – Dominated
Scan all 0 223 152 322 9 7 645 1358 20.3809 –1471 0.5260 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 98 There is no anticoagulation treatment cost following a recurrent VTE
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2756 2828 19.8481 – – Dominated
Wells’s score (strict) 4 27 41 156 4 1 1961 2193 20.0478 – – Dominated
Delphi specificity score 4 48 40 157 4 1 1971 2226 20.0525 – – Dominated
Geneva score 4 82 46 175 5 3 1809 2123 20.0876 – – Dominated
Wells’s score (permissive) 4 87 49 189 5 3 1702 2038 20.1162 – – Dominated
Delphi primary score 4 93 55 224 6 3 1439 1824 20.1854 – – Dominated
PERC score 4 108 57 238 7 3 1332 1750 20.2092 – – Dominated
No scan, treat all 0 0 1181 322 122 0 645 2271 20.2902 – – Dominated
Delphi sensitivity 4 214 73 313 9 7 731 1350 20.3550 – – Dominated
Scan all 0 222 76 322 9 7 645 1282 20.3742 –1547 0.5261 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 99 The expert elicitation exercise was conducted for women with PE as defined in the secondary statistical population
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 16 59 1 0 2657 2734 19.8820 – – No scan, treat none
Wells’s score (strict) 4 27 73 158 4 1 1883 2150 20.0772 – – Wells’s score (strict)
Delphi specificity score 4 49 71 159 4 2 1898 2187 20.0806 – – Delphi specificity score
Geneva score 4 82 84 176 5 3 1738 2092 20.1144 – – Geneva score
Wells’s score (permissive) 4 87 89 189 5 3 1649 2025 20.1382 – – Wells’s score (permissive)
Delphi primary score 4 95 103 224 6 3 1393 1828 20.2051 – – Delphi primary score
PERC score 4 108 108 239 7 3 1276 1745 20.2314 – – PERC score
No scan, treat all 0 0 1259 322 122 0 608 2312 20.3056 – – No scan, treat all
Delphi sensitivity 4 214 143 312 9 7 695 1384 20.3704 – – Delphi sensitivity
Scan all 0 222 150 322 9 7 608 1319 20.3898 –1415 0.5078 Scan all
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 100 The expert elicitation exercise on the risk of mortality from PE was conducted for women with PE as defined in the tertiary statistical population
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 57 1 0 2750 2823 19.8673 – – Dominated by scan all
Wells’s score (strict) 4 28 73 156 4 1 1953 2219 20.0675 – – Dominated by scan all
Delphi specificity score 4 49 71 156 4 2 1976 2262 20.0691 – – Dominated by scan all
Geneva score 4 83 85 174 5 3 1811 2163 20.1043 – – Dominated by scan all
Wells’s score (permissive) 4 87 90 188 5 3 1702 2079 20.1329 – – Dominated by scan all
Delphi primary score 4 95 105 223 6 3 1445 1879 20.2012 – – Dominated by scan all
PERC score 4 109 109 238 7 3 1328 1797 20.2276 – – Dominated by scan all
No scan, treat all 0 0 1254 322 122 0 641 2340 20.3083 – – Dominated by scan all
Delphi sensitivity 4 214 144 312 9 7 727 1417 20.3727 – – Dominated by scan all
Scan all 0 222 151 322 9 7 641 1352 20.3922 –1471 0.5249 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 101 The expert elicitation exercise on the risk of mortality from PE was conducted for women with PE as defined in the quaternary statistical population
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2776 2848 19.8447 – – Dominated
Delphi specificity score 4 49 70 155 4 2 2004 2287 20.0474 – – Dominated
Wells’s score (strict) 4 28 73 157 4 1 1968 2235 20.0491 – – Dominated
Geneva score 4 81 84 174 5 3 1831 2181 20.0852 – – Dominated
Wells’s score (permissive) 4 86 89 188 5 3 1727 2101 20.1130 – – Dominated
Delphi primary score 4 93 103 221 6 3 1476 1906 20.1798 – – Dominated
PERC score 4 107 108 236 6 3 1360 1824 20.2063 – – Dominated
No scan, treat all 0 0 1264 322 122 0 656 2364 20.2910 – – Dominated
Delphi sensitivity score 4 214 144 313 9 7 742 1431 20.3563 – – Dominated
Scan all 0 222 150 322 9 7 656 1367 20.3757 –1481 0.5310 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 102 The expert elicitation exercise on the risk of mortality from PE was conducted for expert one’s answers with PE as defined in the primary statistical population
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 10 36 1 0 3031 3077 19.6578 – – Dominated
Wells’s score (strict) 4 27 69 143 4 1 2310 2557 19.9018 – – Dominated
Delphi specificity score 4 49 67 143 4 2 2383 2651 19.9021 – – Dominated
Geneva score 4 82 81 161 4 3 2220 2555 19.9471 – – Dominated
Wells’s score (permissive) 4 87 86 176 5 3 2115 2475 19.9799 – – Dominated
Delphi primary score 4 94 101 213 6 3 1923 2344 20.0618 – – Dominated
PERC score 4 108 106 230 6 3 1790 2247 20.0969 – – Dominated
No scan, treat all 0 0 1256 321 122 0 1109 2808 20.2194 – – Dominated
Delphi sensitivity score 4 215 143 311 8 7 1192 1880 20.2796 – – Dominated
Scan all 0 223 150 321 9 7 1109 1819 20.3035 –1258 0.6457 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 103 The expert elicitation exercise on the risk of mortality from PE was conducted for expert two’s answers with PE as defined the primary statistical population
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 18 65 1 0 2494 2578 19.9162 – – Dominated
Wells’s score (strict) 4 26 74 162 4 1 1751 2022 20.0964 – – Dominated
Delphi specificity score 4 48 71 162 4 2 1763 2053 20.1001 – – Dominated
Geneva score 4 80 85 179 5 3 1608 1964 20.1311 – – Dominated
Wells’s score (permissive) 4 85 90 191 5 3 1524 1901 20.1528 – – Dominated
Delphi primary score 4 93 104 225 6 3 1272 1707 20.2168 – – Dominated
PERC score 4 107 110 242 7 3 1147 1619 20.2439 – – Dominated
No scan, treat all 0 0 1260 323 122 0 522 2227 20.3031 – – Dominated
Delphi sensitivity score 4 215 144 313 9 7 601 1291 20.3704 – – Dominated
Scan all 0 223 151 323 9 7 522 1233 20.3875 –1345 0.4712 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 104 The expert elicitation exercise on the risk of mortality from PE was conducted for expert 3’s answers with PE as defined in the primary statistical population
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 55 1 0 2807 2878 19.8382 – – Dominated
Wells’s score (strict) 4 27 72 155 4 1 2005 2268 20.0422 – – Dominated
Delphi specificity score 4 49 70 155 4 2 2031 2314 20.0448 – – Dominated
Geneva score 4 81 83 173 5 3 1860 2208 20.0795 – – Dominated
Wells’s score (permissive) 4 86 88 186 5 3 1761 2132 20.1065 – – Dominated
Delphi primary score 4 94 103 223 6 3 1487 1919 20.1786 – – Dominated
PERC score 4 108 108 237 6 3 1373 1839 20.2052 – – Dominated
No scan, treat all 0 0 1256 322 122 0 667 2368 20.2900 – – Dominated
Delphi sensitivity score 4 215 143 312 9 7 758 1447 20.3536 – – Dominated
Scan all 0 223 150 322 9 7 667 1378 20.3737 –1500 0.5356 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 105 The expert elicitation exercise on the risk of mortality from PE was conducted for expert 4’s answers with PE as defined in the primary statistical population
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 12 43 1 0 2795 2851 19.7291 – – Dominated
Delphi specificity score 4 49 70 149 4 2 2180 2456 19.9563 – – Dominated
Wells’s score (strict) 4 28 72 148 4 1 2127 2383 19.9572 – – Dominated
Geneva score 4 83 84 168 4 3 2014 2359 19.9992 – – Dominated
Wells’s score (permissive) 4 86 89 181 5 3 1941 2307 20.0291 – – Dominated
Delphi primary score 4 95 104 218 6 3 1740 2170 20.1036 – – Dominated
PERC score 4 109 109 233 6 3 1644 2108 20.1335 – – Dominated
No scan, treat all 0 0 1257 321 122 0 1023 2723 20.2418 – – Dominated
Delphi sensitivity 4 215 144 310 8 7 1107 1795 20.3013 – – Dominated
Scan all 0 223 152 321 9 7 1023 1734 20.3256 –1117 0.5965 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 106 The risk of PE-related mortality is taken from UKOSS
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 19 68 2 0 2446 2535 19.9641 – – Dominated
Delphi specificity score 4 49 72 163 4 2 1693 1987 20.1326 – – Dominated
Wells’s score (strict) 4 27 75 165 4 1 1676 1951 20.1368 – – Dominated
Geneva score 4 82 86 181 5 3 1547 1907 20.1656 – – Dominated
Wells’s score (permissive) 4 88 91 194 5 3 1450 1833 20.1879 – – Dominated
Delphi primary score 4 95 105 227 6 3 1195 1635 20.2449 – – Dominated
PERC score 4 108 110 241 7 3 1087 1559 20.2678 – – Dominated
No scan, treat all 0 0 1254 323 123 0 439 2139 20.3293 – – Dominated
Delphi sensitivity score 4 214 144 314 9 7 518 1209 20.3967 – – Dominated
Scan all 0 223 151 323 9 7 439 1151 20.4134 –1383 0.4492 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 107 There is a 12.5 kg reduction in the weight of pregnant women who are more than 20 weeks pregnant for the purpose of calculating their anticoagulation dose
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 13 56 1 0 2751 2822 19.8482 – – Dominated
Wells’s score (strict) 4 27 66 156 4 1 1960 2217 20.0481 – – Dominated
Delphi specificity score 4 49 64 156 4 2 1976 2255 20.0511 – – Dominated
Geneva score 4 82 76 174 5 3 1816 2158 20.0857 – – Dominated
Wells’s score (permissive) 4 86 79 186 5 3 1722 2085 20.1109 – – Dominated
Delphi primary score 4 94 92 221 6 3 1462 1882 20.1791 – – Dominated
PERC score 4 108 97 237 6 3 1337 1792 20.2078 – – Dominated
No scan, treat all 0 0 1123 322 122 0 645 2212 20.2898 – – Dominated
Delphi sensitivity score 4 214 126 313 9 7 731 1403 20.3547 – – Dominated
Scan all 0 222 133 322 9 7 645 1338 20.3740 –1484 0.5258 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 108 The cost of CTEPH surgery is £24,000
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 57 1 0 2751 2824 19.8488 – – Dominated
Wells’s score (strict) 4 27 72 155 4 1 1968 2230 20.0455 – – Dominated
Delphi specificity score 4 49 69 155 4 1 1990 2272 20.0475 – – Dominated
Geneva score 4 82 83 173 5 3 1823 2172 20.0837 – – Dominated
Wells’s score (permissive) 4 87 88 186 5 3 1724 2097 20.1097 – – Dominated
Delphi primary score 4 95 103 221 6 3 1462 1893 20.1792 – – Dominated
PERC score 4 109 109 237 6 3 1338 1805 20.2070 – – Dominated
No scan, treat all 0 0 1262 322 122 0 644 2351 20.2891 – – Dominated
Delphi sensitivity score 4 216 143 312 9 7 734 1424 20.3532 – – Dominated
Scan all 0 224 150 322 9 7 644 1357 20.3734 –1466 0.5246 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 109 The cost of CTEPH management is from Schweikert et al.97
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2750 2823 19.8645 – – Dominated
Wells’s score (strict) 4 28 72 156 4 1 2008 2273 20.0642 – – Dominated
Delphi specificity score 4 49 70 155 4 2 2036 2319 20.0643 – – Dominated
Geneva score 4 81 83 174 5 2 1876 2224 20.1011 – – Dominated
Wells’s score (permissive) 4 87 88 187 5 3 1782 2156 20.1277 – – Dominated
Delphi primary score 4 94 102 220 6 3 1551 1980 20.1927 – – Dominated
PERC score 4 107 108 237 6 3 1431 1896 20.2222 – – Dominated
No scan, treat all 0 0 1258 322 122 0 775 2478 20.3049 – – Dominated
Delphi sensitivity 4 215 143 312 9 7 861 1549 20.3685 – – Dominated
Scan all 0 223 150 322 9 7 775 1486 20.3892 –1337 0.5247 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 110 The cost of CTEPH surgery is £24,000 and the cost of CTEPH management is from Schweikert et al.97
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2754 2827 19.8417 – – Dominated
Delphi specificity score 4 49 69 154 4 1 2048 2329 20.0401 – – Dominated
Wells’s score (strict) 4 27 72 156 4 1 2014 2277 20.0417 – – Dominated
Geneva score 4 82 83 173 5 3 1885 2233 20.0781 – – Dominated
Wells’s score (permissive) 4 87 88 187 5 3 1789 2162 20.1051 – – Dominated
Delphi primary score 4 94 102 221 6 3 1549 1979 20.1733 – – Dominated
PERC score 4 108 107 236 6 3 1438 1903 20.1998 – – Dominated
No scan, treat all 0 0 1257 322 122 0 780 2482 20.2841 – – Dominated
Delphi sensitivity score 4 214 142 311 9 7 870 1556 20.3465 – – Dominated
Scan all 0 222 150 322 9 7 780 1490 20.3681 –1337 0.5264 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 111 Women are not at risk from bleeding, recurrent VTE or CTEPH and the risk of death is from the expert elicitation
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 0 0 0 0 0 0 20.0380 – – –
Delphi specificity score 4 49 60 113 0 2 233 461 20.1799 – – Dominated
Wells’s score (strict) 4 28 65 118 0 1 224 440 20.1818 440 0.1437 3060
Geneva score 4 83 76 135 0 3 262 562 20.2045 – – Extendedly dominated
Wells’s score (permissive) 4 87 82 152 0 3 295 623 20.2256 – – Extendedly dominated
Delphi primary score 4 95 98 191 0 3 377 768 20.2736 – – Extendedly dominated
PERC score 4 109 105 212 0 3 411 843 20.2952 75 0.0216 3490
Delphi sensitivity score 4 215 143 299 0 7 553 1220 20.3932 – – Extendedly dominated
Scan all 0 222 151 310 0 7 573 1263 20.4065 420 0.1113 3775
No scan, treat all 0 0 1257 310 0 0 573 2140 20.4091 877 0.0026 337,261
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 112 Women are not at risk from bleeding, recurrent VTE or CTEPH and the risk of death is from the UKOSS patients
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 0 0 0 0 0 0 20.1504 – – –
Delphi specificity score 4 48 62 115 0 1 143 373 20.2587 – – Dominated
Wells’s score (strict) 4 27 66 118 0 1 146 362 20.2622 362 0.1118 3237
Geneva score 4 81 78 137 0 2 170 471 20.2799 – – Extendedly dominated
Wells’s score (permissive) 4 86 84 152 0 2 188 516 20.2940 – – Extendedly dominated
Delphi primary score 4 93 100 193 0 2 239 630 20.3310 – – Extendedly dominated
PERC score 4 107 106 210 0 3 260 689 20.3462 327 0.0840 3897
Delphi sensitivity score 4 214 145 299 0 5 370 1038 20.4303 – – Extendedly dominated
Scan all 0 222 153 310 0 5 384 1075 20.4408 385 0.0946 4072
No scan, treat all 0 0 1259 310 0 0 384 1953 20.4427 879 0.0019 469,304
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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TABLE 113 All scanning-induced cancers present within 15 years
Strategy
Costs (£)
QALYs
Incremental
ICER (£/QALY gained)DR Scans Drugs VTE Bleeds
Induced
cancers CTEPH Total Costs (£) QALYs
No scan, treat none 0 0 15 56 1 0 2751 2824 19.8474 – – Dominated
Delphi specificity score 4 28 72 157 4 2 1949 2216 20.0468 – – Dominated
Wells’s score (strict) 4 49 70 156 4 4 1976 2263 20.0469 – – Dominated
Geneva score 4 81 84 175 5 7 1805 2160 20.0817 – – Dominated
Wells’s score (permissive) 4 86 88 188 5 7 1709 2087 20.1070 – – Dominated
Delphi primary score 4 95 103 223 6 8 1448 1886 20.1762 – – Dominated
PERC score 4 108 108 238 7 9 1330 1803 20.2021 – – Dominated
Delphi sensitivity score 0 0 1257 322 122 0 644 2346 20.2887 – – Dominated
Scan all 4 215 143 312 9 17 733 1432 20.3403 – – Dominated
No scan, treat all 0 223 150 322 9 18 644 1366 20.3600 –1458 0.5126 Dominant
DR, decision rule; –, no incremental comparison of costs or QALYs was conducted for this option, as it was either dominated, extendedly dominated or was the least effective strategy in
terms of QALYs accrued.
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